

# **New York University**

**Report on Federal Awards in Accordance With  
the OMB Uniform Guidance**

**August 31, 2023**

**Entity Identification Number: 13-5562308**

**New York University**  
**Index**  
**August 31, 2023 and 2022**

---

	<b>Page(s)</b>
<b>Part I – Financial Statements</b>	
<b>Report of Independent Auditors</b> .....	1–3
<b>Consolidated Financial Statements</b>	
Balance Sheets .....	4
Statements of Activities .....	5
Statements of Cash Flows .....	6
Notes to Financial Statements .....	7–46
<b>Appendix A</b>	
Supplemental Schedules .....	47–56
Note to Consolidating Supplemental Schedules .....	57
<b>Part II – Supplemental Schedule of Expenditures of Federal Awards</b>	
Schedule of Expenditures of Federal Awards .....	58–82
Notes to Schedule of Expenditures of Federal Awards .....	83–85
Schedule of Financial Responsibility Data .....	86
<b>Part III – Reports on Internal Control and Compliance</b>	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> .....	87–88
Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance .....	89–91
<b>Part IV – Findings</b>	
Schedule of Findings and Questioned Costs .....	92–94
Summary Schedule of Status of Prior Audit Findings .....	95
Management’s View and Corrective Action Plan .....	96-97

**Part I**  
**Financial Statements**



## **Report of Independent Auditors**

To the Board of Trustees of  
New York University

### **Report on the Audit of the Consolidated Financial Statements**

#### ***Opinion***

We have audited the accompanying consolidated financial statements of New York University and its subsidiaries (the “Company”), which comprise the consolidated balance sheets as of August 31, 2023 and 2022, and the related consolidated statements of activities, and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”).

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of August 31, 2023 and 2022, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### ***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### ***Responsibilities of Management for the Consolidated Financial Statements***

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

#### ***Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements***

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of



not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### ***Supplemental Information***

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The accompanying consolidating balance sheets – summary, consolidating balance sheets – detail, consolidating statements of activities – summary, consolidating statements of activities – detail and consolidating statements of cash flows – summary as of and for the years ended August 31, 2023 and 2022 included in Appendix A (the “supplemental information”) is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. The consolidating information is not intended to present, and we do not express an opinion on, the financial position, changes in net assets and cash flows of the individual companies. The supplemental information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The supplemental information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended August 31,



2023 and schedule of financial responsibility data as of and for the year ended August 31, 2023 are presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the Department of Education, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards and schedule of financial responsibility data are fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

**Other Reporting Required by *Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated December 20, 2023, except with respect to Note 20 to the consolidated financial statements and the opinion on the schedule of financial responsibility data, as to which the date is April 24, 2024, on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended August 31, 2023. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control over financial reporting and compliance.

*PricewaterhouseCoopers LLP*

New York, New York

December 20, 2023, except with respect to Note 20 to the consolidated financial statements and the opinion on the schedule of financial responsibility data, as to which the date is April 24, 2024

**New York University**  
**Consolidated Balance Sheets**  
**August 31, 2023 and 2022**

<i>(in thousands of dollars)</i>	<b>2023</b>	<b>2022</b>
<b>Assets</b>		
Cash and cash equivalents	\$ 1,390,097	\$ 3,014,564
Short-term investments (Note 5)	2,373,694	175,945
Accounts and loans receivable, net (Note 6)	833,750	847,849
Patient accounts receivable, net (Note 4)	1,230,323	1,215,720
Contributions receivable, net (Note 7)	694,649	622,216
Other assets (Note 8)	1,253,139	1,074,070
Deposits with trustees (Note 9)	344,368	622,951
Long-term investments (Note 5)	6,812,105	6,479,554
Operating right-of-use assets (Note 11)	2,040,225	2,154,222
Assets held for professional liabilities (Note 13)	1,096,600	950,996
Land, buildings, and equipment, net (Note 10)	14,519,779	13,524,087
Total assets	<u>\$ 32,588,729</u>	<u>\$ 30,682,174</u>
<b>Liabilities and Net Assets</b>		
Liabilities		
Accounts payable and accrued expenses	\$ 2,575,692	\$ 2,551,333
Deferred revenue	1,451,814	1,413,925
Operating lease liability (Note 11)	2,226,362	2,316,986
Professional liabilities (Note 13)	967,037	917,229
Debt and other obligations (Note 12)	9,668,268	9,566,406
Funds held for others (Notes 6 and 8)	552,544	493,479
Accrued benefit obligation (Note 14)	229,087	398,718
Accrued postretirement obligation (Note 14)	456,817	510,738
Asset retirement obligation	301,943	287,047
Total liabilities	<u>18,429,564</u>	<u>18,455,861</u>
Net assets		
Without donor restrictions	9,123,054	7,489,240
With donor restrictions (Note 17)	5,036,111	4,737,073
Total net assets	<u>14,159,165</u>	<u>12,226,313</u>
Total liabilities and net assets	<u>\$ 32,588,729</u>	<u>\$ 30,682,174</u>

The accompanying notes are an integral part of these consolidated financial statements.

**New York University**  
**Consolidated Statements of Activities**  
**Years Ended August 31, 2023 and 2022**

<i>(in thousands of dollars)</i>	<b>2023</b>	<b>2022</b>
<b>Changes in net assets without donor restrictions</b>		
Operating revenues		
Tuition and fees (net of financial aid awards of \$897,928 and \$852,272)	\$ 2,511,289	\$ 2,452,721
Grants and contracts (Note 2)	1,522,489	1,391,271
Patient care (Note 4)	9,831,332	8,862,837
Hospital affiliations (Note 15)	479,934	448,827
Insurance premiums earned	117,784	108,014
Contributions	77,437	74,415
Endowment distribution (Note 5)	228,903	198,345
Return on short-term investments (Note 5)	164,359	45,157
Auxiliary enterprises (net of financial aid awards of \$91,060 and \$70,701)	417,367	382,105
Program fees and other	1,002,574	687,937
Net assets released from restrictions	165,296	173,496
Total operating revenues	<u>16,518,764</u>	<u>14,825,125</u>
Expenses (Note 16)		
Salaries and fringe	9,453,003	8,394,663
Medical and pharmaceutical costs	1,759,994	1,477,431
Professional services	808,704	737,180
Facilities costs	947,386	904,243
Fees, insurance and taxes	487,551	460,450
Depreciation and amortization	1,012,445	945,911
Interest	372,396	368,647
Other	1,159,458	818,674
Total expenses	<u>16,000,937</u>	<u>14,107,199</u>
Excess of operating revenues over expenses	517,827	717,926
Nonoperating activities		
Investment return (Note 5)	329,835	(475,133)
Appropriation of endowment distribution (Note 5)	(73,286)	(64,208)
Pension and postretirement nonservice costs (Note 14)	18,870	26,171
Changes in pension and postretirement obligations (Note 14)	229,863	271,079
Net assets released from restrictions for capital	103,597	20,215
Nonclinical COVID costs	(3,129)	(37,792)
Proceeds from settlement agreement (Note 18)	508,000	-
Other	2,237	94,842
Increase in net assets without donor restrictions	<u>1,633,814</u>	<u>553,100</u>
<b>Changes in net assets with donor restrictions</b>		
Contributions	451,952	299,803
Investment return (Note 5)	273,997	(339,241)
Appropriation of endowment distribution (Note 5)	(155,617)	(134,137)
Other	(2,401)	(8,542)
Net assets released from restrictions	(268,893)	(193,711)
Increase (decrease) in net assets with donor restrictions	<u>299,038</u>	<u>(375,828)</u>
Increase in net assets	<u>\$ 1,932,852</u>	<u>\$ 177,272</u>

The accompanying notes are an integral part of these consolidated financial statements.



# New York University

## Consolidated Statements of Cash Flows

### Years Ended August 31, 2023 and 2022

(in thousands of dollars)

	2023	2022
<b>Cash flows from operating activities</b>		
Change in net assets	\$ 1,932,852	\$ 177,272
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Depreciation and amortization	1,012,445	945,911
Gain on sale or disposal of land, buildings and equipment	(7,349)	(201)
Net (gain) loss on investments, deposits with trustees, and split-interest agreements	(534,863)	893,019
Bad debt expense	7,962	18,407
Pension and postretirement obligation change	(229,863)	(271,079)
Contributions received for permanent investment and capital	(130,768)	(113,609)
Proceeds from FEMA award for future mitigation	(13,264)	(1,191)
Amortization of operating right-of-use assets	272,806	265,324
Acquisition of Long Island Community Hospital	-	(105,967)
Changes in operating assets and liabilities		
Decrease (increase) in accounts and loans receivable, net	7,434	(90,233)
Increase in patient accounts receivable	(14,603)	(129,017)
(Increase) decrease in nonendowment and noncapital contributions receivable	(73,732)	9,425
Increase in other assets	(86,812)	(31,740)
Decrease in asset retirement obligation	(1,326)	(16,265)
Decrease in accounts payable and accrued expenses	9,875	(389,796)
Decrease in operating lease liability	(252,425)	(252,314)
Increase in professional liabilities	49,809	45,374
Increase in deferred revenue	37,890	86,336
Decrease in accrued benefit obligation	(15,342)	(1,452)
Increase in accrued postretirement obligation	3,771	11,830
Net cash provided by operating activities	<u>1,974,497</u>	<u>1,050,034</u>
<b>Cash flows from investing activities</b>		
Purchases of investments	(5,091,772)	(3,271,831)
Sales and maturities of investments	3,128,453	2,951,822
Drawdowns of unexpended bond proceeds	121,034	87,603
Additions to land, buildings, and equipment	(1,651,615)	(1,377,026)
Cash from acquisition of Long Island Community Hospital	-	86,068
Net cash used in investing activities	<u>(3,493,900)</u>	<u>(1,523,364)</u>
<b>Cash flows from financing activities</b>		
Contributions received for permanent investment and capital	130,768	113,609
Proceeds from FEMA award for future mitigation	13,264	1,191
Proceeds from finance lease incentives	15,077	38,870
Principal payments on long-term borrowings and finance leases	(221,884)	(231,619)
Decrease in funds held for others	(19,781)	(5,590)
Net cash used in financing activities	<u>(82,556)</u>	<u>(83,539)</u>
Net decrease in cash, cash equivalents and restricted cash	(1,601,959)	(556,869)
<b>Cash, cash equivalents and restricted cash</b>		
Beginning of year	<u>3,373,326</u>	<u>3,930,195</u>
End of year	<u>\$ 1,771,367</u>	<u>\$ 3,373,326</u>
<b>Supplemental disclosure of cash flow information</b>		
Interest paid	\$ 390,054	\$ 385,168
Change in noncash acquisitions of land, buildings, and equipment	147,455	60,097
Right-of-use assets obtained		
In exchange for new operating lease obligations	\$ 205,015	\$ 249,270
In exchange for new finance lease obligations	233,624	50,243

The accompanying notes are an integral part of these consolidated financial statements.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

*(in thousands of dollars)*

#### 1. Description of New York University

Founded in 1831, New York University (NYU) is a private institution of higher education, research, and patient care located primarily in New York City. NYU is recognized both nationally and internationally as a leader in scholarship and is a member of the distinguished Association of American Universities.

The consolidated reporting entities for NYU consist of the University and NYU Langone Health, which represents the activities of NYU Langone Health System (Health System) and its two medical schools: the NYU Robert I. Grossman School of Medicine (NYUGSoM) and NYU Grossman Long Island School of Medicine (collectively the NYU Schools of Medicine).

#### The University

The University includes the following colleges, schools, divisions, institutes and portal campuses, each with its own traditions, programs and faculty, listed in order of founding date: the College of Arts and Science, School of Law, NYUGSoM (reported as a part of NYU Langone Health), College of Dentistry, Graduate School of Arts and Science, Steinhardt School of Culture, Education and Human Development, Leonard N. Stern School of Business, Courant Institute of Mathematical Sciences, School of Professional Studies, Institute of Fine Arts, Robert F. Wagner Graduate School of Public Service, Silver School of Social Work, Tisch School of the Arts, Gallatin School of Individualized Study, NYU Abu Dhabi, Tandon School of Engineering (formerly Polytechnic University founded in 1854), Rory Meyers College of Nursing, Institute for the Study of the Ancient World, School of Global Public Health, and NYU Grossman Long Island School of Medicine (reported as part of NYU Langone Health). The University also operates academic program sites and research programs in other parts of the United States and abroad.

In addition to the above colleges, schools, divisions, institutes and portal campuses, NYU has a degree-granting campus in Shanghai, People's Republic of China, NYU Shanghai, which operates as a joint venture with East China Normal University. The New York-based activities of NYU Shanghai are reported in the University's consolidated balance sheets and consolidated statements of activities.

#### NYU Langone Health

The Health System is the sole corporate member of NYU Langone Hospitals, which is a quaternary care teaching hospital that operates five inpatient acute care facilities and over 40 ambulatory facilities in Manhattan, Brooklyn, and Long Island. The 813-bed inpatient facilities in Manhattan are comprised of the Kimmel Pavilion (which also houses the Hassenfeld Children's Hospital) and Tisch Hospital. The NYU Langone Orthopedic Hospital, also located in Manhattan, is a 225-bed facility specializing in orthopedic, neurologic, and rheumatologic services. NYU Langone Hospital-Brooklyn is a 444-bed facility in the Sunset Park section of Brooklyn. NYU Langone Hospital-Long Island is a 591-bed acute care facility located in Mineola, New York. Ambulatory facilities include the Laura and Isaac Perlmutter Cancer Center, a comprehensive cancer and ambulatory care center, as well as the Joseph S. and Diane H. Steinberg Ambulatory Care Center, in the Cobble Hill section of Brooklyn, which includes a free-standing emergency department, amongst others.

On March 1, 2022, the Health System completed an affiliation agreement (the Affiliation) with and became the sole corporate member of Brookhaven Health Care Services Corporation, d/b/a Long Island Community Hospital Foundation and Brookhaven Memorial Hospital Medical Center Inc., d/b/a Long Island Community Hospital. Brookhaven Memorial Hospital Medical Center Inc.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

subsequently changed its name to Long Island Community Hospital at NYU Langone Health (LICH). LICH is a 306-bed acute care hospital located in Patchogue, New York.

NYUGSoM employs approximately 3,500 faculty physicians (the Faculty Group Practice) who render patient care in more than 350 practice locations primarily in the New York City region, and two practice locations in Delray Beach and West Palm Beach, Florida. These physicians constitute the principal clinical service providers for NYU Langone Hospitals' facilities.

NYU Langone Hospitals is the sole corporate member of CCC550 Insurance, SCC. (CCC550), which provides the hospitals' professional and general liability insurance, as well as insurance to physicians employed by the NYUGSoM. CCC550 is subject to taxation in accordance with Section 29 of the Exempt Insurance Act in Barbados.

**Affiliation With Long Island Community Hospital**

The Health System's Affiliation with and the subsequent change in control of LICH was accounted for as a business combination in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC), Topic 805, *Business Combinations*, and ASC 958-805-05, *Acquisition by a Not-for-Profit Entity*. NYU recorded \$101,557 of nonoperating income in the 2022 consolidated statement of activities which represents LICH's net assets without donor restriction at March 1, 2022, and the excess of the fair value of assets acquired over the fair value of liabilities assumed. No consideration was exchanged for the acquisition.

As a result of the Affiliation, LICH changed its fiscal year from a calendar year to a fiscal year beginning September 1st and ending August 31st to align with the fiscal year of the Health System. As a result of this change, obtaining revenues and changes in net assets as though the acquisition occurred at the beginning of fiscal year 2022 was impracticable.

The following is a summary of the LICH activity from March 1, 2022 to August 31, 2022 included in the 2022 consolidated statement of activities:

<b>Net assets without donor restriction as of March 1, 2022</b>	\$ 100,540
Excess fair value of assets acquired over liabilities	1,017
Acquisition of Long Island Community Hospital	<u>101,557</u>
Operating revenues	118,815
Operating expenses	<u>138,522</u>
	(19,707)
Nonoperating activities	<u>(6,733)</u>
Change in net assets without donor restrictions	75,117
Change in net assets with donor restrictions	3,861
Total change in net assets as a result of acquisition	<u>\$ 78,978</u>

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

(in thousands of dollars)

The following is a summary of the LICH amounts included in the consolidated balance sheet as of August 31, 2022:

Assets	\$	293,466
Liabilities		214,488
Net assets without donor restrictions		75,117
Net assets with donor restrictions		3,861

## 2. Summary of Significant Accounting Policies

### Basis of Presentation

The consolidated financial statements of NYU have, in all material respects, been prepared on an accrual basis in accordance with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements include the accounts of NYU, as well as its separately incorporated affiliates. NYU and, generally, all of its affiliates are exempt from federal income taxes under the provisions of Section 501(c)(3) of the Internal Revenue Code.

NYU prepares its consolidated financial statements in accordance with the provisions of FASB ASC 958, *Not for Profit Entities*. This standard focuses on the entity as a whole and requires classification of net assets as determined by the existence or absence of restrictions placed on the assets' uses by donors or by provision of law. A description of the net asset classifications follows:

*Without Donor Restrictions:* Net assets of NYU that are used to carry out its missions of education, research and patient care which are not subject to donor restrictions.

*With Donor Restrictions:* Net assets subject to donor-imposed restrictions that will be met either by the actions of NYU or the passage of time. Items that are included in donor restricted net assets are gifts for which donor-imposed restrictions have not been met in the year of receipt; endowments, annuity, and life income gifts; pledges; investment return on donor restricted endowment funds; and endowments where the principal may be expended upon the passage of a stated period of time. Expirations of restrictions on net assets with donor restrictions are reported as net assets released from restrictions. In addition, NYU has elected the simultaneous release option for contributions that are also subject to purpose restrictions.

### Activities

Revenues and expenses related to conducting programmatic activities and provision of services by NYU are classified as operating in the consolidated statements of activities. Investment return relating to board-designated endowment funds and the related endowment appropriation, as well as nonservice changes in pension and postretirement obligations, incremental nonclinical COVID-19 related expenses, proceeds from settlement agreement (Note 18), and other activity that is not part of NYU's core activities, are classified as nonoperating in the consolidated statements of activities.

### Tuition and Fees

Tuition and fees are derived from degree-granting programs as well as executive and continuing education programs. Tuition and fee revenue is recognized within the fiscal year in which the related educational services are provided as the performance obligation is satisfied. Tuition and fee receipts received in advance of a semester are recorded as deferred revenue. Financial aid, in

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

(in thousands of dollars)

the form of scholarships and grants, including amounts funded by the endowment, research funds, and gifts reduces the published price of tuition for students receiving such aid. As such, financial aid is referred to as a tuition discount and represents the difference between the stated charge for tuition and fees and the amount that is billed to the student and/or third parties making payments on behalf of the student. Tuition and fees are reported net of financial aid on the consolidated statements of activities.

#### **Auxiliary Enterprises**

Auxiliary enterprises are self-supporting activities that furnish goods or services to students, faculty, staff, or incidentally to the general public, and charge a fee directly related to, although not necessarily equal to, the cost of the goods or services. Auxiliary enterprises include student housing and dining, real estate rental income, student health, and other similar activities. Student housing and dining services are delivered over the academic terms and revenues are recognized ratably as the performance obligation is satisfied. Student housing and dining services are presented net of financial aid on the consolidated statements of activities.

#### **Grants and Contracts**

NYU receives funding for sponsored programs from various government agencies, foundations, and corporations. The funding may represent a reciprocal transaction in exchange for an equivalent benefit in return, or it may be a nonreciprocal nonexchange transaction in which the funding provided is for the benefit of NYU, the funding organization's mission, or the public at large.

Revenues from nonexchange transactions may be subject to conditions, in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments). NYU's grants and contracts are primarily conditional nonexchange transactions and revenues are recognized when expenses are incurred. Unspent conditional contributions from grants and contracts total \$1,081,800 and \$1,096,310 at August 31, 2023 and 2022, respectively. Revenues from unconditional nonexchange transactions are recognized in the period awarded.

During the years ended August 31, 2023 and 2022, grants and contracts revenue recognized from U.S. governmental sources totaled \$805,568 and \$761,319, respectively. Such sponsored grants and contracts generally provide for the recovery of indirect costs supporting these activities. Indirect costs, included in grant and contract revenues, are recovered at rates established in advance by NYU through negotiations with the U.S. federal government and other private sponsors and totaled \$239,871 and \$219,185, respectively.

#### **Contributions**

Contributions, including unconditional promises to give, are recognized as revenue in the period received at their fair value. Contributions receivable are reported at their discounted present value, using an estimated interest rate for the year in which the promise was received and considering market and credit risk as applicable (4.84% in 2023 and 4.15% in 2022). Amortization of the discount is recorded as additional contribution revenue. Allowances are recorded for estimated uncollectible contributions based upon management's judgment and analysis of the creditworthiness of the donors, past collection experience and other relevant factors.

#### **Fair Value Measurements**

Authoritative guidance of fair value measurements, ASC 820, *Fair Value Measurements*, establishes a hierarchy of valuation methodologies based on the extent to which asset valuations are observable in the marketplace.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

*(in thousands of dollars)*

The following describes the hierarchy of methodologies used to measure fair value of investments:

Fair value for Level 1 is based on unadjusted quoted prices in actively traded markets that NYU has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets.

Fair value for Level 2 is based on quoted prices for instruments similar to those held by NYU in actively traded markets, quoted prices for identical instruments held by NYU in markets that are not actively traded and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data. Inputs are obtained from various sources including market participants, dealers and brokers.

Fair value for Level 3 is based on valuation techniques used to assess prices that are unobservable as the assets trade infrequently or not at all.

Investments for which fair value is measured at net asset value (NAV) per share as a practical expedient consist primarily of NYU's ownership in alternative investments (principally limited partnership interests in public equity, hedge funds, credit, real assets, private equity, real estate, and other similar funds). The NAV of the securities held by limited partnerships that do not have readily determinable fair values are determined by the general partner and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investment securities, the fair value is determined by the general partner taking into consideration, among other things, the cost of the securities, prices of recent significant placements of securities of the same issuer and subsequent developments concerning the companies to which the securities relate. NYU has performed due diligence on these investments and believes the reported NAV as a practical expedient is an appropriate measure of fair value as of August 31, 2023 and 2022.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while NYU believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

#### **Cash and Cash Equivalents**

Cash and cash equivalents include cash and all highly-liquid debt instruments with original maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates fair value due to the short-term maturity of the instruments. NYU maintains its deposits with high credit quality financial institutions, with balances that exceed federal depository insurance limits. Management does not believe the credit risk related to these deposits is significant. All short-term, highly liquid investments, which would otherwise qualify as cash equivalents that are included in NYU's investment pool within long-term investments, are treated as investments and are therefore excluded from cash and cash equivalents in the consolidated statements of cash flows.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

*(in thousands of dollars)*

The following table provides a reconciliation of cash and cash equivalents reported within the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows at August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
Cash and cash equivalents	\$ 1,390,097	\$ 3,014,564
Cash in short-term investments	199,459	-
Cash in long-term investment pool (Note 5)	142,250	123,227
Cash in other long-term investments (Note 5)	1,952	7,097
Cash in other assets (Note 8)	-	845
Cash in deposits with trustees (Note 9)	8,774	189,996
Cash in assets held for professional liabilities (Note 13)	28,835	37,597
	<u>\$ 1,771,367</u>	<u>\$ 3,373,326</u>
Cash, cash equivalents and restricted cash		

**Investments**

Short-term investments consist primarily of cash equivalents, money market funds, and U.S. Treasury bills with original maturities greater than three months and up to twelve months when purchased. Long-term investments consist primarily of public equity securities, fixed income securities, and assets held in the NYU investment pool (Note 5).

**Land, Buildings, and Equipment**

Land, buildings, and equipment are carried at their acquisition or construction cost. If donated, these assets are recorded at their fair value on the date of the gift. Buildings and equipment are depreciated over their estimated useful lives (buildings and building improvements 10-60 years, equipment 3-20 years) using the straight-line method. Repairs and maintenance expenditures are expensed when incurred.

**Leases**

NYU leases certain academic spaces, medical offices, administrative offices, and equipment under finance and operating leases. Operating lease right-of-use (ROU) assets and operating lease obligations are recognized based on the present value of lease payments over the lease term, where the initial term of the lease exceeds 12 months. NYU uses its incremental borrowing rate to calculate the present value of lease payments because the leases do not have a readily determinable implicit discount rate. As a practical expedient, NYU elected to include both lease and nonlease components in the calculation of the operating lease ROU asset and operating lease obligation. Variable lease payments are excluded for purposes of calculating the operating ROU asset and operating lease obligation unless the variable lease payments depend on an index or rate or are in substance fixed payments. Lease payments related to periods subject to renewal options are also excluded for purposes of calculating the operating ROU asset and operating lease obligation unless NYU is reasonably certain to exercise the option to extend the lease.

Lease expense for operating leases is recognized on a straight-line basis over the term of the lease.

**Collections**

The University does not assign a value to collection items. Collection items are generally held for educational purposes and consist of pieces of art. Collection items are not disposed of for financial gain or otherwise encumbered in any manner.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

(in thousands of dollars)

#### **Deferred Revenue**

Deferred revenue consists of tuition and fees and student housing and dining fees received in advance of the Fall semester as well as funding received for grants and contracts in advance of incurring the qualifying expenses.

#### **Asset Retirement Obligation**

NYU recognizes asset retirement obligations on future events, such as the abatement of asbestos and removal of lead-based paint and petroleum bulk storage tanks from buildings. The fair value of the liability for a conditional asset retirement obligation is recognized in the period in which it occurred, provided that it can be reasonably estimated. Corresponding asset retirement costs (net of accumulated depreciation) have been included in land, buildings, and equipment.

#### **Funds Held for Others**

Funds held for others consist of NYU's federal grants refundable and liabilities associated with 457(b) deferred compensation plans. Corresponding assets are included within accounts receivable (Note 6) and other assets (Note 8), respectively.

#### **Accounting Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingencies at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### **New Authoritative Pronouncements Not Yet Adopted**

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments*. The new standard removes the previous requirement that a credit loss be probable of occurring for it to be recognized, and requires entities to use historical experience, current conditions, and reasonable and supportable forecasts to estimate their future expected credit losses. The standard is required to be applied using the modified retrospective approach with a cumulative-effect adjustment to net assets, if any, upon adoption. This ASU is effective for fiscal years beginning after December 15, 2022. NYU does not expect the adoption to have a material impact on NYU's consolidated financial statements.



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

**3. Financial Assets and Liquidity Resources**

As of August 31, 2023 and 2022, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt, and capital expenditures not financed with debt, were as follows:

	<b>2023</b>	<b>2022</b>
<b>Financial assets</b>		
Cash and short-term investments	\$ 3,763,791	\$ 3,190,509
Investments available for general purposes	846,753	1,094,856
Accounts receivable, net	262,374	213,674
Grants and contracts receivable, net	213,252	206,917
Insurance premiums and recoveries receivable	122,421	110,633
Patient accounts receivable, net	1,230,323	1,215,720
Nonendowment pledge payments due within one year	97,544	79,807
Other assets	46,870	25,697
Subsequent year endowment distribution	250,526	228,903
Total financial assets available within one year	<u>6,833,854</u>	<u>6,366,716</u>
<b>Liquidity resources</b>		
Undrawn bank lines of credit (Note 12)	1,444,470	1,446,770
Funds functioning as endowment available for operations (Note 17)	<u>1,931,507</u>	<u>1,712,150</u>
Total liquidity resources	<u>3,375,977</u>	<u>3,158,920</u>
Total financial assets and liquidity resources available within one year	<u>\$ 10,209,831</u>	<u>\$ 9,525,636</u>

The University's cash flows have seasonal variations during the year attributable to tuition billing cycles and, at times, a concentration of contributions received at calendar year end. The University's Reserve and Liquidity Management Policy provides guidelines for calculating and reporting the global cash position on a daily basis as well as rigorous cash flow forecasting. This approach is adopted to maximize the portion of working capital funds that may remain invested. The Working Capital Fund Investment Policy (the Investment Policy) has a primary objective of aligning the maturity and liquidity profile of the working capital portfolio with the University's anticipated spending needs, while preserving the principal invested and maximizing return among a subset of approved investment grade products and providers. The Investment Policy establishes concentration limits for both investments and banking institutions. Liquidity resources are available with NYU board of trustees' approval.

As part of NYU Langone Health's liquidity management, financial assets are structured to be available as its general expenditures, liabilities and other obligations come due. In addition, NYU Langone Health may invest cash in excess of daily requirements in short-term or liquid investments.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

(in thousands of dollars)

#### 4. Patient Care Revenue and Receivable

Patient care revenue and receivables consist primarily of patient care services provided by NYU Langone Health. The University's College of Dentistry provides dental clinic services to patients as part of a student's training.

NYU Langone Health has agreements with third party payors that provide for payments at amounts different from its established rates (i.e. gross charges). Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges and per diem payments.

NYU Langone Health grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor arrangements. NYU Langone Health bills patients and third-party payers several days after the services are performed and/or the patient is discharged. Patient care revenue is recognized as performance obligations are satisfied over time based on actual charges incurred in relation to total expected charges. Generally, performance obligations over time relate to patients receiving inpatient acute care services or patients receiving services in NYU Langone Health's outpatient and ambulatory care centers. NYU Langone Health measures the performance obligation from admission into the hospital or the commencement of an outpatient or physician service to the point when it is no longer required to provide services to that patient, which is generally the time of discharge or the completion of the outpatient or physician visit.

As substantially all of its performance obligations relate to contracts with a duration of less than one year, NYU Langone Health has elected to apply the optional exemption provided in ASC 606-10-50-14(a) *Revenue from Contracts with Customers* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

NYU Langone Health determines the transaction price based on gross charges for services provided, reduced by adjustments provided to third-party payers based on contractual agreements, discounts provided to uninsured patients in accordance with NYU Langone Health's policy, and implicit concessions provided to uninsured patients.

NYU's patient accounts receivable, after contractual adjustments and implicit price concessions, is \$1,230,323 and \$1,215,720 at August 31, 2023 and 2022, respectively. NYU Langone Health estimates its implicit price concessions using a quarterly standardized approach to review historical collections based on major payor classification as a practical expedient to account for patient contracts as collective groups rather than individually. Based on historical collection trends, the financial statement effects of using this practical expedient are not materially different from an individual contract approach. In addition, NYU Langone Health assesses the current state of its billing functions in order to identify any known collection or reimbursement issues and assess the impact, if any, on estimates. NYU Langone Health believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably those related to obtaining the correct information in order to bill effectively for the services it provides. Subsequent changes to the estimate of transaction price are recorded as adjustments to net patient care revenue in the period of the change. Certain patient care revenues received are subject to retroactive

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

adjustments under reimbursement agreements with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined.

NYU Langone Health has established estimates, based on information presently available, of amounts due to or from Medicare and non-Medicare payors for adjustments to current and prior year payment rates, based on industry-wide and hospital-specific data. The amounts due to third party payors included in accounts payable and accrued expenses on the consolidated balance sheets is \$163,077 and \$140,281 at August 31, 2023 and 2022, respectively. Additionally, certain payors' payment rates for various years have been appealed by NYU Langone Health. If the appeals are successful, additional income applicable to those years will be realized.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. NYU Langone Hospitals' cost reports have been audited by the Medicare fiscal intermediary through August 31, 2018; however, final settlements are pending for 2003 and 2004. NYU Langone Hospital-Brooklyn's cost reports have been audited by the Medicare fiscal intermediary through December 31, 2015; however, final settlements are pending for the years 2008 to 2013. NYU Langone Hospital-Long Island's Medicare cost reports have been audited by the Medicare fiscal intermediary through July 31, 2019, and there are no final settlements pending. LICH's Medicare cost reports have been audited by the Medicare fiscal intermediary through December 31, 2020.

The mix of patient care revenue for the years ended August 31, 2023 and 2022 are as follows:

	2023		2022	
	Health System	NYUGSoM	Health System	NYUGSoM
Medicare	17 %	17 %	18 %	17 %
Medicaid	2	1	2	1
Medicare and Medicaid managed care	21	14	22	14
Blue Cross	26	20	26	20
Managed care and other	34	48	32	48
	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>

The mix of patient accounts receivable, net from patients and third-party payors at August 31, 2023 and 2022 are as follows:

	2023		2022	
	Health System	NYUGSoM	Health System	NYUGSoM
Medicare	9 %	11 %	9 %	12 %
Medicaid	2	1	2	1
Medicare and Medicaid managed care	23	13	21	15
Blue Cross	27	22	26	21
Managed care and other	39	53	42	51
	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

*(in thousands of dollars)*

NYU Langone Health is committed to ensuring that its care is not limited to those who have insurance coverage or the means to pay for care. NYU Langone Health recognizes that there are times when patients in need of care will have difficulty paying for the services provided. Accordingly, NYU Langone Health has implemented a discount policy and financial aid program that is consistent with the mission, values, and capacity of NYU Langone Health, while considering an individual's ability to contribute to their care.

As a matter of policy, NYU Langone Health provides significant amounts of partially or totally uncompensated patient care under its charity care policy or through its financial aid program. NYU Langone Health's charity care policy, in accordance with the New York State Department of Health guidelines, ensures the provision of quality health care to the community served while carefully considering the ability of the patient to pay. The policy has sliding fee schedules for inpatient, ambulatory and emergency services provided to the uninsured and under-insured patients that qualify. Patients are eligible for the charity care fee schedule if they meet certain income tests. Since payment of the difference between NYU Langone Health's standard charges and the charity care fee schedules is not sought, these forgone charges for charity care are not reported as revenue. Federal and state law requires that hospitals provide emergency services regardless of a patient's ability to pay. Under NYU Langone Health's charity care policy, the discount offered to uninsured patients is reflected as a reduction to net patient service revenue at the time the uninsured billings are recorded.

Uninsured patients seen in the emergency department, including patients subsequently admitted for inpatient services, often do not provide information necessary to allow NYU Langone Health to qualify such patients for charity care. Net patient service revenue related to uninsured patients who do not qualify for either Medicaid assistance or NYU Langone Health's financial aid program is recognized for the amount of consideration to which NYU Langone Health expects to be entitled in exchange for providing patient care, net of implicit price concessions based on historical collections. Implicit price concession rates for uninsured patients are refined on an annual basis.

Total charges associated with providing care to charity patients for the years ended August 31, 2023 and 2022, are \$407,466 and \$380,228, respectively. NYU Langone Health determines the cost of providing these services based on a ratio of cost to charges, as summarized in the table below.

New York State regulations provide for the distribution of funds from an indigent care pool, which is intended to partially offset the cost of uncompensated care and services provided to uninsured patients. The funds are distributed to NYU Langone Health based on an uninsured methodology. NYU Langone Health paid \$77,740 and \$70,146 into the indigent care pool for the years ended August 31, 2023 and 2022, respectively. Subsidy payments recognized as revenue to offset the cost of charity care provided are included in the table below.

In addition, over 67% of NYU Langone Health's discharged patients during the years ended August 31, 2023 and 2022 were insured through government payors. NYU Langone Health incurs material costs in treating those patients, and does so at a loss given the shortfall in both Medicare and Medicaid reimbursement.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

The following table summarizes the estimated cost of the services provided, net reimbursement, and cost in excess of reimbursement for the years ended August 31, 2023 and 2022:

	2023	2022
<b>Costs of services provided</b>		
Charity Care	\$ 144,858	\$ 135,056
Governmental Payors	5,720,451	5,067,188
	<u>5,865,309</u>	<u>5,202,244</u>
<b>Net reimbursement</b>		
Charity Care	56,964	53,241
Governmental Payors	3,910,722	3,441,497
	<u>3,967,686</u>	<u>3,494,738</u>
<b>Costs of services in excess of reimbursement</b>		
Charity Care	87,894	81,815
Governmental Payors	1,809,729	1,625,691
	<u>\$ 1,897,623</u>	<u>\$ 1,707,506</u>

**5. Investments**

**Asset Classes**

NYU invests across a broad range of asset classes, including public equity, fixed income, hedge funds, credit, real assets, private equity, real estate, and cash and other. NYU may invest directly in the securities of these asset classes, or indirectly through interests in funds and limited partnerships. Securities held directly by NYU are valued at their observable market prices. The value of holdings in funds and limited partnerships are in accordance with the valuations provided by their investment managers. Funds and limited partnerships may make investments in securities that are publicly traded, which are generally valued based on observable market prices. Managers of investment funds and limited partnerships value those investments based upon the best information available for a given circumstance and may incorporate assumptions that are the investment manager's best estimates after consideration of a variety of internal and external factors.

Investments held by NYU's investment pool are categorized as follows:

**Public Equity**

Public equity consists of publicly-traded equity, mutual funds, and other commingled funds (which may include passive index exposure).

**Fixed Income**

Fixed income includes investments in securities such as U.S. government securities, non-U.S. sovereign bonds, and corporate and asset-backed securities.

**Real Assets**

Real assets include public and private investments in real asset funds.

**Cash and Other**

Cash and other predominantly includes cash and cash equivalents.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

*(in thousands of dollars)*

**U.S. Treasury Bills**

U.S. treasury bills include investments of U.S. treasury bills with an original maturity greater than three months at the time of purchase.

**Hedge Funds**

Hedge funds include investments with managers who invest across different strategies such as long and short equity, multi-strategy, event driven and relative value funds. These managers typically employ some leverage.

**Credit**

Credit includes public and private investments in strategies including distressed debt and special situations.

**Private Equity**

Private equity investments include limited partnership investments in funds pursuing strategies in corporate buyouts, growth equity, and venture capital.

**Real Estate**

Real estate includes public and private investments in real estate funds.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

The following tables summarize the fair value of investments at August 31, 2023 and 2022:

	<b>2023</b>			<b>Total</b>
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	
<b>Long-term investments-investment pool</b>				
Public equity	\$ 1,462,316	\$ -	\$ -	\$ 1,462,316
Fixed income	-	425,436	-	425,436
Real assets	-	-	-	-
Cash and other	142,250	-	-	142,250
	<u>1,604,566</u>	<u>425,436</u>	<u>-</u>	<u>2,030,002</u>
Alternative investments measured at NAV as a practical expedient				<u>3,868,965</u>
Subtotal investment pool				<u>5,898,967</u>
<b>Other long-term investments</b>				
Public equity	893,347	3,702	-	897,049
Fixed Income	9,217	-	-	9,217
Cash and other	1,952	-	4,920	6,872
Subtotal other long-term investments	<u>904,516</u>	<u>3,702</u>	<u>4,920</u>	<u>913,138</u>
Total long-term investments	<u>\$ 2,509,082</u>	<u>\$ 429,138</u>	<u>\$ 4,920</u>	<u>\$ 6,812,105</u>
<b>Short-term investments</b>				
Cash and other	\$ 457,077	\$ -	\$ -	\$ 457,077
U.S. Treasury bills	1,916,617	-	-	1,916,617
Total short-term investments	<u>\$ 2,373,694</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 2,373,694</u>
<b>2022</b>				
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	<b>Total</b>
<b>Long-term investments-investment pool</b>				
Public equity	\$ 1,284,792	\$ -	\$ -	\$ 1,284,792
Fixed income	-	366,606	-	366,606
Real assets	16,768	-	-	16,768
Cash and other	123,227	-	-	123,227
	<u>1,424,787</u>	<u>366,606</u>	<u>-</u>	<u>1,791,393</u>
Alternative investments measured at NAV as a practical expedient				<u>3,505,993</u>
Subtotal investment pool				<u>5,297,386</u>
<b>Other long-term investments</b>				
Public equity	1,103,060	2,701	-	1,105,761
Fixed income	65,230	-	-	65,230
Cash and other	7,097	-	4,080	11,177
Subtotal other long-term investments	<u>1,175,387</u>	<u>2,701</u>	<u>4,080</u>	<u>1,182,168</u>
Total long-term investments	<u>\$ 2,600,174</u>	<u>\$ 369,307</u>	<u>\$ 4,080</u>	<u>\$ 6,479,554</u>
<b>Short-term investments</b>				
Cash and other	\$ 175,945	\$ -	\$ -	\$ 175,945
Total short-term investments	<u>\$ 175,945</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 175,945</u>

Level 3 activity was not significant for either of the years ended August 31, 2023 or 2022.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

The following tables represent NYU's investments measured at NAV as a practical expedient by asset class and the respective liquidity terms as of August 31, 2023 and 2022:

<b>2023</b>				
<b>Asset Category</b>	<b>Redemption Frequency</b>		<b>Redemption</b>	<b>Fair Value</b>
<b>Redeemable Alternative Investments</b>	<b>(if currently eligible)</b>		<b>Notice Period</b>	
Public equity	Daily, Weekly, Monthly, Quarterly, Annual		1 to 365 days	\$ 1,477,590
Hedge funds	Monthly, Quarterly, Semi-Annual, Annual, Bi-Annual		15 to 365 days	890,061
				<u>2,367,651</u>
<b>Nonredeemable Alternative Investments</b>	<b>Remaining Life</b>	<b>Time To Draw Commitment</b>	<b>Unfunded Commitments</b>	<b>Fair Value</b>
Private equity	Up to 13 years	7–14 days	\$ 919,765	\$ 911,695
Credit	Up to 6 years	7–14 days	108,706	235,150
Real assets	Up to 2 years	7–14 days	2,450	38,376
Real estate	Up to 12 years	7–14 days	313,957	316,093
			<u>\$ 1,344,878</u>	<u>1,501,314</u>
				<u>\$ 3,868,965</u>

<b>2022</b>				
<b>Asset Category</b>	<b>Redemption Frequency</b>		<b>Redemption</b>	<b>Fair Value</b>
<b>Redeemable Alternative Investments</b>	<b>(if currently eligible)</b>		<b>Notice Period</b>	
Public equity	Daily, Weekly, Monthly, Quarterly, Annually		1 to 90 days	\$ 1,334,845
Hedge funds	Monthly, Quarterly, Semi-Annual, Annual, Bi-Annual		15 to 100 days	818,719
				<u>2,153,564</u>
<b>Nonredeemable Alternative Investments</b>	<b>Remaining Life</b>	<b>Time To Draw Commitment</b>	<b>Unfunded Commitments</b>	<b>Fair Value</b>
Private equity	Up to 10 years	7–14 days	\$ 888,993	\$ 814,670
Credit	Up to 7 years	7–14 days	99,950	203,241
Real assets	Up to 3 years	7–14 days	2,682	57,832
Real estate	Up to 13 years	7–14 days	303,828	276,686
			<u>\$ 1,295,453</u>	<u>1,352,429</u>
				<u>\$ 3,505,993</u>



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

*(in thousands of dollars)*

NYU maintains an investment pool for its long-term investments which include its endowment and similar funds. The pool is managed to achieve the maximum long-term return given prudent risk parameters. NYU relies on a total return strategy, the objective of which is to achieve a long-term rate of return consisting of a combination of current income and capital appreciation, recognizing that changes in market conditions and interest rates will result in varying strategies in an attempt to optimize results. Investment return (realized and unrealized net gains or losses, interest and dividends) and the appropriation for the approved endowment distribution for board-designated endowment funds are reported as nonoperating activities in the consolidated statements of activities. Investment return and the appropriation for the approved endowment distribution for donor-restricted endowment funds are reported as changes in net assets with donor restrictions in the consolidated statements of activities.

NYU's Board of Trustees has authorized an endowment spending policy designed to allow asset growth while providing a predictable flow of return to support activities. Distributions from the endowment to support activities (approximately 4.5% in 2023 and 2022) are based on a fixed percentage of the 12-quarter average market value. To preserve the endowment's purchasing power, the endowment spending policy considers several factors including the purpose of the endowment funds, general economic conditions, the effect of inflation or deflation, expected return, availability of alternative sources of funding, and the investment policy.

**6. Accounts and Loans Receivable, Net**

Accounts and loans receivable, net of allowances for uncollectable amounts, consist of the following at August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
Students and other	\$ 272,488	\$ 257,059
Grants and contracts	220,737	217,977
Student loans	59,617	77,764
FEMA award receivable	91,570	104,477
Housing loans and other loans to employees	58,996	59,258
Insurance premiums and recoveries (Note 13)	190,227	199,763
	<u>893,635</u>	<u>916,298</u>
Allowance for uncollectible amounts	<u>(59,885)</u>	<u>(68,449)</u>
Accounts and loans receivable, net	<u>\$ 833,750</u>	<u>\$ 847,849</u>

Student loans consist primarily of Federal advances to the University under Perkins and other Federal loan programs which totaled \$21,305 and \$41,015 at August 31, 2023 and 2022, respectively. NYU records a liability on its consolidated balance sheets for these advances within funds held for others.

A reasonable estimate of the fair value of loans receivable from students under government loan programs could not be made because the notes cannot be sold and can only be assigned to the U.S. government or its designees. The fair value of loans receivable from students under NYU's loan programs approximates carrying value.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

Housing loans and other loans to employees are secured by an interest in the underlying property or continued employment.

NYU Langone Health has a balance due from FEMA of \$74,336 at August 31, 2023 and 2022, for reimbursement of eligible operating expenses and capital expenditures relating to COVID, as well as a balance due of \$17,234 and \$30,141 at August 31, 2023 and 2022, respectively, relating to hazard mitigation projects as a result of Superstorm Sandy.

Management regularly assesses the adequacy of the allowance for credit losses by performing ongoing evaluation of the accounts and loans receivable portfolios.

**7. Contributions Receivable**

Contributions receivable consist of the following at August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
<b>Amounts expected to be collected in</b>		
Less than one year	\$ 265,474	\$ 279,816
One to five years	376,646	313,822
More than five years	197,916	149,588
	<u>840,036</u>	<u>743,226</u>
Discount	(46,130)	(29,295)
Allowance for uncollectible amounts	(99,257)	(91,715)
	<u>\$ 694,649</u>	<u>\$ 622,216</u>
Contributions receivable, net		

Contributions receivable activity for the years ended August 31, 2023 and 2022 is as follows:

	<b>2023</b>	<b>2022</b>
Contributions receivable, gross, beginning of year	\$ 743,226	\$ 753,176
New pledges received	290,320	178,243
Adjustments and write-offs	(14,006)	(6,803)
Pledge payments received	(179,504)	(181,390)
	<u>840,036</u>	<u>743,226</u>
Contributions receivable, gross, end of year		
Discount and allowance for uncollectible amounts	(145,387)	(121,010)
	<u>\$ 694,649</u>	<u>\$ 622,216</u>
Contributions receivable, net, end of year		

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

Conditional promises to give are not reported in the consolidated balance sheets and consist of the following as of August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
Bequests	\$ 1,158,403	\$ 791,304
Intentions to give	106,674	123,674
Conditional promises to give	<u>316,213</u>	<u>323,871</u>
	<u>\$ 1,581,290</u>	<u>\$ 1,238,849</u>

Expenses related to fundraising activities are \$60,591 and \$57,563 for the years ended August 31, 2023 and 2022, respectively.

**8. Other Assets**

Other assets consist of the following at August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
Deferred compensation plan assets held for others	\$ 530,882	\$ 452,035
Prepaid expenses and deferred charges	221,029	208,351
Supplies inventory	210,329	189,964
Intangible assets and goodwill	51,105	51,199
Third-party payor receivables	75,755	32,256
Split-interest agreements	38,078	36,553
Net benefit asset (Note 14)	17,882	-
Other	<u>108,079</u>	<u>103,712</u>
Other assets	<u>\$ 1,253,139</u>	<u>\$ 1,074,070</u>

Deferred compensation plan assets held for others represent employee contributions and investment return for NYU's 457(b) plans. A corresponding obligation is recorded within funds held for others on the consolidated balance sheets.

NYU invests in various retirement plan assets as part of the deferred compensation plans. In addition to the asset classes described in Note 5, investments held by the deferred compensation plans also include:

**Variable Annuity**

Variable annuity contracts invest in a variety of public equity securities to generate varying rates of return based on the underlying public equities.

**Fixed Income Annuity**

Fixed income annuities are used to purchase a guaranteed amount of future retirement benefits.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

The following tables summarize the fair value of other assets at August 31, 2023 and 2022:

	<b>2023</b>			<b>Total</b>
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	
<b>Other financial instruments</b>				
Split-interest agreements	\$ -	\$ -	\$ 38,078	\$ 38,078
<b>Deferred compensation plan assets held for others</b>				
Variable annuity contracts	\$ 161,464	\$ 54,805	\$ -	\$ 216,269
Fixed income annuities	20,128	6,186	51,883	78,197
Public equity	232,706	3,710	-	236,416
Total deferred compensation plan assets held for others	<u>\$ 414,298</u>	<u>\$ 64,701</u>	<u>\$ 51,883</u>	<u>\$ 530,882</u>
<b>2022</b>				
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	<b>Total</b>
<b>Other financial instruments</b>				
Split-interest agreements	\$ -	\$ -	\$ 36,553	\$ 36,553
<b>Deferred compensation plan assets held for others</b>				
Variable annuity contracts	\$ 131,453	\$ 51,921	\$ -	\$ 183,374
Fixed income annuities	23,200	7,503	48,609	79,312
Public equity	187,551	1,798	-	189,349
Total deferred compensation plan assets held for others	<u>\$ 342,204</u>	<u>\$ 61,222</u>	<u>\$ 48,609</u>	<u>\$ 452,035</u>

Level 3 activity was not significant for either of the years ended August 31, 2023 or 2022.

**9. Deposits with Trustees**

Deposits with Trustees include unexpended bond proceeds to fund various construction projects held by the trustee, the Dormitory Authority of the State of New York (DASNY), and debt service funds, consist of the following at August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
Construction funds held by DASNY	\$ 322,870	\$ 597,930
Debt service reserve funds	20,396	23,929
Other	1,102	1,092
	<u>\$ 344,368</u>	<u>\$ 622,951</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

The following tables summarize the fair value of deposits with trustees at August 31, 2023 and 2022 according to the asset categories defined in Note 5.

	<b>2023</b>			<b>Total</b>
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	
Fixed income	\$ 216,562	\$ 119,032	\$ -	\$ 335,594
Cash and other	8,774	-	-	8,774
Total deposits with trustees	<u>\$ 225,336</u>	<u>\$ 119,032</u>	<u>\$ -</u>	<u>\$ 344,368</u>

  

	<b>2022</b>			<b>Total</b>
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	
Fixed income	\$ 432,955	\$ -	\$ -	\$ 432,955
Cash and other	189,996	-	-	189,996
Total deposits with trustees	<u>\$ 622,951</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 622,951</u>

**10. Land, Buildings, and Equipment**

Land, buildings, and equipment consist of the following at August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
Land	\$ 403,038	\$ 403,038
Buildings and building improvements	16,704,403	14,831,709
Equipment	3,831,432	3,289,833
Finance leases	1,852,624	1,606,877
Construction in progress	1,349,040	2,009,444
	<u>24,140,537</u>	<u>22,140,901</u>
Less: Accumulated depreciation	<u>(9,620,758)</u>	<u>(8,616,814)</u>
Land, buildings, and equipment, net	<u>\$ 14,519,779</u>	<u>\$ 13,524,087</u>

Depreciation expense is \$1,020,036 and \$968,151 for the years ended August 31, 2023 and 2022, respectively.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

**11. Leases**

The components of lease expense included in the consolidated statements of activities consist of the following for the years ended August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
<b>Lease cost</b>		
Finance lease cost		
Amortization of assets held under finance leases	\$ 88,994	\$ 89,946
Interest on finance lease obligations	74,726	63,840
Total finance lease cost	<u>163,720</u>	<u>153,786</u>
Operating lease cost	316,346	313,461
Short-term and variable lease costs	40,042	46,669
Total operating lease cost included in facilities costs	<u>356,388</u>	<u>360,130</u>
Total lease cost	<u>\$ 520,108</u>	<u>\$ 513,916</u>
<b>Other information</b>		
Cash paid for amounts included in the measurement of lease obligations		
Operating cash flows for operating leases	\$ 296,942	\$ 292,073
Operating cash flows for finance leases	74,726	63,840
Financing cash flows for finance leases	56,463	66,235
Right-of-use assets obtained		
In exchange for new operating lease obligations	\$ 205,015	\$ 249,270
In exchange for new finance lease obligations (Note 10)	233,624	50,243
Weighted-average remaining lease term		
Operating leases	18.3 years	18.2 years
Operating leases excluding ground lease through 2087	11.8 years	11.8 years
Finance leases	26.7 years	26.6 years
Weighted-average discount rate		
Operating leases	3.20 %	2.79 %
Finance leases	4.01 %	3.83 %

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

(in thousands of dollars)

Aggregate future minimum lease payments under operating leases as of August 31, 2023 are as follows:

2024	\$ 298,889
2025	288,538
2026	254,353
2027	227,353
2028	176,718
Thereafter	<u>1,917,193</u>
Total minimum lease payments	3,163,044
Less: Imputed interest	<u>(936,682)</u>
Total operating lease obligation	<u>\$ 2,226,362</u>

The difference between fixed operating lease payments and lease expense on a straight line basis is \$186,137 at August 31, 2023 and is recorded as a reduction to the operating ROU asset on the consolidated balance sheet.

## 12. Debt and Other Obligations

NYU has various bond issues outstanding, primarily issued through DASNY. The University and NYU Schools of Medicine are considered the legally obligated group for certain borrowings presented below as the "Obligated Group."

Debt and other obligations consist of the following at August 31, 2023 and 2022:

Issuer	2023				Consolidated NYU
	University	NYU Schools of Medicine	Total Obligated Group	Health System	
Dormitory Authority of the State of New York (DASNY)	\$ 3,581,126	\$ 785,226	\$ 4,366,352	\$ 770,279	\$ 5,136,631
New York University	234,395	52,616	287,011	-	287,011
NYU Langone Hospitals	-	-	-	2,040,206	2,040,206
Nassau County Local Economic Assistance Corporation	-	-	-	26,576	26,576
Brookhaven Local Development Corporation	-	-	-	82,199	82,199
Other obligations	<u>165,640</u>	<u>1,590,156</u>	<u>1,755,796</u>	<u>339,849</u>	<u>2,095,645</u>
Debt and other obligations	<u>\$ 3,981,161</u>	<u>\$ 2,427,998</u>	<u>\$ 6,409,159</u>	<u>\$ 3,259,109</u>	<u>\$ 9,668,268</u>

Issuer	2022				Consolidated NYU
	University	NYU Schools of Medicine	Total Obligated Group	Health System	
Dormitory Authority of the State of New York (DASNY)	\$ 3,696,789	\$ 808,785	\$ 4,505,574	\$ 794,135	\$ 5,299,709
New York University	245,581	57,096	302,677	-	302,677
NYU Langone Hospitals	-	-	-	2,039,751	2,039,751
Nassau County Local Economic Assistance Corporation	-	-	-	28,222	28,222
Brookhaven Local Development Corporation	-	-	-	83,866	83,866
Other obligations	<u>167,638</u>	<u>1,268,851</u>	<u>1,436,489</u>	<u>375,692</u>	<u>1,812,181</u>
Debt and other obligations	<u>\$ 4,110,008</u>	<u>\$ 2,134,732</u>	<u>\$ 6,244,740</u>	<u>\$ 3,321,666</u>	<u>\$ 9,566,406</u>

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

(in thousands of dollars)

The principal amounts outstanding for debt and other obligations consist of the following at August 31, 2023 and 2022:

	2023				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
<b>DASNY</b>					
Series 1998A bonds, with interest rates ranging from 5.75% to 6.00%, maturing serially through July 2020, payable thereafter in annual sinking fund installments to maturity in 2027 (including premium of \$770)	\$ 64,605	\$ -	\$ 64,605	\$ -	\$ 64,605
2001 Series 1 bonds, with an interest rate of 5.50%, maturing serially from July 2011, through July 2025, payable thereafter in annual sinking fund installments to maturities in July 2031 and July 2040 (including premiums of \$1,392 and \$1,794)	50,718	42,152	92,870	-	92,870
Series 2012C taxable bonds, with interest rates ranging from 1.93% to 3.62%, maturing serially through July 2027	9,225	-	9,225	-	9,225
Series 2013B taxable bonds, with interest rates ranging from 2.33% to 5.25%, maturing serially through July 2028, payable thereafter in annual sinking fund installments to maturities in July 2033 and July 2043	20,065	-	20,065	-	20,065
Series 2014 bonds, with interest rate ranging from 2.00% to 5.00%, maturing serially through July 2032 and July 2036 (including premium of \$5,737)	-	-	-	62,467	62,467
Series 2014 S2 bonds, with interest rate ranging from 3.75% to 4.95%, maturing serially through July 2034 and July 2035 (including premium of \$10,755)	-	-	-	75,820	75,820
Series 2014A taxable bonds, with an interest rate of 2.59% maturing in July 2034, payable in annual sinking fund installments through July 2034	40,205	-	40,205	-	40,205
Series 2015 bonds, with interest rates ranging from 2.00% to 5.50%, maturing serially through July 2035, payable in annual sinking fund installments from July 2036 to July 2048 (including premium of \$49,266)	585,871	-	585,871	-	585,871
Series 2016A bonds, with interest rates ranging from 2.00% to 5.00%, maturing serially through July 2036 payable thereafter in annual sinking fund installments until July 2043 (including premiums of \$48,996 and \$18,103)	439,741	132,893	572,634	-	572,634
Series 2016B taxable bonds, with interest rates ranging from 1.20% to 5.00%, maturing serially through July 2022 payable thereafter in annual sinking fund installments until July 2046	141,090	29,970	171,060	-	171,060
Series 2016A bonds, with interest rates ranging from 3.53% to 4.77%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2043 (including premium of \$16,568)	-	-	-	121,053	121,053
Series 2017A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2047 (including premium of \$25,459 and \$17,608)	273,243	157,629	430,872	-	430,872
Series 2017B taxable bonds, with interest rates ranging from 1.60% to 4.15%, maturing serially to maturity in July 2032	160,229	50,406	210,635	-	210,635
Series 2018A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$25,942 and \$8,124)	277,407	74,235	351,642	-	351,642
Series 2018B taxable bonds, with interest rates ranging from 2.27% to 4.85%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$5,758 and \$2,428)	145,899	98,638	244,537	-	244,537
Series 2019A bonds, with interest rates ranging from 4.00% to 5.00%, maturing serially through July 2049 payable thereafter in annual sinking fund installments (including premiums of \$66,418 and \$10,939)	567,114	86,744	653,858	-	653,858
Series 2019B-1 taxable bonds, with interest rates ranging from 2.76% to 4.29%, maturing serially through July 2044 payable thereafter in annual sinking fund installments	136,505	20,995	157,500	-	157,500
Series 2019B-2 taxable bonds, with an interest rate of 4.01% payable thereafter in annual sinking fund installments maturing on July 2049	77,925	5,245	83,170	-	83,170



# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

(in thousands of dollars)

	2023				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
Series 2020A bonds, with interest rates ranging from 3.00% to 4.00% maturing serially through July 2053 (including net premiums of \$50,320)	-	-	-	516,625	516,625
Series 2020B taxable bonds, with interest rates ranging from 1.29% to 2.77%, maturing serially through July 2030 and payable thereafter in annual sinking fund installments to maturity in 2043	361,145	34,665	395,810	-	395,810
Series 2021A bonds, with interest rates ranging from 0.66% to 2.23%, maturing serially through July 2041 and payable thereafter in annual sinking fund installments to maturity in 2051 (including premiums of \$37,621 and \$9,607)	210,681	49,242	259,923	-	259,923
Series 2021B taxable bonds, with interest rates ranging from 0.25% to 2.02%, maturing serially through July 2031	29,965	3,760	33,725	-	33,725
Deferred financing costs	(10,507)	(1,348)	(11,855)	(5,686)	(17,541)
Subtotal of DASNY bonds	<u>3,581,126</u>	<u>785,226</u>	<u>4,366,352</u>	<u>770,279</u>	<u>5,136,631</u>
<b>NYU</b>					
Series 2009 taxable bonds, with an interest rate of 5.24%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	10,153	52,967	63,120	-	63,120
Series 2010 taxable bonds, with an interest rate of 4.96%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	15,505	-	15,505	-	15,505
Series 2015 taxable bonds, with interest rates ranging from 1.32% to 4.14%, maturing serially through July 2028, payable in annual sinking fund installments from July 2029 to July 2048	209,415	-	209,415	-	209,415
Deferred financing costs	(678)	(351)	(1,029)	-	(1,029)
Subtotal of NYU bonds	<u>234,395</u>	<u>52,616</u>	<u>287,011</u>	<u>-</u>	<u>287,011</u>
<b>NYU Langone Hospitals</b>					
Series 2012 taxable bonds, with an interest rate of 4.40%, maturing in July 2042 (including discount of \$655)	-	-	-	249,345	249,345
Series 2013 taxable bonds, with an interest rate of 5.75%, maturing in July 2043 (including discount of \$955)	-	-	-	349,045	349,045
Series 2014 taxable bonds, with an interest rate of 4.78%, maturing in July 2044 (including discount of \$879)	-	-	-	299,121	299,121
Series 2017A taxable bonds, with an interest rate ranging from 4.17% to 4.37%, maturing in August 2047	-	-	-	600,000	600,000
Series 2020B taxable bonds, with a fixed interest rate of 3.38% to maturity in July 2055 (including a discount of \$2,441)	-	-	-	548,584	548,584
Deferred financing costs	-	-	-	(5,889)	(5,889)
Subtotal of NYU Langone Hospitals bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>2,040,206</u>	<u>2,040,206</u>
<b>Nassau County Local Economic Assistance Corporation</b>					
Series 2014 taxable bonds, with an interest rate of 2.99%, maturing in July 2036	-	-	-	26,576	26,576
Subtotal of Nassau County Local Economic Assistance Corporation bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>26,576</u>	<u>26,576</u>
<b>Brookhaven Local Development Corporation</b>					
Series 2020A taxable bond series, with varying interest rates of 4.2% to 5.0%, maturing in October 2050 (including premium of \$7,119)	-	-	-	66,254	66,254
Series 2020B taxable bond series, with varying interest rates of 5.5% to 6.0%, maturing in October 2030 (including premium of \$1,290)	-	-	-	15,945	15,945
Subtotal of Brookhaven Local Development Corporation	<u>-</u>	<u>-</u>	<u>-</u>	<u>82,199</u>	<u>82,199</u>
<b>Other obligations</b>					
Mortgage loans	-	142,137	142,137	2,179	144,316
Commercial loans	-	-	-	13,359	13,359
Lines of credit	-	35,330	35,330	-	35,330
Finance leases (Note 10)	165,640	1,412,689	1,578,329	324,311	1,902,640
Subtotal of other obligations	<u>165,640</u>	<u>1,590,156</u>	<u>1,755,796</u>	<u>339,849</u>	<u>2,095,645</u>
Total amounts outstanding	<u>\$ 3,981,161</u>	<u>\$ 2,427,998</u>	<u>\$ 6,409,159</u>	<u>\$ 3,259,109</u>	<u>\$ 9,668,268</u>

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

(in thousands of dollars)

	2022				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
<b>DASNY</b>					
Series 1998A bonds, with interest rates ranging from 5.75% to 6.00%, maturing serially through July 2020, payable thereafter in annual sinking fund installments to maturity in 2027 (including premium of \$1,134)	\$ 78,819	\$ -	\$ 78,819	\$ -	\$ 78,819
2001 Series 1 bonds, with an interest rate of 5.50%, maturing serially from July 2011, through July 2025, payable thereafter in annual sinking fund installments to maturities in July 2031 and July 2040 (including premiums of \$1,532 and \$1,900)	52,591	43,676	96,267	-	96,267
Series 2012C taxable bonds, with interest rates ranging from 1.93% to 3.62%, maturing serially through July 2027	11,440	-	11,440	-	11,440
Series 2013B taxable bonds, with interest rates ranging from 2.33% to 5.25%, maturing serially through July 2028, payable thereafter in annual sinking fund installments to maturities in July 2033 and July 2043	21,480	-	21,480	-	21,480
Series 2014 bonds, with interest rate ranging from 2.00% to 5.00%, maturing serially through July 2032 and July 2036 (including premium of \$6,181)	-	-	-	66,316	66,316
Series 2014 S2 bonds, with interest rate ranging from 3.75% to 4.95%, maturing serially through July 2034 and July 2035 (including premium of \$11,651)	-	-	-	81,011	81,011
Series 2014A taxable bonds, with an interest rate of 2.59% maturing in July 2034, payable in annual sinking fund installments through July 2034	43,325	-	43,325	-	43,325
Series 2015 bonds, with interest rates ranging from 2.00% to 5.50%, maturing serially through July 2035, payable in annual sinking fund installments from July 2036 to July 2048 (including premium of \$53,181)	607,220	-	607,220	-	607,220
Series 2016A bonds, with interest rates ranging from 2.00% to 5.00%, maturing serially through July 2036 payable thereafter in annual sinking fund installments until July 2043 (including premiums of \$53,663 and \$18,896)	458,323	137,471	595,794	-	595,794
Series 2016B taxable bonds, with interest rates ranging from 1.20% to 5.00%, maturing serially through July 2022 payable thereafter in annual sinking fund installments until July 2046	141,090	29,970	171,060	-	171,060
Series 2016A bonds, with interest rates ranging from 3.53% to 4.77%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2043 (including premium of \$17,557)	-	-	-	134,302	134,302
Series 2017A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2047 (including premium of \$28,967 and \$18,347)	289,387	161,677	451,064	-	451,064
Series 2017B taxable bonds, with interest rates ranging from 1.60% to 4.15%, maturing serially to maturity in July 2032	163,804	50,406	214,210	-	214,210
Series 2018A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$28,402 and \$8,453)	287,892	76,523	364,415	-	364,415
Series 2018B taxable bonds, with interest rates ranging from 2.27% to 4.85%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$6,029 and \$2,526)	146,170	100,371	246,541	-	246,541
Series 2019A bonds, with interest rates ranging from 4.00% to 5.00%, maturing serially through July 2049 payable thereafter in annual sinking fund installments (including premiums of \$71,254 and \$11,362)	581,380	87,167	668,547	-	668,547
Series 2019B-1 taxable bonds, with interest rates ranging from 2.76% to 4.29%, maturing serially through July 2044 payable thereafter in annual sinking fund installments	136,505	27,375	163,880	-	163,880
Series 2019B-2 taxable bonds, with an interest rate of 4.01% payable thereafter in annual sinking fund installments maturing on July 2049	77,925	5,245	83,170	-	83,170

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

(in thousands of dollars)

	2022				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
Series 2020A bonds, with interest rates ranging from 3.00% to 4.00% maturing serially through July 2053 (including net premiums of \$52,195)	-	-	-	518,500	518,500
Series 2020B taxable bonds, with interest rates ranging from 1.29% to 2.77%, maturing serially through July 2030 and payable thereafter in annual sinking fund installments to maturity in 2043	368,150	36,255	404,405	-	404,405
Series 2021A bonds, with interest rates ranging from 0.66% to 2.23%, maturing serially through July 2041 and payable thereafter in annual sinking fund installments to maturity in 2051 (including premiums of \$39,679 and \$9,951)	212,739	49,586	262,325	-	262,325
Series 2021B taxable bonds, with interest rates ranging from 0.25% to 2.02%, maturing serially through July 2031	29,965	4,495	34,460	-	34,460
Deferred financing costs	(11,416)	(1,432)	(12,848)	(5,994)	(18,842)
Subtotal of DASNY bonds	<u>3,696,789</u>	<u>808,785</u>	<u>4,505,574</u>	<u>794,135</u>	<u>5,299,709</u>
<b>NYU</b>					
Series 2009 taxable bonds, with an interest rate of 5.24%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	11,019	57,486	68,505	-	68,505
Series 2010 taxable bonds, with an interest rate of 4.96%, maturing in July 2032, payable in annual sinking fund installments from July 2018 through July 2032	16,830	-	16,830	-	16,830
Series 2015 taxable bonds, with interest rates ranging from 1.32% to 4.14%, maturing serially through July 2028, payable in annual sinking fund installments from July 2029 to July 2048	218,485	-	218,485	-	218,485
Deferred financing costs	(753)	(390)	(1,143)	-	(1,143)
Subtotal of NYU bonds	<u>245,581</u>	<u>57,096</u>	<u>302,677</u>	<u>-</u>	<u>302,677</u>
<b>NYU Langone Hospitals</b>					
Series 2012 taxable bonds, with an interest rate of 4.40%, maturing in July 2042 (including discount of \$690)	-	-	-	249,310	249,310
Series 2013 taxable bonds, with an interest rate of 5.75%, maturing in July 2043 (including discount of \$1,003)	-	-	-	348,997	348,997
Series 2014 taxable bonds, with an interest rate of 4.78%, maturing in July 2044 (including discount of \$921)	-	-	-	299,079	299,079
Series 2017A taxable bonds, with an interest rate ranging from 4.17% to 4.37%, maturing in August 2047	-	-	-	600,000	600,000
Series 2020B taxable bonds, with a fixed interest rate of 3.38% to maturity in July 2055 (including a discount of \$2,518)	-	-	-	548,507	548,507
Deferred financing costs	-	-	-	(6,142)	(6,142)
Subtotal of NYU Langone Hospitals bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>2,039,751</u>	<u>2,039,751</u>
<b>Nassau County Local Economic Assistance Corporation</b>					
Series 2014 taxable bonds, with an interest rate of 2.99%, maturing in July 2036	-	-	-	28,222	28,222
Subtotal of Nassau County Local Economic Assistance Corporation bonds	<u>-</u>	<u>-</u>	<u>-</u>	<u>28,222</u>	<u>28,222</u>
<b>Brookhaven Local Development Corporation</b>					
Series 2020A taxable bond series, with varying interest rates of 4.2% to 5.0%, maturing in October 2050 (including premium of \$7,381)	-	-	-	66,516	66,516
Series 2020B taxable bond series, with varying interest rates of 5.5% to 6.0%, maturing in October 2030 (including premium of \$1,470)	-	-	-	17,350	17,350
Subtotal of Brookhaven Local Development Corporation	<u>-</u>	<u>-</u>	<u>-</u>	<u>83,866</u>	<u>83,866</u>
<b>Other obligations</b>					
Mortgage loans	-	39,095	39,095	6,954	46,049
Commercial loans	-	-	-	14,277	14,277
Lines of credit	-	43,030	43,030	-	43,030
Finance leases (Note 10)	167,638	1,186,726	1,354,364	354,461	1,708,825
Subtotal of other obligations	<u>167,638</u>	<u>1,268,851</u>	<u>1,436,489</u>	<u>375,692</u>	<u>1,812,181</u>
Total amounts outstanding	<u>\$ 4,110,008</u>	<u>\$ 2,134,732</u>	<u>\$ 6,244,740</u>	<u>\$ 3,321,666</u>	<u>\$ 9,566,406</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

Interest expense on debt and other obligations totaled \$372,396 and \$368,647 for the years ended August 31, 2023 and 2022, respectively. This excludes \$20,401 and \$18,934 of interest capitalized (net of income earned on deposits with bond trustees) for the years ended August 31, 2023 and 2022, respectively, which is included in land, buildings, and equipment, net.

NYU enters into various debt and other loan agreements that are secured by specific revenue streams, collateral and other real property or improvements, in addition to issuing debt supported by a general obligation of the University, any of which may constrain the use of certain assets. Other agreements include covenants requiring that NYU Langone Hospitals maintains certain financial ratios. At August 31, 2023 and 2022, the Obligated Group and NYU Langone Hospitals is compliant with all financial and administrative covenants.

**Obligations with Financial Institutions**

At both August 31, 2023 and 2022, the Obligated Group has three contractually committed bank credit agreements which total \$800,000. As of August 31, 2023, these agreements expire from August 2024 to March 2026. Interest is accrued at rates based on the Bloomberg Short-Term Bank Yield Index and the Secured Overnight Financing Rate. The amounts outstanding under these agreements are \$35,330 and \$43,030 as of August 31, 2023 and 2022, respectively.

At August 31, 2023 and 2022, NYU Langone Hospitals has four unsecured lines of credit totaling \$679,800 and \$689,800, respectively. As of August 31, 2023 these agreements expire from April 2024 to September 2025. Interest is accrued at rates based on the Secured Overnight Financing Rate. There were no amounts outstanding as of August 31, 2023 and 2022, respectively.

**Future Principal Payments**

The aggregate required principal payments on all debt and other obligations, including capital leases, for each of the next five fiscal years, and thereafter to maturity, are as follows:

Year Ending August 31,	Debt and Other Obligations	Finance Leases	Total
2024	\$ 168,184	\$ 117,148	\$ 285,332
2025	210,981	109,691	320,672
2026	178,449	109,728	288,177
2027	286,025	74,906	360,931
2028	172,497	102,208	274,705
Thereafter	<u>6,356,870</u>	<u>2,837,464</u>	<u>9,194,334</u>
	7,373,006	3,351,145	10,724,151
Unamortized premiums and discounts, net	417,081	-	417,081
Unamortized deferred financing costs	(24,459)	-	(24,459)
Less: Imputed interest	-	(1,448,505)	(1,448,505)
	<u>\$ 7,765,628</u>	<u>\$ 1,902,640</u>	<u>\$ 9,668,268</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

**13. Professional Liabilities**

NYU Langone Hospitals' professional liabilities are reported on a discounted basis and comprise estimates for known reported losses and loss expenses plus a provision for losses incurred but not reported. Losses are actuarially determined and are based on the loss experience of the insured. In management's opinion, recorded reserves for both self-insured and commercially insured exposures are adequate to cover the ultimate net cost of losses incurred to date; however, the provision is based on estimates and may ultimately be settled for a significantly greater or lesser amount.

Professional liabilities consist of the following as of August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
CCC550 professional liabilities	\$ 840,264	\$ 771,867
Self-insured liabilities	45,200	50,900
LICH self-insured liabilities	30,147	31,400
Commercially insured liabilities	<u>51,426</u>	<u>63,062</u>
Professional liabilities	<u>\$ 967,037</u>	<u>\$ 917,229</u>

NYU Langone Hospitals is self-insured for professional and general liabilities on an occurrence basis through CCC550. CCC550 provides insurance coverage to certain voluntary attending physicians and other nonemployed physicians serving NYUGSoM and NYU Langone Hospitals. The cost of this insurance coverage is the responsibility of such physicians.

Prior to July 1, 2017, NYU Langone Hospital-Long Island was self-insured for professional liabilities and designated funds in a revocable trust for satisfaction of claims and expenses. LICH is self-insured for professional liabilities.

Commercially insured liabilities relate to policies purchased by NYU Langone Hospital-Brooklyn and NYU Langone Hospital-Long Island (for certain of its physicians) covering periods prior to October 1, 2015 and July 1, 2017, respectively. NYU Langone Hospitals recorded a corresponding insurance recovery receivable for claims covered by these policies within accounts and loans receivable, net on the consolidated balance sheets (Note 6).

Assets held for professional liabilities consist of the following at August 31, 2023 and 2022:

	<b>2023</b>	<b>2022</b>
Assets held by CCC550	\$ 1,044,422	\$ 899,260
Self-insurance trust	<u>52,178</u>	<u>51,736</u>
Assets held for professional liabilities	<u>\$ 1,096,600</u>	<u>\$ 950,996</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

The following tables summarize the fair value of assets held for professional liabilities at August 31, 2023 and 2022 according to the asset categories defined in Note 5:

	2023			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 109,292	\$ 788,926	\$ -	\$ 898,218
Equity	169,547	-	-	169,547
Cash and other	28,835	-	-	28,835
Total assets held for professional liabilities	<u>\$ 307,674</u>	<u>\$ 788,926</u>	<u>\$ -</u>	<u>\$ 1,096,600</u>

  

	2022			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 51,736	\$ 726,287	\$ -	\$ 778,023
Equity	135,376	-	-	135,376
Cash and other	37,597	-	-	37,597
Total assets held for professional liabilities	<u>\$ 224,709</u>	<u>\$ 726,287</u>	<u>\$ -</u>	<u>\$ 950,996</u>

**14. Pension Plans and Other Postretirement Benefits**

**Pension Plans**

Substantially all NYU employees are covered by retirement plans including various defined contribution plans, multi-employer defined benefit plans, and three NYU-sponsored benefit plans.

*Defined Contribution Plans*

Contributions to the defined contribution plans are based on rates required by union contracts or other contractual arrangements. Contributions of \$331,747 and \$302,766 in 2023 and 2022, respectively, are reported as expenses in the consolidated statements of activities. There is no obligation on the consolidated balance sheets for these plans.

*Multi-Employer Defined Benefit Plans*

Contributions to the multi-employer defined benefit plans are based on rates required by union contracts and other contractual arrangements. Contributions of \$266,009 and \$230,010 in 2023 and 2022, respectively, are reported as expenses in the consolidated statements of activities. There is no obligation on the consolidated balance sheets for these plans.

*Defined Benefit Plans*

Contributions to the three defined benefit plans are intended to provide benefits attributed to service to date, as well as for those expected to be earned in the future. Contributions are made in amounts sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974 as amended under the Pension Protection Act of 2006 (ERISA), plus such additional amounts as the sponsors may deem appropriate. Pension benefits under these defined benefit plans are based on participants' final average compensation levels and years of service and are accrued during the period the employees provide service to NYU. Contributions of \$17,450 and \$16,699 in 2023 and 2022, respectively, are reported as a reduction in the accrued benefit obligation on the consolidated balance sheets for these plans.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

**Postretirement Benefits**

NYU has three defined benefit health and welfare plans that provide certain health care and life insurance benefits for eligible retired employees. NYU employees may become eligible for these benefits if they reach the age and service requirements of the plan while working for NYU. The costs related to these plans are accrued during the period the employees provide service to NYU. Contributions of \$28,750 and \$28,178 in 2023 and 2022, respectively, are reported as a reduction in the accrued postretirement obligation on the consolidated balance sheets for these plans.

The following tables provide information with respect to the defined benefit and other postretirement benefit plans for the years ended August 31:

**Plans' Funded Status**

	Defined Benefit Pension Plans		Postretirement Benefit Plans	
	2023	2022	2023	2022
<b>Change in benefit obligation</b>				
Benefit obligation as of beginning of year	\$ 2,214,034	\$ 2,892,896	\$ 705,504	\$ 850,054
Service cost	38,507	59,031	14,992	22,395
Interest cost	103,033	70,614	32,313	23,775
Actuarial gain	(204,325)	(698,354)	(53,138)	(169,265)
Benefits paid	(102,984)	(108,705)	(32,221)	(30,310)
Participant contributions	-	-	8,725	7,947
Retiree drug subsidy receipts	-	-	1,131	908
Administrative expenses	(2,049)	(1,448)	-	-
Benefit obligation as of end of year	2,046,216	2,214,034	677,306	705,504
<b>Change in fair value of plan assets</b>				
Fair value of plan assets as of beginning of year	1,815,316	2,355,449	194,766	217,344
Actual return on plan assets	107,278	(446,679)	19,338	(29,301)
Employer contributions	17,450	16,699	28,750	28,178
Benefits paid	(102,984)	(108,705)	(32,221)	(30,310)
Participant contributions	-	-	8,725	7,947
Retiree drug subsidy receipts	-	-	1,131	908
Administrative expenses	(2,049)	(1,448)	-	-
Fair value of plan assets, end of year	1,835,011	1,815,316	220,489	194,766
Net benefit asset (Note 8)	(17,882)	-	-	-
Accrued benefit obligation	\$ 229,087	\$ 398,718	\$ 456,817	\$ 510,738
<b>Benefit obligation range of assumptions as of August 31</b>				
Discount rate	5.30%–5.61%	4.70%–4.95%	5.24%–5.57%	4.65%–4.91%
Rate of increase in compensation levels	2.91%–6.00%	2.91%–5.00%	N/A	N/A

The accumulated benefit obligation for the defined benefit pension plans is \$1,941,263 and \$2,078,546 at August 31, 2023 and 2022, respectively.

Actuarial gains were the result of asset returns in excess of planned return as well as changes in discount rates and plan experience for the year ended August 31, 2023 and 2022.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

**Net Periodic Benefit Cost**

	<b>Defined Benefit Pension Plans</b>		<b>Postretirement Benefit Plans</b>	
	<b>2023</b>	<b>2022</b>	<b>2023</b>	<b>2022</b>
<b>Components of net periodic benefit cost</b>				
Operating expense				
Service cost in salary and fringe	\$ 38,507	\$ 59,031	\$ 14,992	\$ 22,395
Nonoperating expense				
Interest cost	103,033	70,614	32,313	23,775
Expected return on plan assets	(139,431)	(147,122)	(11,602)	(13,014)
Amortization of prior service credit	-	-	(4,113)	(4,113)
Amortization of actuarial loss	-	32,723	930	10,966
Total nonservice costs	<u>(36,398)</u>	<u>(43,785)</u>	<u>17,528</u>	<u>17,614</u>
Net periodic benefit cost	<u>\$ 2,109</u>	<u>\$ 15,246</u>	<u>\$ 32,520</u>	<u>\$ 40,009</u>
<b>Other changes recognized in net assets without donor restrictions</b>				
Actuarial net gain arising during period	\$ (172,171)	\$ (104,554)	\$ (60,875)	\$ (126,949)
Amortization of prior service credit	-	-	4,113	4,113
Amortization of actuarial loss	-	(32,723)	(930)	(10,966)
Total changes in pension and postretirement obligations	<u>\$ (172,171)</u>	<u>\$ (137,277)</u>	<u>\$ (57,692)</u>	<u>\$ (133,802)</u>
<b>Net periodic benefit cost range of assumptions</b>				
Discount rate	4.70%–5.00%	2.32%–3.15%	4.89%–5.25%	2.80%–2.95%
Rate of increase in compensation levels	2.91%–5.00%	2.91%–5.00%	N/A	N/A
Expected long-term rate of return on plan assets	6.00%–7.00%	6.00%–7.00%	6.00%–7.00%	6.00%–7.00%
Initial healthcare cost trend	N/A	N/A	6.50%–10.05%	6.50%–9.19%
Ultimate retiree health-care cost trend	N/A	N/A	4.50%	4.50%
Year ultimate trend rate is achieved	N/A	N/A	2030–2032	2024–2031

Amounts not yet reflected in net periodic benefit cost and included in net assets without donor restrictions for the defined benefit pension plans totaled \$119,818 and \$291,989 for the years ended August 31, 2023 and 2022, respectively. Amounts not yet reflected in net periodic benefit cost and included in net assets without donor restrictions for the postretirement benefit plans totaled (\$107,965) and (\$50,274) for the years ended August 31, 2023 and 2022, respectively.

**Plan Assets**

The following table presents the fair value of the defined benefit plan investments at August 31, 2023 and 2022 according to the asset categories defined in Note 5:

	<b>2023</b>			<b>Total</b>
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	
Public equity	\$ 734,669	\$ 304,102	\$ -	\$ 1,038,771
Fixed income	484,655	240,254	-	724,909
Cash and other	70,894	-	-	70,894
	<u>\$ 1,290,218</u>	<u>\$ 544,356</u>	<u>\$ -</u>	<u>1,834,574</u>
Alternative investments measured at NAV as a practical expedient				<u>437</u>
				<u>\$ 1,835,011</u>



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

	<b>2022</b>			
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	<b>Total</b>
Public equity	\$ 821,255	\$ 260,154	\$ -	\$ 1,081,409
Fixed income	396,333	247,713	-	644,046
Real estate	17,484	-	-	17,484
Cash and other	71,853	-	-	71,853
	<u>\$ 1,306,925</u>	<u>\$ 507,867</u>	<u>\$ -</u>	<u>1,814,792</u>
Alternative investments measured at NAV as a practical expedient				<u>524</u>
				<u>\$ 1,815,316</u>

The defined benefit pension assets seek to: (1) provide retirement benefits to its participants and beneficiaries; and (2) achieve full funding of the pension liability, while incurring an acceptable level of risk for the sponsor. The pension liability growth rate together with the objective to achieve and maintain a fully-funded level over a reasonable timeline implies a minimum absolute rate of return to be met through either: (1) annual budgeted contributions, (2) pension assets growth, (3) plan de-risking improvements, or (4) a combination thereof.

The strategy for achieving and maintaining a fully funded pension liability may vary with the prevailing funded level and other parameters related to the overall goal. The asset allocation process is designed to be dynamic and employ a liability-driven, glide path investment strategy, which reframes risk and performance relative to the pension liability. This approach is expected to enable pension assets to more reliably track the value of the pension liability, with less funded level volatility, than a static total-return investment. Broad target allocations at the current funded level are 55-75% return-seeking assets, such as equity and real estate (REIT) funds, and 25-45% liability-hedging assets, such as fixed income funds. The expected long-term rate of return assumption is determined by adding expected inflation to expected long-term real returns of various asset classes, weighing the asset class returns by the plans' investment in each class, and taking into account expected volatility and correlation between the returns of various asset classes. NYU management believes 6-7% is a reasonable estimate of long-term rates of return on plan assets for 2023 and will continue to evaluate the actuarial assumptions and adjust them as necessary.

The following table presents the fair value of the postretirement benefit plan investments at August 31, 2023 and 2022 according to the asset categories defined in Note 5:

	<b>2023</b>			
	<b>Active Markets (Level 1)</b>	<b>Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>	<b>Total</b>
Public equity	\$ 149,162	\$ -	\$ -	\$ 149,162
Fixed income	64,207	7,120	-	71,327
	<u>\$ 213,369</u>	<u>\$ 7,120</u>	<u>\$ -</u>	<u>\$ 220,489</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

	2022			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Public equity	\$ 128,620	\$ -	\$ -	\$ 128,620
Fixed income	55,844	10,174	-	66,018
Cash and other	128	-	-	128
	<u>\$ 184,592</u>	<u>\$ 10,174</u>	<u>\$ -</u>	<u>\$ 194,766</u>

The plans' investment objectives seek a long-term total rate of return to meet NYU's current and future plan obligations.

The postretirement benefit plan target asset allocation mix is 70% equity and 30% fixed income and cash, for which each asset class has a permitted range of +/- 10%.

The expected long-term rate of return assumption is determined by adding expected inflation to expected long-term real returns of various asset classes, taking into account expected volatility and correlation between the returns of various asset classes. NYU management believes that 6%-7% is a reasonable range of long-term rates of return on plan assets for 2023 and will continue to evaluate the actuarial assumptions and adjust them as necessary.

**Contributions**

NYU determines the annual contributions to the plans based upon calculations prepared by the plans' actuaries. Total expected contributions for the defined benefit pension plans and other postretirement benefit plans in fiscal year 2024 are \$43,943 and \$34,145, respectively.

**Benefit Payments**

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid in the following years:

Year Ending August 31,	Defined Benefit Pension Plans	Postretirement Benefit Plans
2024	\$ 106,643	\$ 33,267
2025	111,341	34,888
2026	116,737	36,807
2027	121,839	38,834
2028	127,109	41,027
2029-2033	697,667	233,839

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

**Multi-Employer Benefit Plans**

NYU participates in multi-employer defined benefit pension plans. NYU makes cash contributions to these plans under the terms of collective-bargaining agreements that cover its union employees based on a fixed rate and hours worked per week by the covered employees. The risks of participating in these multi-employer plans are different from other single-employer plans in the following aspects: (1) assets contributed to the multi-employer plan by one employer may be used to provide benefits to employees of other participating employers; (2) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers; and (3) if NYU chooses to stop participating in some of its multi-employer plans, NYU may be required to pay those plans an amount based on the underfunded status of the plan, referred to as a withdrawal liability.

NYU's contributions to the following multi-employer defined benefit pension and postretirement plans are reported as salary and fringe expenses in the consolidated statements of activities for the years ended August 31, 2023 and 2022:

	2023	2022
1199 SEIU Health Care Employees Health & Welfare Fund	\$ 169,469	\$ 143,426
1199 SEIU Health Care Employees Pension Fund	64,593	57,130
United Federation of Teachers Welfare Fund	19,758	19,992
Local 810 United Wire, Metal & Machine Health & Welfare Fund	5,579	5,172
Local 810 United Wire, Metal & Machine Pension Fund	3,873	3,542
Local 202 Health and Welfare Fund	1,342	-
Local 32B Pension Fund	425	401
Local 30 Health and Welfare	662	65
Local 30 Pension Fund	254	228
Local 153 Pension Fund	54	54
	<u>\$ 266,009</u>	<u>\$ 230,010</u>

NYU is in withdrawal status for the Local 153 Pension Fund with quarterly withdrawal payments continuing through 2033.

The Pension Protection Act zone status indicates a pension plan's funded status of either at least 80% funded (green) or less than 80% funded (yellow or red). A zone status of red requires the pension plan sponsor to implement a Funding Improvement Plan (FIP) or Rehabilitation Plan (RP). The following table includes information for the 1199 and Local 810 pension funds for the plan years ended December 31, 2022 and 2021.

Pension Plan Name	EIN/Pension Plan Number	Pension Protection Act Zone Status		FIP/RP Status Pending/Implemented	Surcharge Imposed	Expiration Date of Collective-Bargaining Agreement
		2022	2021			
1199 Pension Fund	13-3604862	Green	Green	N/A	No	September 2026
Local 810 United Wire Pension Fund	13-6596940	Red	Red	Yes	Yes	June 2024

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

*(in thousands of dollars)*

NYU's contributions to the 1199 Pension Fund and Local 810 United Wire Pension Fund represent greater than 5% of the respective total plan contributions based on the most recent IRS Form 5500s available.

#### **15. Hospital Affiliations**

NYUGSoM has a master affiliation and three supplemental affiliation agreements with the New York City Health and Hospitals Corporation to provide general care and mental health services. The three supplemental agreements are with Woodhull Medical and Mental Health Center and Cumberland Diagnostic and Treatment Center, Bellevue Hospital Center and Gouverneur Healthcare Services, and Coler Rehabilitation and Nursing Care Center and Henry J. Carter Specialty Hospital and Nursing Facility. The current master affiliation agreement covers the period July 1, 2021 through June 30, 2025. NYUGSoM recognized revenues from these affiliation agreements of \$454,582 and \$421,490 for the years ended August 31, 2023 and 2022, respectively.

NYU Langone Hospitals has several clinical affiliation agreements with New York City area hospitals where physicians provide patient care and supervision of residents at affiliated organizations. NYU Langone Hospitals also maintains an affiliation agreement with Sunset Park Health Council, Inc., a New York not-for-profit corporation, d/b/a Family Health Centers at NYU Langone. NYU Langone Hospitals recognized revenue from these affiliation agreements of \$25,352 and \$27,337 for the years ended August 31, 2023 and 2022, respectively.

#### **16. Functional Classification of Expenses**

NYU's primary program services are instruction, research and patient care. NYU's additional program services are student services and libraries and auxiliary enterprises. Expenses reported as institutional services are incurred in support of one or more of NYU's program services. Natural expenses attributed to more than one functional expense category are allocated using a variety of cost allocation techniques such as square footage and time and effort. Nonclinical COVID-19 costs in nonoperating activities of \$3,129 and \$37,792 are classified as institutional services for the years ended August 31, 2023 and 2022, respectively.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

(in thousands of dollars)

Expenses by functional classification for the years ended August 31, 2023 and 2022 consist of the following:

	2023						
	Instruction and Other Academic Programs	Research and Other Sponsored Programs	Patient Care	Student Services and Libraries	Auxiliary Enterprises	Institutional Services	Total
Salaries and fringe	\$ 1,549,535	\$ 675,903	\$ 5,662,372	\$ 160,349	\$ 163,857	\$ 1,240,987	\$ 9,453,003
Medical and pharmaceutical costs	68	2,242	1,753,875	14	-	3,795	1,759,994
Professional services	127,321	40,022	305,913	24,596	79,356	231,496	808,704
Facilities costs	124,373	207,637	178,971	16,186	192,105	228,114	947,386
Fees, insurance and taxes	9,822	569	259,498	1,919	15,004	200,739	487,551
Depreciation and amortization	97,578	35,475	486,823	22,486	118,156	251,927	1,012,445
Interest	97,728	9,013	145,576	7,299	39,407	73,373	372,396
Other	243,499	358,213	53,222	69,592	19,500	415,432	1,159,458
	<u>\$ 2,249,924</u>	<u>\$ 1,329,074</u>	<u>\$ 8,846,250</u>	<u>\$ 302,441</u>	<u>\$ 627,385</u>	<u>\$ 2,645,863</u>	<u>\$ 16,000,937</u>
University	\$ 2,169,602	\$ 328,677	\$ 58,184	\$ 282,538	\$ 476,602	\$ 642,024	\$ 3,957,627
NYU Langone Health	80,322	1,000,397	8,788,066	19,903	155,521	2,011,926	12,056,135
	<u>\$ 2,249,924</u>	<u>\$ 1,329,074</u>	<u>\$ 8,846,250</u>	<u>\$ 302,441</u>	<u>\$ 632,123</u>	<u>\$ 2,653,950</u>	16,013,762
						Eliminations	(12,825)
							<u>\$ 16,000,937</u>

  

	2022						
	Instruction and Other Academic Programs	Research and Other Sponsored Programs	Patient Care	Student Services and Libraries	Auxiliary Enterprises	Institutional Services	Total
Salaries and fringe	\$ 1,477,844	\$ 613,201	\$ 5,059,729	\$ 137,527	\$ 127,921	\$ 978,441	\$ 8,394,663
Medical and pharmaceutical costs	86	1,072	1,476,271	2	-	-	1,477,431
Professional services	134,027	33,966	262,464	19,353	61,731	225,639	737,180
Facilities costs	124,777	176,427	164,444	13,450	234,268	190,877	904,243
Fees, insurance and taxes	6,139	408	257,635	1,668	13,090	181,510	460,450
Depreciation and amortization	91,257	39,189	479,112	17,394	99,763	219,196	945,911
Interest	103,082	8,713	146,801	5,875	38,509	65,667	368,647
Other	162,735	268,082	129,654	53,430	10,598	194,175	818,674
	<u>\$ 2,099,947</u>	<u>\$ 1,141,058</u>	<u>\$ 7,976,110</u>	<u>\$ 248,699</u>	<u>\$ 585,880</u>	<u>\$ 2,055,505</u>	<u>\$ 14,107,199</u>
University	\$ 2,033,905	\$ 298,461	\$ 56,698	\$ 231,274	\$ 448,184	\$ 532,961	\$ 3,601,483
NYU Langone Health	66,042	842,597	7,919,412	17,425	142,562	1,530,457	10,518,495
	<u>\$ 2,099,947</u>	<u>\$ 1,141,058</u>	<u>\$ 7,976,110</u>	<u>\$ 248,699</u>	<u>\$ 590,746</u>	<u>\$ 2,063,418</u>	14,119,978
						Eliminations	(12,779)
							<u>\$ 14,107,199</u>

**17. Components of Net Assets with Donor Restrictions**

Net assets with donor restrictions are available for the following purposes at August 31, 2023 and 2022:

	2023	2022
Scholarships and fellowships	\$ 1,628,582	\$ 1,516,716
Contributions and earnings for operating purposes	1,712,629	1,498,322
Faculty and staff salaries	879,906	865,140
Program support	657,485	634,812
FEMA award for mitigation	-	38,698
Annuity trust agreements	38,919	37,796
Contributions for buildings and equipment	8,159	37,955
Other	110,431	107,634
	<u>\$ 5,036,111</u>	<u>\$ 4,737,073</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

*(in thousands of dollars)*

NYU's investment pools include individual endowed funds established for a variety of purposes. Pooled assets include both donor restricted endowment funds and funds designated by the board to function as endowments.

NYU classifies as net assets with donor restrictions the historical value of donor-restricted endowment funds, which includes: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment required by the applicable donor gift instrument. Also included in net assets with donor restrictions is accumulated unspent earnings on donor restricted endowment funds which are available for expenditure in a manner consistent with the standard of prudence described by the New York Prudent Management of Institutional Funds Act (NYPMIFA), and deficiencies associated with funds where the value of the fund has fallen below the original value of the gift. The historical value of NYU's donor-restricted endowment funds totaled \$2,954,093 and \$2,690,456 at August 31, 2023 and 2022, respectively.

NYU defines the appropriation of endowment net assets for expenditure as the authorization of its investment spending rate as approved annually by the Board of Trustees (Note 5). However, when donors have expressly stipulated the payout percentage of earnings on endowments that differs from NYU policies, the donors' intent prevails. In making a determination to appropriate or accumulate, NYU adheres to the standard of prudence prescribed by NYPMIFA and considers the following factors: the duration and preservation of the endowment fund; NYU's mission and the purpose of the endowment fund; general economic conditions; the possible effect of inflation or deflation; the expected total return from income and the appreciation of investments; other resources of NYU; where appropriate and circumstances would otherwise warrant, alternatives to expenditures of the endowment fund giving due consideration to the effect that such alternatives may have on NYU; and the investment policy of NYU.

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor required to be retained as a fund of perpetual duration. Deficiencies of this nature are reported in net assets with donor restrictions. As of August 31, 2023 and 2022, 34 funds and 117 funds, respectively, with original gift values of \$14,899 and \$94,432 were underwater by \$302 and \$4,114.

All endowment funds included within net assets without donor restrictions are board-designated. The following table provides the changes in the net asset classes of NYU's endowment funds at August 31:

	<b>2023</b>		
	<b>Without Donor Restrictions</b>	<b>With Donor Restrictions</b>	<b>Total</b>
<b>Investment pool net assets, beginning of year</b>	\$ 1,712,150	\$ 3,585,236	\$ 5,297,386
Contributions	139,107	239,395	378,502
Investment pool return	157,648	306,758	464,406
Endowment distribution	(73,286)	(155,617)	(228,903)
Liquidations	(4,112)	(8,312)	(12,424)
<b>Investment pool net assets, end of year</b>	<b>\$ 1,931,507</b>	<b>\$ 3,967,460</b>	<b>\$ 5,898,967</b>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

---

(in thousands of dollars)

	<b>2022</b>		
	<b>Without Donor Restrictions</b>	<b>With Donor Restrictions</b>	<b>Total</b>
<b>Investment pool net assets, beginning of year</b>	\$ 1,849,753	\$ 3,928,681	\$ 5,778,434
Contributions	105,706	142,056	247,762
Investment pool return	(175,386)	(342,708)	(518,094)
Endowment distribution	(64,208)	(134,137)	(198,345)
Liquidations	(3,715)	(8,656)	(12,371)
<b>Investment pool net assets, end of year</b>	<b>\$ 1,712,150</b>	<b>\$ 3,585,236</b>	<b>\$ 5,297,386</b>

**18. Commitments and Contingencies**

NYU has ongoing construction projects with contractual commitments totaling \$414,290 at August 31, 2023.

NYU is self-insured for workers' compensation. The University purchases an excess workers' compensation insurance policy with a retention of \$500 per claim and has maintained a surety bond in the amount of \$10,526 at August 31, 2023 and 2022. Additionally, NYU Langone Health has maintained stand-by letters of credit aggregating approximately \$89,389 and \$79,670 at August 31, 2023 and 2022, respectively.

In 2015, NYU Langone Health initiated lawsuits against a construction contractor for damages to property and business interruption arising from Superstorm Sandy in 2012. The litigation was resolved in March 2023 through an agreement in settlement of all claims, pursuant to which NYU Langone Hospitals received \$508,000, specifically for unrecovered business interruption losses. These proceeds were recorded within nonoperating activities on the consolidated statement of activities for the year ended August 31, 2023.

NYU is a defendant in various legal actions arising from the normal course of its activities and amounts expended under government grants and contracts are subject to audit by governmental agencies. In addition, amounts received for patient care from Medicare and Medicaid are subject to audit. Although the final outcome of such actions and audits cannot be determined, management believes that eventual liability, if any, will not have a material effect on NYU's consolidated balance sheets.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2023 and 2022

---

#### 19. Subsequent Events

NYU performed an evaluation of subsequent events through December 20, 2023, which is the date the consolidated financial statements were issued.

In November 2023, the Centers for Medicare and Medicaid Services (CMS) issued a final rule outlining the remedy for invalidated charges for calendar years 2018 through 2022. As part of this rule, NYU Langone Hospitals will receive \$122,300 in full satisfaction of the underpayments related to those years.

#### *Events Subsequent to Original Issuance of Financial Statements (Unaudited)*

In connection with the reissuance of the consolidated financial statements, NYU has evaluated subsequent events through April 24, 2024, the date the consolidated financial statements were reissued.

In January 2024, NYU Langone Hospitals received payments totaling \$122,300 in full satisfaction of the CMS final rule issued in November 2023.

In April 2024, the Obligated Group, through DASNY, instituted a Commercial Paper notes program in a maximum aggregate principal amount not to exceed \$250,000. The notes will be issued in denominations of \$100 or multiples of \$5 in excess thereof, maturing not later than 270 days after issuance date with interest rates not to exceed 12% for non-taxable notes and 15% for taxable notes. The proceeds will be used to fund or refinance various construction and renovation projects.



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2023 and 2022**

**20. Financial Responsibility Data**

NYU participates in federal Title IV student financial assistance programs, which require it to meet standards of financial responsibility based on criteria determined by the U.S. Department of Education (ED), as set forth in 34 CFR 668.171. The criteria for private institutions include the annual calculation by ED of a financial responsibility composite score, as further outlined in 34 CFR 668.172, using audited financial statements submitted through ED's eZ-Audit system. The composite score is based on three ratios: Primary Reserve, Equity, and Net Income.

These ratios utilize the following financial data of NYU, which are not otherwise presented in the consolidated financial statements or other notes to the financial statements, as of and for the year ended August 31, 2023:

*(in thousands of dollars)*

Required input per standards	Ratio(s) Uses	Input Amount	Related financial statement amount not used as input on supplementary schedule
Property, plant and equipment, net - pre-implementation	Primary reserve	\$ 8,349,991	
Property, plant and equipment, net - post-implementation with outstanding debt for original purchase	Primary reserve	2,740,881	
Property, plant and equipment, net - post-implementation without outstanding debt for original purchase	Primary reserve	2,224,534	
Construction in progress - post-implementation	Primary reserve	1,204,373	
Total property, plant, and equipment, net	N/A		\$ 14,519,779
Long-term debt - for long-term purposes pre-implementation	Primary reserve	\$ 6,637,111	
Long-term debt - for long-term purposes post-implementation	Primary reserve	2,995,827	
Line of Credit for Construction in progress		35,330	
Total long-term debt	Primary reserve	\$ 9,668,268	
Net assets with donor restrictions: restricted by purpose or time			
Annuities and life income funds with donor restrictions	Primary reserve	\$ 89,167	
Term endowments with donor restrictions	Primary reserve	4,640	
Net assets with donor restrictions: Other, for purpose or time	N/A		2,127,924
Net assets with donor restrictions: restricted in perpetuity	Primary reserve	2,814,380	
Total net assets with donor restrictions	N/A		\$ 5,036,111
Unsecured related party receivable	Primary reserve; Equity	\$ 296,239	
Inputs directly from the statement of activities			
Total expenses without donor restrictions (operating)	Primary reserve	\$ 16,000,937	
Plus: non-operating expenses and other losses	Primary reserve	3,129	
Total expenses and losses without donor restrictions	Primary reserve	\$ 16,004,066	
Total operating revenue and other additions	Net income	\$ 16,518,764	
Less: investment return appropriated for spending	Net income	(73,286)	
Plus: non-operating revenues and other gains	Net income	1,192,402	
Total revenue and gains without donor restrictions	Net income	\$ 17,637,880	

**Appendix A**  
**Supplemental Information**

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Summary)**  
**August 31, 2023**

	2023			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
<b>Assets</b>				
Cash and cash equivalents	\$ 986,758	\$ 403,339	\$ -	\$ 1,390,097
Short-term investments (Note 5)	257,619	2,116,075	-	2,373,694
Accounts and loans receivable, net (Note 6)	429,183	489,529	(84,962)	833,750
Patient accounts receivable, net (Note 4)	7,235	1,223,088	-	1,230,323
Contributions receivable, net (Note 7)	226,896	467,753	-	694,649
Other assets (Note 8)	320,506	932,633	-	1,253,139
Deposits with trustees (Note 9)	214,220	130,148	-	344,368
Long-term investments (Note 5)	4,591,720	2,220,385	-	6,812,105
Operating right-of-use assets (Note 11)	543,129	1,497,096	-	2,040,225
Assets held for professional liabilities (Note 13)	-	1,096,600	-	1,096,600
Land, buildings, and equipment, net (Note 10)	5,196,180	9,323,599	-	14,519,779
Total assets	<u>\$ 12,773,446</u>	<u>\$ 19,900,245</u>	<u>\$ (84,962)</u>	<u>\$ 32,588,729</u>
<b>Liabilities and Net Assets</b>				
<b>Liabilities</b>				
Accounts payable and accrued expenses	\$ 499,836	\$ 2,160,818	\$ (84,962)	\$ 2,575,692
Deferred revenue	1,263,145	188,669	-	1,451,814
Operating lease liability (Note 11)	578,506	1,647,856	-	2,226,362
Professional liabilities (Note 13)	-	967,037	-	967,037
Debt and other obligations (Note 12)	3,981,161	5,687,107	-	9,668,268
Funds held for others (Notes 6 and 8)	144,389	408,155	-	552,544
Accrued benefit obligation (Note 14)	-	229,087	-	229,087
Accrued postretirement obligation (Note 14)	283,366	173,451	-	456,817
Asset retirement obligation	214,005	87,938	-	301,943
Total liabilities	<u>6,964,408</u>	<u>11,550,118</u>	<u>(84,962)</u>	<u>18,429,564</u>
<b>Net assets</b>				
Without donor restrictions	2,555,388	6,567,666	-	9,123,054
With donor restrictions (Note 17)	3,253,650	1,782,461	-	5,036,111
Total net assets	<u>5,809,038</u>	<u>8,350,127</u>	<u>-</u>	<u>14,159,165</u>
Total liabilities and net assets	<u>\$ 12,773,446</u>	<u>\$ 19,900,245</u>	<u>\$ (84,962)</u>	<u>\$ 32,588,729</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Summary)**  
**August 31, 2022**

	2022			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
<b>Assets</b>				
Cash and cash equivalents	\$ 1,376,923	\$ 1,637,641	\$ -	\$ 3,014,564
Short-term investments (Note 5)	175,945	-	-	175,945
Accounts and loans receivable, net (Note 6)	422,442	496,485	(71,078)	847,849
Patient accounts receivable, net (Note 4)	7,134	1,208,586	-	1,215,720
Contributions receivable, net (Note 7)	270,975	351,241	-	622,216
Other assets (Note 8)	285,011	789,059	-	1,074,070
Deposits with trustees (Note 9)	325,185	297,766	-	622,951
Long-term investments (Note 5)	4,132,485	2,347,069	-	6,479,554
Operating right-of-use assets (Note 11)	586,294	1,567,928	-	2,154,222
Assets held for professional liabilities (Note 13)	-	950,996	-	950,996
Land, buildings, and equipment, net (Note 10)	4,929,156	8,594,931	-	13,524,087
Total assets	<u>\$ 12,511,550</u>	<u>\$ 18,241,702</u>	<u>\$ (71,078)</u>	<u>\$ 30,682,174</u>
<b>Liabilities and Net Assets</b>				
<b>Liabilities</b>				
Accounts payable and accrued expenses	\$ 508,168	\$ 2,114,243	\$ (71,078)	\$ 2,551,333
Deferred revenue	1,245,891	168,034	-	1,413,925
Operating lease liability (Note 11)	619,501	1,697,485	-	2,316,986
Professional liabilities (Note 13)	-	917,229	-	917,229
Debt and other obligations (Note 12)	4,110,008	5,456,398	-	9,566,406
Funds held for others (Notes 6 and 8)	152,149	341,330	-	493,479
Accrued benefit obligation (Note 14)	9,018	389,700	-	398,718
Accrued postretirement obligation (Note 14)	341,252	169,486	-	510,738
Asset retirement obligation	204,476	82,571	-	287,047
Total liabilities	<u>7,190,463</u>	<u>11,336,476</u>	<u>(71,078)</u>	<u>18,455,861</u>
<b>Net assets</b>				
Without donor restrictions	2,198,755	5,290,485	-	7,489,240
With donor restrictions (Note 17)	3,122,332	1,614,741	-	4,737,073
Total net assets	<u>5,321,087</u>	<u>6,905,226</u>	<u>-</u>	<u>12,226,313</u>
Total liabilities and net assets	<u>\$ 12,511,550</u>	<u>\$ 18,241,702</u>	<u>\$ (71,078)</u>	<u>\$ 30,682,174</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Detail)**  
**August 31, 2023**

	2023						Total
<i>(in thousands of dollars)</i>	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	Consolidated NYU
<b>Assets</b>							
Cash and cash equivalents	\$ 986,758	58,764	\$ -	\$ 1,045,522	\$ 344,575	\$ -	\$ 1,390,097
Short-term investments (Note 5)	257,619	-	-	257,619	2,116,075	-	2,373,694
Accounts and loans receivable, net (Note 6)	429,183	210,923	(68,943)	571,163	487,227	(224,640)	833,750
Patient accounts receivable, net (Note 4)	7,235	157,965	-	165,200	1,065,123	-	1,230,323
Contributions receivable, net (Note 7)	226,896	108,041	-	334,937	359,712	-	694,649
Other assets (Note 8)	320,506	461,709	-	782,215	470,924	-	1,253,139
Deposits with trustees (Note 9)	214,220	-	-	214,220	130,148	-	344,368
Long-term investments (Note 5)	4,591,720	1,291,554	-	5,883,274	928,831	-	6,812,105
Operating right-of-use assets (Note 11)	543,129	984,405	-	1,527,534	512,691	-	2,040,225
Assets held for professional liabilities (Note 13)	-	-	-	-	1,096,600	-	1,096,600
Land, buildings, and equipment, net (Note 10)	5,196,180	3,979,446	-	9,175,626	5,344,153	-	14,519,779
Total assets	<u>\$ 12,773,446</u>	<u>\$ 7,252,807</u>	<u>\$ (68,943)</u>	<u>\$ 19,957,310</u>	<u>\$ 12,856,059</u>	<u>\$ (224,640)</u>	<u>\$ 32,588,729</u>
<b>Liabilities and Net Assets</b>							
<b>Liabilities</b>							
Accounts payable and accrued expenses	\$ 499,836	\$ 997,368	\$ (68,943)	\$ 1,428,261	\$ 1,372,071	\$ (224,640)	\$ 2,575,692
Deferred revenue	1,263,145	54,528	-	1,317,673	134,141	-	1,451,814
Operating lease liability (Note 11)	578,506	1,077,269	-	1,655,775	570,587	-	2,226,362
Professional liabilities (Note 13)	-	-	-	-	967,037	-	967,037
Debt and other obligations (Note 12)	3,981,161	2,427,998	-	6,409,159	3,259,109	-	9,668,268
Funds held for others (Notes 6 and 8)	144,389	360,756	-	505,145	47,399	-	552,544
Accrued benefit obligation (Note 14)	-	-	-	-	229,087	-	229,087
Accrued postretirement obligation (Note 14)	283,366	99,268	-	382,634	74,183	-	456,817
Asset retirement obligation	214,005	28,326	-	242,331	59,612	-	301,943
Total liabilities	<u>6,964,408</u>	<u>5,045,513</u>	<u>(68,943)</u>	<u>11,940,978</u>	<u>6,713,226</u>	<u>(224,640)</u>	<u>18,429,564</u>
<b>Net assets</b>							
Without donor restrictions	2,555,388	954,404	-	3,509,792	5,613,262	-	9,123,054
With donor restrictions (Note 17)	3,253,650	1,252,890	-	4,506,540	529,571	-	5,036,111
Total net assets	<u>5,809,038</u>	<u>2,207,294</u>	<u>-</u>	<u>8,016,332</u>	<u>6,142,833</u>	<u>-</u>	<u>14,159,165</u>
Total liabilities and net assets	<u>\$ 12,773,446</u>	<u>\$ 7,252,807</u>	<u>\$ (68,943)</u>	<u>\$ 19,957,310</u>	<u>\$ 12,856,059</u>	<u>\$ (224,640)</u>	<u>\$ 32,588,729</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Detail)**  
**August 31, 2022**

	2022						Total Consolidated NYU
	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	
<i>(in thousands of dollars)</i>							
<b>Assets</b>							
Cash and cash equivalents	\$ 1,376,923	\$ 47,346	\$ -	\$ 1,424,269	\$ 1,590,295	\$ -	\$ 3,014,564
Short-term investments (Note 5)	175,945	-	-	175,945	-	-	175,945
Accounts and loans receivable, net (Note 6)	422,442	199,319	(49,739)	572,022	355,756	(79,929)	847,849
Patient accounts receivable, net (Note 4)	7,134	146,025	-	153,159	1,062,561	-	1,215,720
Contributions receivable, net (Note 7)	270,975	123,181	-	394,156	228,060	-	622,216
Other assets (Note 8)	285,011	393,939	-	678,950	395,120	-	1,074,070
Deposits with trustees (Note 9)	325,185	-	-	325,185	297,766	-	622,951
Long-term investments (Note 5)	4,132,485	1,185,739	-	5,318,224	1,161,330	-	6,479,554
Operating right-of-use assets (Note 11)	586,294	1,019,076	-	1,605,370	548,852	-	2,154,222
Assets held for professional liabilities (Note 13)	-	-	-	-	950,996	-	950,996
Land, buildings, and equipment, net (Note 10)	4,929,156	3,499,330	-	8,428,486	5,095,601	-	13,524,087
Total assets	<u>\$ 12,511,550</u>	<u>\$ 6,613,955</u>	<u>\$ (49,739)</u>	<u>\$ 19,075,766</u>	<u>\$ 11,686,337</u>	<u>\$ (79,929)</u>	<u>\$ 30,682,174</u>
<b>Liabilities and Net Assets</b>							
<b>Liabilities</b>							
Accounts payable and accrued expenses	\$ 508,168	\$ 872,494	\$ (49,739)	\$ 1,330,923	\$ 1,300,339	\$ (79,929)	\$ 2,551,333
Deferred revenue	1,245,891	42,111	-	1,288,002	125,923	-	1,413,925
Operating lease liability (Note 11)	619,501	1,097,812	-	1,717,313	599,673	-	2,316,986
Professional liabilities (Note 13)	-	-	-	-	917,229	-	917,229
Debt and other obligations (Note 12)	4,110,008	2,134,732	-	6,244,740	3,321,666	-	9,566,406
Funds held for others (Notes 6 and 8)	152,149	300,743	-	452,892	40,587	-	493,479
Accrued benefit obligation (Note 14)	9,018	-	-	9,018	389,700	-	398,718
Accrued postretirement obligation (Note 14)	341,252	95,558	-	436,810	73,928	-	510,738
Asset retirement obligation	204,476	23,043	-	227,519	59,528	-	287,047
Total liabilities	<u>7,190,463</u>	<u>4,566,493</u>	<u>(49,739)</u>	<u>11,707,217</u>	<u>6,828,573</u>	<u>(79,929)</u>	<u>18,455,861</u>
<b>Net assets</b>							
Without donor restrictions	2,198,755	828,790	-	3,027,545	4,461,695	-	7,489,240
With donor restrictions (Note 17)	3,122,332	1,218,672	-	4,341,004	396,069	-	4,737,073
Total net assets	<u>5,321,087</u>	<u>2,047,462</u>	<u>-</u>	<u>7,368,549</u>	<u>4,857,764</u>	<u>-</u>	<u>12,226,313</u>
Total liabilities and net assets	<u>\$ 12,511,550</u>	<u>\$ 6,613,955</u>	<u>\$ (49,739)</u>	<u>\$ 19,075,766</u>	<u>\$ 11,686,337</u>	<u>\$ (79,929)</u>	<u>\$ 30,682,174</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Summary)**  
**Year Ended August 31, 2023**

	2023			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
<b>Changes in net assets without donor restrictions</b>				
Operating revenues				
Tuition and fees (net of financial aid awards of \$869,082 University; \$28,846 NYU Langone Health)	\$ 2,465,425	\$ 45,864	\$ -	\$ 2,511,289
Grants and contracts (Note 2)	761,334	761,155	-	1,522,489
Patient care (Note 4)	51,770	9,779,562	-	9,831,332
Hospital affiliations (Note 15)	-	479,934	-	479,934
Insurance premiums earned	-	117,784	-	117,784
Contributions	43,674	33,763	-	77,437
Endowment distribution (Note 5)	177,125	51,778	-	228,903
Return on short-term investments (Note 5)	51,045	113,314	-	164,359
Auxiliary enterprises (net of financial aid awards of \$91,060)	371,774	50,331	(4,738)	417,367
Program fees and other	125,006	885,655	(8,087)	1,002,574
Net assets released from restrictions	99,962	65,334	-	165,296
Total operating revenues	<u>4,147,115</u>	<u>12,384,474</u>	<u>(12,825)</u>	<u>16,518,764</u>
Expenses (Note 16)				
Salaries and fringe	2,300,619	7,152,384	-	9,453,003
Medical and pharmaceutical costs	-	1,759,994	-	1,759,994
Professional services	309,033	499,671	-	808,704
Facilities costs	387,805	564,319	(4,738)	947,386
Fees, insurance and taxes	64,107	423,444	-	487,551
Depreciation and amortization	285,058	727,387	-	1,012,445
Interest	153,009	219,387	-	372,396
Other	457,996	709,549	(8,087)	1,159,458
Total expenses	<u>3,957,627</u>	<u>12,056,135</u>	<u>(12,825)</u>	<u>16,000,937</u>
Excess of operating revenues over expenses	189,488	328,339	-	517,827
Nonoperating activities				
Investment return (Note 5)	167,130	162,705	-	329,835
Appropriation of endowment distribution (Note 5)	(62,510)	(10,776)	-	(73,286)
Pension and postretirement nonservice costs (Note 14)	(9,309)	28,179	-	18,870
Changes in pension and postretirement obligations (Note 14)	74,136	155,727	-	229,863
Net assets released from restrictions for capital	28	103,569	-	103,597
Nonclinical COVID costs (Note 2)	(3,129)	-	-	(3,129)
Proceeds from settlement agreement (Note 18)	-	508,000	-	508,000
Other	799	1,438	-	2,237
Increase in net assets without donor restrictions	<u>356,633</u>	<u>1,277,181</u>	<u>-</u>	<u>1,633,814</u>
<b>Changes in net assets with donor restrictions</b>				
Contributions	168,593	283,359	-	451,952
Investment return (Note 5)	179,982	94,015	-	273,997
Appropriation of endowment distribution (Note 5)	(114,615)	(41,002)	-	(155,617)
Other	(2,652)	251	-	(2,401)
Net assets released from restrictions	(99,990)	(168,903)	-	(268,893)
Increase in net assets with donor restrictions	<u>131,318</u>	<u>167,720</u>	<u>-</u>	<u>299,038</u>
Increase in net assets	<u>\$ 487,951</u>	<u>\$ 1,444,901</u>	<u>\$ -</u>	<u>\$ 1,932,852</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Summary)**  
**Year Ended August 31, 2022**

	2022			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
<b>Changes in net assets without donor restrictions</b>				
Operating revenues				
Tuition and fees (net of financial aid awards of \$827,239 University; \$25,033 NYU Langone Health)	\$ 2,408,966	\$ 43,755	\$ -	\$ 2,452,721
Grants and contracts (Note 2)	736,715	654,556	-	1,391,271
Patient care (Note 4)	49,154	8,813,683	-	8,862,837
Hospital affiliations (Note 15)	-	448,827	-	448,827
Insurance premiums earned	-	108,014	-	108,014
Contributions	36,946	37,469	-	74,415
Endowment distribution (Note 5)	153,281	45,064	-	198,345
Return on short-term investments (Note 5)	9,791	35,366	-	45,157
Auxiliary enterprises (net of financial aid awards of \$70,701)	339,752	47,219	(4,866)	382,105
Program fees and other	47,714	648,136	(7,913)	687,937
Net assets released from restrictions	110,711	62,785	-	173,496
Total operating revenues	<u>3,893,030</u>	<u>10,944,874</u>	<u>(12,779)</u>	<u>14,825,125</u>
Expenses (Note 16)				
Salaries and fringe	2,123,823	6,270,840	-	8,394,663
Medical and pharmaceutical costs	-	1,477,431	-	1,477,431
Professional services	288,469	448,711	-	737,180
Facilities costs	379,607	529,502	(4,866)	904,243
Fees, insurance and taxes	53,285	407,165	-	460,450
Depreciation and amortization	260,521	685,390	-	945,911
Interest	156,654	211,993	-	368,647
Other	339,124	487,463	(7,913)	818,674
Total expenses	<u>3,601,483</u>	<u>10,518,495</u>	<u>(12,779)</u>	<u>14,107,199</u>
Excess of operating revenues over expenses	291,547	426,379	-	717,926
Nonoperating activities				
Investment return (Note 5)	(148,564)	(326,569)	-	(475,133)
Appropriation of endowment distribution (Note 5)	(54,751)	(9,457)	-	(64,208)
Pension and postretirement nonservice costs (Note 14)	3,720	22,451	-	26,171
Changes in pension and postretirement obligations (Note 14)	80,641	190,438	-	271,079
Net assets released from restrictions for capital	8,225	11,990	-	20,215
Nonclinical COVID costs (Note 2)	(37,792)	-	-	(37,792)
Other	(1,547)	96,389	-	94,842
Increase in net assets without donor restrictions	<u>141,479</u>	<u>411,621</u>	<u>-</u>	<u>553,100</u>
<b>Changes in net assets with donor restrictions</b>				
Contributions	162,011	137,792	-	299,803
Investment return (Note 5)	(245,069)	(94,172)	-	(339,241)
Appropriation of endowment distribution (Note 5)	(98,530)	(35,607)	-	(134,137)
Other	(13,136)	4,594	-	(8,542)
Net assets released from restrictions	<u>(118,936)</u>	<u>(74,775)</u>	<u>-</u>	<u>(193,711)</u>
Decrease in net assets with donor restrictions	<u>(313,660)</u>	<u>(62,168)</u>	<u>-</u>	<u>(375,828)</u>
(Decrease) increase in net assets	<u>\$ (172,181)</u>	<u>\$ 349,453</u>	<u>\$ -</u>	<u>\$ 177,272</u>

The accompanying note is an integral part of these supplemental schedules.



**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Detail)**  
**Year Ended August 31, 2023**

	2023						Total
<i>(in thousands of dollars)</i>	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	Consolidated NYU
<b>Changes in net assets without donor restrictions</b>							
Operating revenues							
Tuition and fees (net of financial aid awards of \$869,082 University; and \$28,846 NYU Langone Health)	\$ 2,465,425	\$ 45,622	\$ -	\$ 2,511,047	\$ 242	\$ -	\$ 2,511,289
Grants and contracts (Note 2)	761,334	756,228	-	1,517,562	4,927	-	1,522,489
Patient care (Note 4)	51,770	3,284,254	-	3,336,024	7,388,560	(893,252)	9,831,332
Hospital affiliations (Note 15)	-	454,582	-	454,582	25,352	-	479,934
Insurance premiums earned	-	-	-	-	117,784	-	117,784
Contributions	43,674	24,119	-	67,793	9,644	-	77,437
Endowment distribution (Note 5)	177,125	49,381	-	226,506	2,397	-	228,903
Return on short-term investments (Note 5)	51,045	489	-	51,534	112,825	-	164,359
Auxiliary enterprises (net of financial aid awards of \$91,060)	371,774	25,529	(4,738)	392,565	24,802	-	417,367
Program fees and other	125,006	516,978	(8,087)	633,897	883,038	(514,361)	1,002,574
Net assets released from restrictions	99,962	40,194	-	140,156	25,140	-	165,296
Total operating revenues	<u>4,147,115</u>	<u>5,197,376</u>	<u>(12,825)</u>	<u>9,331,666</u>	<u>8,594,711</u>	<u>(1,407,613)</u>	<u>16,518,764</u>
Expenses (Note 16)							
Salaries and fringe	2,300,619	3,885,936	-	6,186,555	3,309,777	(43,329)	9,453,003
Medical and pharmaceutical costs	-	98,661	-	98,661	1,661,333	-	1,759,994
Professional services	309,033	213,595	-	522,628	1,558,362	(1,272,286)	808,704
Facilities costs	387,805	313,094	(4,738)	696,161	251,225	-	947,386
Fees, insurance and taxes	64,107	285,835	-	349,942	137,609	-	487,551
Depreciation and amortization	285,058	264,522	-	549,580	462,865	-	1,012,445
Interest	153,009	93,841	-	246,850	125,546	-	372,396
Other	457,996	313,364	(8,087)	763,273	488,183	(91,998)	1,159,458
Total expenses	<u>3,957,627</u>	<u>5,468,848</u>	<u>(12,825)</u>	<u>9,413,650</u>	<u>7,994,900</u>	<u>(1,407,613)</u>	<u>16,000,937</u>
Excess (deficiency) of operating revenues over expenses	189,488	(271,472)	-	(81,984)	599,811	-	517,827
Nonoperating activities							
Investment return (Note 5)	167,130	24,376	-	191,506	138,329	-	329,835
Appropriation of endowment distribution (Note 5)	(62,510)	(10,602)	-	(73,112)	(174)	-	(73,286)
Pension and postretirement nonservice costs (Note 14)	(9,309)	4,542	-	(4,767)	23,637	-	18,870
Changes in pension and postretirement obligations (Note 14)	74,136	(1,411)	-	72,725	157,138	-	229,863
Net assets released from restrictions for capital	28	45,238	-	45,266	58,331	-	103,597
Nonclinical COVID costs (Note 2)	(3,129)	-	-	(3,129)	-	-	(3,129)
Proceeds from settlement agreement (Note 18)	-	-	-	-	508,000	-	508,000
Other	799	284,943	-	285,742	(283,505)	-	2,237
Mission based payment	-	50,000	-	50,000	(50,000)	-	-
Increase in net assets without donor restrictions	<u>356,633</u>	<u>125,614</u>	<u>-</u>	<u>482,247</u>	<u>1,151,567</u>	<u>-</u>	<u>1,633,814</u>
<b>Changes in net assets with donor restrictions</b>							
Contributions	168,593	92,642	-	261,235	190,717	-	451,952
Investment return (Note 5)	179,982	86,875	-	266,857	7,140	-	273,997
Appropriation of endowment distribution (Note 5)	(114,615)	(38,779)	-	(153,394)	(2,223)	-	(155,617)
Other	(2,652)	(21,088)	-	(23,740)	21,339	-	(2,401)
Net assets released from restrictions	(99,990)	(85,432)	-	(185,422)	(83,471)	-	(268,893)
Increase in net assets with donor restrictions	<u>131,318</u>	<u>34,218</u>	<u>-</u>	<u>165,536</u>	<u>133,502</u>	<u>-</u>	<u>299,038</u>
Increase in net assets	<u>\$ 487,951</u>	<u>\$ 159,832</u>	<u>\$ -</u>	<u>\$ 647,783</u>	<u>\$ 1,285,069</u>	<u>\$ -</u>	<u>\$ 1,932,852</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Detail)**  
**Year Ended August 31, 2022**

	2022						Total Consolidated NYU
(in thousands of dollars)	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	
<b>Changes in net assets without donor restrictions</b>							
Operating revenues							
Tuition and fees (net of financial aid awards of \$827,239 University; and \$25,033 NYU Langone Health)	\$ 2,408,966	\$ 43,253	\$ -	\$ 2,452,219	\$ 502	\$ -	\$ 2,452,721
Grants and contracts (Note 2)	736,715	641,069	-	1,377,784	13,487	-	1,391,271
Patient care (Note 4)	49,154	2,997,408	-	3,046,562	6,651,470	(835,195)	8,862,837
Hospital affiliations (Note 15)	-	421,490	-	421,490	27,337	-	448,827
Insurance premiums earned	-	-	-	-	108,014	-	108,014
Contributions	36,946	22,548	-	59,494	14,921	-	74,415
Endowment distribution (Note 5)	153,281	43,074	-	196,355	1,990	-	198,345
Return on short-term investments (Note 5)	9,791	1	-	9,792	35,365	-	45,157
Auxiliary enterprises (net of financial aid awards of \$70,701)	339,752	25,839	(4,866)	360,725	21,380	-	382,105
Program fees and other	47,714	329,765	(7,913)	369,566	685,842	(367,471)	687,937
Net assets released from restrictions	110,711	43,646	-	154,357	19,139	-	173,496
Total operating revenues	3,893,030	4,568,093	(12,779)	8,448,344	7,579,447	(1,202,666)	14,825,125
Expenses (Note 16)							
Salaries and fringe	2,123,823	3,392,242	-	5,516,065	2,932,604	(54,006)	8,394,663
Medical and pharmaceutical costs	-	91,038	-	91,038	1,386,393	-	1,477,431
Professional services	288,469	202,780	-	491,249	1,295,512	(1,049,581)	737,180
Facilities costs	379,607	289,206	(4,866)	663,947	240,296	-	904,243
Fees, insurance and taxes	53,285	279,285	-	332,570	127,880	-	460,450
Depreciation and amortization	260,521	244,228	-	504,749	441,162	-	945,911
Interest	156,654	84,518	-	241,172	127,475	-	368,647
Other	339,124	222,997	(7,913)	554,208	363,545	(99,079)	818,674
Total expenses	3,601,483	4,806,294	(12,779)	8,394,998	6,914,867	(1,202,666)	14,107,199
Excess (deficiency) of operating revenues over expenses	291,547	(238,201)	-	53,346	664,580	-	717,926
Nonoperating activities							
Investment return (Note 5)	(148,564)	(32,541)	-	(181,105)	(294,028)	-	(475,133)
Appropriation of endowment distribution (Note 5)	(54,751)	(9,295)	-	(64,046)	(162)	-	(64,208)
Pension and postretirement nonservice costs (Note 14)	3,720	4,461	-	8,181	17,990	-	26,171
Changes in pension and postretirement obligations (Note 14)	80,641	29,177	-	109,818	161,261	-	271,079
Net assets released from restrictions for capital	8,225	2,787	-	11,012	9,203	-	20,215
Nonclinical COVID costs (Note 2)	(37,792)	-	-	(37,792)	-	-	(37,792)
Other	(1,547)	303,919	-	302,372	(207,530)	-	94,842
Mission based payment	-	50,000	-	50,000	(50,000)	-	-
Increase in net assets without donor restrictions	141,479	110,307	-	251,786	301,314	-	553,100
<b>Changes in net assets with donor restrictions</b>							
Contributions	162,011	82,840	-	244,851	54,952	-	299,803
Investment return (Note 5)	(245,069)	(88,164)	-	(333,233)	(6,008)	-	(339,241)
Appropriation of endowment distribution (Note 5)	(98,530)	(33,779)	-	(132,309)	(1,828)	-	(134,137)
Other	(13,136)	1,958	-	(11,178)	2,636	-	(8,542)
Net assets released from restrictions	(118,936)	(46,433)	-	(165,369)	(28,342)	-	(193,711)
(Decrease) increase in net assets with donor restrictions	(313,660)	(83,578)	-	(397,238)	21,410	-	(375,828)
(Decrease) increase in net assets	\$ (172,181)	\$ 26,729	\$ -	\$ (145,452)	\$ 322,724	\$ -	\$ 177,272

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Cash Flows for NYU – Summary)**  
**Year Ended August 31, 2023**

	2023			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
<b>Cash flows from operating activities</b>				
Change in net assets	\$ 487,951	\$ 1,444,901	\$ -	\$ 1,932,852
Adjustments to reconcile change in net assets to net cash provided by operating activities				
Depreciation and amortization	285,058	727,387	-	1,012,445
Gain on sale or disposal of land, buildings and equipment	(7,236)	(113)	-	(7,349)
Net gain on investments, deposits with trustees and split-interest agreements	(314,842)	(220,021)	-	(534,863)
Bad debt expense	7,543	419	-	7,962
Pension and postretirement obligation change	(74,136)	(155,727)	-	(229,863)
Contributions received for permanent investment and capital	(87,836)	(42,932)	-	(130,768)
Proceeds from FEMA award for future mitigation	-	(13,264)	-	(13,264)
Amortization of operating right-of-use assets	113,164	159,642	-	272,806
Changes in operating assets and liabilities				
(Increase) decrease in accounts and loans receivable, net	(12,985)	6,535	13,884	7,434
Increase in patient accounts receivable	(101)	(14,502)	-	(14,603)
Decrease (increase) in nonendowment and noncapital contributions receivable	42,780	(116,512)	-	(73,732)
Increase in other assets	(3,712)	(83,100)	-	(86,812)
(Decrease) increase in asset retirement obligation	(1,410)	84	-	(1,326)
(Decrease) increase in accounts payable and accrued expenses	(40,445)	64,204	(13,884)	9,875
Decrease in operating lease liability	(110,994)	(141,431)	-	(252,425)
Increase in professional liabilities	-	49,809	-	49,809
Increase in deferred revenue	17,254	20,636	-	37,890
Decrease in accrued benefit obligation	(10,364)	(4,978)	-	(15,342)
(Decrease) increase in accrued postretirement obligation	(286)	4,057	-	3,771
Net cash provided by operating activities	<u>289,403</u>	<u>1,685,094</u>	<u>-</u>	<u>1,974,497</u>
<b>Cash flows from investing activities</b>				
Purchases of investments	(1,573,587)	(3,518,185)	-	(5,091,772)
Sales and maturities of investments	1,333,413	1,795,040	-	3,128,453
Drawdowns of unexpended bond proceeds	121,034	-	-	121,034
Additions to land, buildings, and equipment	(522,744)	(1,128,871)	-	(1,651,615)
Net cash used in investing activities	<u>(641,884)</u>	<u>(2,852,016)</u>	<u>-</u>	<u>(3,493,900)</u>
<b>Cash flows from financing activities</b>				
Contributions restricted for permanent investment and capital	87,836	42,932	-	130,768
Proceeds from FEMA award for future mitigation	-	13,264	-	13,264
Proceeds from finance lease incentives	-	15,077	-	15,077
Principal payments on long-term borrowings and finance leases	(107,613)	(114,271)	-	(221,884)
Decrease in funds held for others	(19,781)	-	-	(19,781)
Net cash used in financing activities	<u>(39,558)</u>	<u>(42,998)</u>	<u>-</u>	<u>(82,556)</u>
Net decrease in cash, cash equivalents and restricted cash	<u>(392,039)</u>	<u>(1,209,920)</u>	<u>-</u>	<u>(1,601,959)</u>
<b>Cash, cash equivalents and restricted cash</b>				
Beginning of year	1,493,728	1,879,598	-	3,373,326
End of year	<u>\$ 1,101,689</u>	<u>\$ 669,678</u>	<u>\$ -</u>	<u>\$ 1,771,367</u>
<b>Supplemental disclosure of cash flow information</b>				
Interest paid	\$ 158,532	\$ 231,522	\$ -	\$ 390,054
Change in noncash acquisitions of land, buildings, and equipment	32,113	115,342	-	147,455
Right-of-use assets obtained				
In exchange for new operating lease obligations	55,260	149,755	-	205,015
In exchange for new finance lease obligations	-	233,624	-	233,624

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Cash Flows for NYU – Summary)**  
**Year Ended August 31, 2022**

	2022			Consolidated NYU
	University	NYU Langone Health	Eliminations	
<i>(in thousands of dollars)</i>				
<b>Cash flows from operating activities</b>				
Change in net assets	\$ (172,181)	\$ 349,453	\$ -	\$ 177,272
Adjustments to reconcile change in net assets to net cash provided by operating activities				
Depreciation and amortization	260,521	685,390	-	945,911
Loss (gain) on sale or disposal of land, buildings and equipment	353	(554)	-	(201)
Net loss on investments, deposits with trustees and split-interest agreements	442,371	450,648	-	893,019
Bad debt expense	16,550	1,857	-	18,407
Pension and postretirement obligation change	(80,641)	(190,438)	-	(271,079)
Contributions received for permanent investment and capital	(86,290)	(27,319)	-	(113,609)
Proceeds from FEMA award for future mitigation	-	(1,191)	-	(1,191)
Amortization of operating right-of-use assets	113,573	151,751	-	265,324
Acquisition of Long Island Community Hospital	-	(105,967)	-	(105,967)
Changes in operating assets and liabilities				
Increase in accounts and loans receivable, net	(72,060)	(22,767)	4,594	(90,233)
Decrease (increase) in patient accounts receivable	1,000	(130,017)	-	(129,017)
Decrease (increase) in nonendowment and noncapital contributions receivable	49,916	(40,491)	-	9,425
Increase in other assets	(12,908)	(18,832)	-	(31,740)
Decrease in asset retirement obligation	(4,561)	(11,704)	-	(16,265)
Increase (decrease) in accounts payable and accrued expenses	22,494	(407,696)	(4,594)	(389,796)
Decrease in operating lease liability	(110,403)	(141,911)	-	(252,314)
Increase in professional liabilities	-	45,374	-	45,374
Increase in deferred revenue	70,685	15,651	-	86,336
(Decrease) increase in accrued benefit obligation	(11,524)	10,072	-	(1,452)
Increase in accrued postretirement obligation	1,060	10,770	-	11,830
Net cash provided by operating activities	<u>427,955</u>	<u>622,079</u>	<u>-</u>	<u>1,050,034</u>
<b>Cash flows from investing activities</b>				
Purchases of investments	(1,345,486)	(1,926,345)	-	(3,271,831)
Sales and maturities of investments	1,127,052	1,824,770	-	2,951,822
Drawdowns of unexpended bond proceeds	87,603	-	-	87,603
Additions to land, buildings, and equipment	(490,435)	(886,591)	-	(1,377,026)
Cash from acquisition of Long Island Community Hospital	-	86,068	-	86,068
Net cash used in investing activities	<u>(621,266)</u>	<u>(902,098)</u>	<u>-</u>	<u>(1,523,364)</u>
<b>Cash flows from financing activities</b>				
Contributions restricted for permanent investment and capital	86,290	27,319	-	113,609
Proceeds from FEMA award for future mitigation	-	1,191	-	1,191
Proceeds from finance lease incentives	-	38,870	-	38,870
Principal payments on long-term borrowings and finance leases	(105,275)	(126,344)	-	(231,619)
Decrease in funds held for others	(5,590)	-	-	(5,590)
Net cash used in financing activities	<u>(24,575)</u>	<u>(58,964)</u>	<u>-</u>	<u>(83,539)</u>
Net decrease in cash, cash equivalents, and restricted cash	(217,886)	(338,983)	-	(556,869)
<b>Cash, cash equivalents and restricted cash</b>				
Beginning of year	1,711,614	2,218,581	-	3,930,195
End of year	<u>\$ 1,493,728</u>	<u>\$ 1,879,598</u>	<u>\$ -</u>	<u>\$ 3,373,326</u>
<b>Supplemental disclosure of cash flow information</b>				
Interest paid	\$ 162,077	\$ 223,091	\$ -	\$ 385,168
Change in noncash acquisitions of land, buildings, and equipment	30,238	29,859	-	60,097
Right-of-use assets obtained				
In exchange for new operating lease obligations	53,179	196,091	-	249,270
In exchange for new finance lease obligations	-	50,243	-	50,243

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Note to Consolidating Supplemental Schedules**  
**August 31, 2023 and 2022**

---

**1. Basis of Presentation – Consolidating Supplemental Schedules**

The consolidating supplemental schedules (consolidating information) presented on pages 47-56 was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, changes in net assets and cash flows of the individual companies within NYU and is not a required part of the consolidated financial statements. The individual reporting entities within NYU as presented within the consolidating information are disclosed within Note 1 to the consolidated financial statements.

The consolidating financial statements were prepared on an accrual basis of accounting, consistent with the consolidated financial statements (Note 2). All transactions between and amounts due to (from) the reporting entities within NYU have been eliminated within the consolidating supplemental schedules.

**Part II**  
**Supplemental Schedule of Expenditures of Federal Awards**

# New York University Schedule of Expenditures of Federal Awards Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Research and Development Cluster:								
U.S. Department of Agriculture								
	Agricultural Research Basic and Applied Research	10.001	\$ 17,869	\$ -			\$ 17,869	\$ -
	Organic Agriculture Research and Extension Initiative	10.307	99,555	-			99,555	21,651
	Agriculture and Food Research Initiative (AFRI)	10.310	522,658	-			522,658	88,143
	Agriculture and Food Research Initiative (AFRI)	10.310	209,886	-			209,886	108,439
	Agriculture and Food Research Initiative (AFRI)	10.310	-	132,440	Iowa State University	024408G Amd 04	132,440	-
	Cooperative Extension Service	10.500	1,860,670	-			1,860,670	-
	Cooperative Extension Service	10.500	-	(155,100)	Pennsylvania State University	5001734-USDA	(155,100)	-
	Cooperative Extension Service	10.500	-	485,704	Pennsylvania State University	5002857-USDA	485,704	-
	State Agency: Farm to School Program Training and Curricula	10.531	-	24,850	National Center for Appropriate Technology	Subcontract Agreement	24,850	-
	<b>Total U.S. Department of Agriculture</b>		<b>2,710,638</b>	<b>487,894</b>			<b>3,198,532</b>	<b>218,233</b>
U.S. Department of Commerce								
	Climate and Atmospheric Research	11.431	233,790	-			233,790	-
	Climate and Atmospheric Research	11.431	-	64,631	University of Puerto Rico Medical Sciences Campus	530907-NYU Amd 2	64,631	-
	Center for Sponsored Coastal Ocean Research Coastal Ocean Program	11.478	-	103,087	Mote Marine Laboratory and Aquarium	193-549-4	103,087	-
	Multi Modal Robot-Assisted Visual Localization System for First Responders	11.RD	-	26,220	Indiana University	Phase II	26,220	-
	<b>Total U.S. Department of Commerce</b>		<b>233,790</b>	<b>193,938</b>			<b>427,728</b>	<b>-</b>
U.S. Department of Defense								
	Basic and Applied Scientific Research	12.300	3,954,395	-			3,954,395	1,265,747
	Basic and Applied Scientific Research	12.300	-	78,699	City University of New York	CM00005538-00	78,699	-
	Basic and Applied Scientific Research	12.300	-	(35,588)	Texas A&M Engineering Experiment Station	M1801652 Amd 006	(35,588)	-
	Basic and Applied Scientific Research	12.300	-	393,179	University of California Berkeley	00011181 YR2 FUNDING	393,179	-
	Basic and Applied Scientific Research	12.300	-	304,180	University of Nebraska Lincoln	25-0509-0202-004 A07	304,180	-
	Basic and Applied Scientific Research	12.300	-	122,792	University of California Davis	A17-0260-S003	122,792	-
	Basic and Applied Scientific Research	12.300	-	28,775	Trustees of Dartmouth College	Amendment No 2 NCE	28,775	-
	Military Medical Research and Development	12.420	5,509,283	-			5,509,283	523,299
	Military Medical Research and Development	12.420	1,589,893	-			1,589,893	-
	Military Medical Research and Development	12.420	-	100,788	Columbia University	1(GG018807-01)	100,788	-
	Military Medical Research and Development	12.420	-	74,812	Johns Hopkins University	2005785713	74,812	-
	Military Medical Research and Development	12.420	-	(1,146)	University of Alabama at Birmingham	000516840-009-T001	(1,146)	-
	Military Medical Research and Development	12.420	-	10,987	University of Connecticut Health Center	436326	10,987	-
	Military Medical Research and Development	12.420	-	60,350	Yale University	CON-80004524(GR120458)	60,350	-
	Military Medical Research and Development	12.420	-	(3,471)	Thomas Jefferson University	080-27000-X17501	(3,471)	-
	Military Medical Research and Development	12.420	-	5,377	Altrazeal Life Sciences Inc.	20-00-00-1005760	5,377	-
	Military Medical Research and Development	12.420	-	1,070	Oregon Health and Science University	1019348_NYU	1,070	-
	Military Medical Research and Development	12.420	-	43,284	University of Arkansas	UA2023-358	43,284	-
	Basic Scientific Research	12.431	1,782,556	-			1,782,556	-
	Basic Scientific Research	12.431	-	78,779	University of Chicago	AWD103298 (SUB00000861)	78,779	-
	Basic Scientific Research	12.431	-	97,024	University of Chicago	AWD101110 (SUB00000271) A01	97,024	-
	Basic Scientific Research	12.431	-	51,957	University of Maryland	110193-28470203 Amendment A	51,957	-
	Basic Scientific Research	12.431	-	6,798	University of Southern California	79573913 A09	6,798	-
	Basic Scientific Research	12.431	-	90,918	Massachusetts Institute of Technology	s5887	90,918	-
	Basic, Applied, and Advanced Research in Science and Engineering	12.630	-	1,000	Rochester Institute of Technology	A21-0754-001	1,000	-
	Basic, Applied, and Advanced Research in Science and Engineering	12.630	-	148,835	University of Pennsylvania	579327Amd 5	148,835	-
	Air Force Defense Research Sciences Program	12.800	669,875	-			669,875	-
	Air Force Defense Research Sciences Program	12.800	-	2,522	Research Foundation of CUNY on Behalf of City University of New York	CM00005540-03 Amd 3	2,522	-
	Air Force Defense Research Sciences Program	12.800	-	321,713	University of Central Florida	24086226-01 A03	321,713	-
	Air Force Defense Research Sciences Program	12.800	-	62,335	University of Michigan	SUBK00010366 Amendment 3	62,335	-
	Air Force Defense Research Sciences Program	12.800	-	11,374	Massachusetts Institute of Technology	S5204 POW534323	11,374	-
	Research and Technology Development	12.910	1,266,505	-			1,266,505	95,381
	Research and Technology Development	12.910	4,313,879	-			4,313,879	790,801

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Research and Technology Development	12.910	-	125,864	Columbia University	3(GG017183-01) Amendment 05	125,864	-
	Research and Technology Development	12.910	-	506,324	Oregon State University	X-0220A-B Amd 07	506,324	-
	Research and Technology Development	12.910	-	157,348	QuEra Computing Inc.	140D0422C0035-NYUJ A01	157,348	-
	Air Force Medical Readiness Agency Mental Health Resilience Program Evaluation and Enhancement	12.RD	-	101,040	Cherokee Insights LLC	29700-0005 Amd 003	101,040	-
	Applications Driving Architectures (ADA) Center	12.RD	-	131,890	University of Michigan	SUBK00013583 Amd 05	131,890	-
	Automatic Implementation of Secure Silicon (AISS) Program	12.RD	-	30,794	Texas A&M Engineering Experiment Station	M2002172	30,794	-
	Program	12.RD	-	101,615	University of Maryland College Park	91466-Z9568201 Amd C (Phase II)	101,615	27,320
	Multi-Level Randomized Algorithms for High-Frequency Wave Propagation	12.RD	238,001	-		A18-0379-005	238,001	-
	Department of Defense Cyber Scholarship Program	12.RD	34,425	-		A21-0896-001	34,425	-
	Real-Time Multi-Modal Measurements from Subcomponents for Late Stage Attack Detection/Mitigation	12.RD	357,364	-		A23-0298-002	357,364	179,243
	Probabilistic Simulations	12.RD	431,004	-		A19-0511-007	431,004	175,569
	STTR: Phase 2: Multi-Input Strength Loss Sensing for Webbing Structures	12.RD	-	132,562	Luna Innovations	374802NYU	132,562	-
	Trebuchet	12.RD	-	52,582	Duality Technologies Inc.	A21-0464-003	52,582	-
	<b>Total U.S. Department of Defense</b>		<u>20,147,180</u>	<u>3,397,362</u>			<u>23,544,542</u>	<u>3,057,360</u>
	U.S. Department of Housing and Urban Development							
	General Research and Technology Activity	14.506	150,426	-			150,426	14,515
	Research, Evaluation, and Demonstrations	14.536	354,281	-			354,281	-
	<b>Total U.S. Department of Housing and Urban Development</b>		<u>504,707</u>	<u>-</u>			<u>504,707</u>	<u>14,515</u>
	Department of the Interior							
	American Battlefield Protection	15.926	-	6,305	The Fort Ticonderoga Association	2022-01	6,305	-
	<b>Total Department of the Interior</b>		<u>-</u>	<u>6,305</u>			<u>6,305</u>	<u>-</u>
	U.S. Department of Justice							
	Services for Trafficking Victims	16.320	-	28,057	RTI International	1-312-0218345-66908L Mod 1	28,057	-
	National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	-	49,354	Northeastern University	504629-78052 NCE 01	49,354	-
	National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	-	44,764	RTI International	2-312-0217807-66610L Mod1	44,764	-
	Public Safety Partnership and Community Policing Grants	16.710	-	17,793	Seattle Police Department	15JCOPS-21-GG-02288-SPPS	17,793	-
	Public Safety Partnership and Community Policing Grants	16.710	-	24,974	Seattle Police Department	A23-0551-001	24,974	-
	Edward Byrne Memorial Justice Assistance Grant Program	16.738	256,074	-			256,074	-
	Harold Rogers Prescription Drug Monitoring Program	16.754	-	38,848	Pennsylvania Department of Corrections	PO 43006782393 NCE	38,848	-
	Second Chance Act Reentry Initiative	16.812	-	38,494	Persevere	A22-0685-003	38,494	-
	Byrne Criminal Justice Innovation Program	16.817	-	11,447	Vallejo Police Department	A22-0891-001	11,447	-
	Smart Prosecution Initiative	16.825	-	117,944	Winnebago County (WI)	NCE datd 2023-10-16	117,944	-
	Swift, Certain, and Fair Supervision Program: Applying the Principles Behind Project HOPE	16.828	520,777	-			520,777	-
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	1,239	Bronx County (NY)	2018-AR-BX-K025	1,239	-
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	62,691	Dekalb County Court Services	A22-0898-001	62,691	-
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	5,778	Harris County (TX)	2018-AR-BX-K030 (19/0313 NCE)	5,778	-
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	108,703	Ohio Department of Rehabilitation and Correction	2019-BJA-ODRC-VRAT-0001 (Year 4 Funding )	108,703	99,177
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	23,775	Seattle Police Department	22-02331	23,775	-
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	13,173	Winnebago County (WI)	20210914	13,173	-
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	76,459	Winnebago County (WI)	A22-0351-001	76,459	-
	Comprehensive Opioid, Stimulant, and other Substances Use Program	16.838	-	98,973	Davidson Co. Tennessee	A22-0645-002	98,973	-
	Comprehensive Opioid Addition Program	16.RD	-	10,840	Dekalb County Court Services	2018-NYUCOAP1 - Amendment 1	10,840	-
	<b>Total U.S. Department of Justice</b>		<u>776,851</u>	<u>773,306</u>			<u>1,550,157</u>	<u>99,177</u>



# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
U.S. Department of Labor	Reentry Employment Opportunities	17.270	1,224,368	-			1,224,368	504,349
	Reimagine Workforce Center at New York Designs	17.RD	-	131,721	New York State Empire State Development	134510	131,721	13,590
<b>Total U.S. Department of Labor</b>			<u>1,224,368</u>	<u>131,721</u>			<u>1,356,089</u>	<u>517,939</u>
U.S. Department of State	International Programs to Combat Human Trafficking	19.019	917,260	-			917,260	725,693
	International Programs to Combat Human Trafficking	19.019	-	376,751	University of Georgia	SUB00002737 Mod 05	376,751	287,891
	International Programs to Combat Human Trafficking	19.019	-	162,794	University of Georgia	SUB00002736 Mod 03	162,794	63,169
	International Programs to Combat Human Trafficking	19.019	-	13,847	University of Massachusetts Lowell	S5100000046677 Amd 2	13,847	-
	International Programs to Combat Human Trafficking	19.019	-	38,325	International Organization for Migration (Foreign)	A23-0218-002	38,325	-
	Investing in People in The Middle East and North Africa	19.021	28,725	-			28,725	-
	International Programs to Support Democracy, Human Rights and Labor	19.345	721,952	-			721,952	424,937
	Academic Exchange Programs - Scholars	19.401	-	88,256	University of Montana	PG22-26974-02 Amd 2	88,256	-
<b>Total U.S. Department of State</b>			<u>1,667,937</u>	<u>679,973</u>			<u>2,347,910</u>	<u>1,501,690</u>
U.S. Department of Transportation	Federal Support for Local Decision-Making	20.RD	-	671	Weris Inc.	BTS TO-1 (693JK422D800007)	671	-
	Synthesis Support	20.RD	-	8,271	Noblis	20S1DEPNYU Mod 02	8,271	-
	Synthesis Support	20.RD	-	207,953	Noblis	22S155T3NY Modification 2	207,953	-
<b>Total U.S. Department of Transportation</b>			<u>-</u>	<u>216,895</u>			<u>216,895</u>	<u>-</u>
National Aeronautics and Space Administration	Science	43.001	1,214,266	-			1,214,266	99,632
	Science	43.001	-	209,669	American Museum of Natural History	627-2016-1 Amd 8	209,669	-
	Science	43.001	-	14,905	Smithsonian Astrophysical Observatory	G00-21102X A03	14,905	-
	Science	43.001	-	19,015	University of Chicago	FP070308-01 A04	19,015	-
	Science	43.001	-	38,181	Jet Propulsion Laboratory (NASA)	1592259	38,181	-
	Science	43.001	-	69,280	Jet Propulsion Laboratory (NASA)	1679798	69,280	-
	Science	43.001	-	5,682	Jet Propulsion Laboratory (NASA)	RSA No. 1.1693762	5,682	-
	Decoding Extragalactic Stellar Streams: What Will They Teach Us About Dark Matter?	43.RD	-	41,994	Space Telescope Science Institute	HST-HF2-51466.001-A A01 REVISED	41,994	-
	Decoding Extragalactic Stellar Streams: What Will They Teach Us About Dark Matter?	43.RD	-	84,840	Space Telescope Science Institute	HST-HF2-51466.001-A A02	84,840	-
	Hyperrealist, Precise Position, Multi-Astronaut Training With XR Redirected Walking	43.RD	-	74,980	Space Villages	80NSSC22PB193 - NYU Sub 01	74,980	-
	Illuminating the Primeval Universe With Lyman-Alpha	43.RD	-	80,932	Space Telescope Science Institute	HST-HF2-51507.002-A	80,932	-
	Oceans Melting Greenland (OMG)	43.RD	-	(447)	Jet Propulsion Laboratory (NASA)	1541570 Mod 005	(447)	-
	Single-Step Production of Kerosene-Based Fuels from Carbon Dioxide and Hydrogen	43.RD	-	44,953	Air Company	A22-0834-001	44,953	-
	Magnetic Resonance Imaging (MRI) to Assess Changes to Trabecular Microarchitecture of the Hip	43.RD	8,104	-			8,104	-
<b>Total National Aeronautics and Space Administration</b>			<u>1,222,370</u>	<u>683,984</u>			<u>1,906,354</u>	<u>99,632</u>
National Endowment for the Humanities	Promotion of the Humanities Research	45.161	30,784	-			30,784	-
	Promotion of the Humanities Office of Digital Humanities	45.169	28,287	-			28,287	4,853
<b>Total National Endowment for the Humanities</b>			<u>59,071</u>	<u>-</u>			<u>59,071</u>	<u>4,853</u>

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
National Science Foundation								
	COVID-19 Engineering Grants	47.041	3,555,319	-			3,555,319	233,581
	Engineering	47.041	-	64,334	John Jay College of Criminal Justice (CUNY)	CM00007109-01	64,334	-
	Engineering	47.041	-	41,739	New York Institute of Technology	C8ET-1856032-NYU-3 A04	41,739	-
	Engineering	47.041	-	(25,416)	Research Foundation of CUNY on Behalf of City College of New York	CM00001891-03	(25,416)	-
	Engineering	47.041	-	702	Research Foundation of CUNY on Behalf of City College of New York	CM00001891-02	702	-
	Engineering	47.041	-	(5,775)	Research Foundation of CUNY on Behalf of City University of New York	CM00001895-00 Amd 2	(5,775)	-
	Engineering	47.041	-	436,035	Research Foundation of CUNY on Behalf of City University of New York	CM00007240-02	436,035	-
	Engineering	47.041	-	78,351	University of Colorado Boulder	1563012 Amd 01	78,351	-
	Engineering	47.041	-	9,371	University of Wisconsin Madison	893K432 Amendment3	9,371	-
	Engineering	47.041	-	24,796	Worcester Polytechnic Institute	11118-GR Amd 01	24,796	-
	Engineering Grants	47.041	24,224	-			24,224	-
	Mathematical and Physical Sciences	47.049	103,998	-			103,998	-
	Mathematical and Physical Sciences	47.049	9,141,590	-			9,141,590	69,522
	Mathematical and Physical Sciences	47.049	-	108,879	Clemson University	2340-206-2014878 A02	108,879	-
	Mathematical and Physical Sciences	47.049	-	43,222	Columbia University	1(GG017158-01) Amendment 02	43,222	-
	Mathematical and Physical Sciences	47.049	-	60,264	Columbia University	37(GG016228-37) A06	60,264	-
	Mathematical and Physical Sciences	47.049	-	33,556	Cornell University	138361-21049 Amendment No 1	33,556	-
	Mathematical and Physical Sciences	47.049	-	2,282	Queens College (CUNY)	CM00001826-01 (PI Change)	2,282	-
	Mathematical and Physical Sciences	47.049	-	15,134	University of Notre Dame	204303NYU	15,134	-
	Geosciences	47.050	670,054	-			670,054	263,306
	Geosciences	47.050	-	25,254	The University of North Carolina at Charlotte	20190599-01-NYU	25,254	-
	Geosciences	47.050	-	9,272	University Corporation of Atmospheric Research	SUBAWD002258 Mod 1	9,272	-
	Computer and Information Science and Engineering	47.070	4,019	-			4,019	-
	Computer and Information Science and Engineering	47.070	10,439,210	-			10,439,210	47,219
	Computer and Information Science and Engineering	47.070	(23,869)	-			(23,869)	-
	Computer and Information Science and Engineering	47.070	-	7,027	Columbia University	23(GG014586-02) SAPO G16339	7,027	-
	Computer and Information Science and Engineering	47.070	-	5,025	Computing Research Association	CIF2020-NYU-51	5,025	-
	Computer and Information Science and Engineering	47.070	-	137,280	Computing Research Association	2021CIF-NewYork-43 Amd 001	137,280	-
	Computer and Information Science and Engineering	47.070	-	20,619	Cornell University	90026-11333 Amendment 2	20,619	-
	Computer and Information Science and Engineering	47.070	-	3,273	Cornell University	138698-21082 (early termination)	3,273	-
	Computer and Information Science and Engineering	47.070	-	(3)	Princeton University	SUB0000278 A05	(3)	-
	Computer and Information Science and Engineering	47.070	-	1,312	University of California Berkeley	00010971 - Amendment 01	1,312	-
	Computer and Information Science and Engineering	47.070	-	15,620	University of California Los Angeles	0287 G LC410	15,620	-
	Computer and Information Science and Engineering	47.070	-	30,333	University of Southern California	SCON-00002553	30,333	-
	Computer and Information Science and Engineering	47.070	-	92,067	University of Southern California	SCON-00003372 Amendment 1	92,067	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Computer and Information Science and Engineering	47.070	-	10,513	Massachusetts Institute of Technology	55957 Amendment #1	10,513	-
	Biological Sciences	47.074	1,497,738	-			1,497,738	-
	Biological Sciences	47.074	2,387,055	-			2,387,055	306,502
	Biological Sciences	47.074	-	105,849	Cold Spring Harbor Laboratory	52670414 A06	105,849	-
	Biological Sciences	47.074	-	3,274	Columbia University	3(GG016611-01) Amendment 2	3,274	-
	Biological Sciences	47.074	-	143	New Jersey Institute of Technology	997905 Amd 1	143	-
	Biological Sciences	47.074	-	126,980	Rutgers University	1103 MOD 2	126,980	-
	Biological Sciences	47.074	-	260,964	University of Colorado Boulder	1559641	260,964	-
	Biological Sciences	47.074	-	137,193	University of Michigan	3004704725	137,193	-
	Biological Sciences	47.074	-	26,213	University of Nevada Las Vegas	GR15413 A01	26,213	-
	Biological Sciences	47.074	-	64,253	Yale University	GR110626 (CON-80002608) A04	64,253	-
	Biological Sciences	47.074	-	225,325	University of Illinois Urbana-Champaign	101519-18743 A03	225,325	-
	Social, Behavioral, and Economic Sciences	47.075	242,052	-			242,052	-
	Social, Behavioral, and Economic Sciences	47.075	2,417,600	-			2,417,600	73,599
	Social, Behavioral, and Economic Sciences	47.075	49,424	-			49,424	(26,797)
	Social, Behavioral, and Economic Sciences	47.075	-	1,682	The University of Texas at Dallas	1907751_AMD 004	1,682	-
	Social, Behavioral, and Economic Sciences	47.075	-	13,603	The University of Texas at Dallas	2008625_002	13,603	-
	Social, Behavioral, and Economic Sciences	47.075	-	17,674	University of Georgia	SUB00002945	17,674	-
	Social, Behavioral, and Economic Sciences	47.075	-	309	University of Montana	PG19-66897-01	309	-
	Social, Behavioral, and Economic Sciences	47.075	-	51,312	University of Pennsylvania	574835 NCE	51,312	-
	Social, Behavioral, and Economic Sciences	47.075	-	9,781	Villanova University	525919NYU A03	9,781	-
	Education and Human Resources	47.076	149,159	-			149,159	-
	STEM Education (formerly Education and Human Resources)	47.076	8,580,350	-			8,580,350	404,178
	STEM Education (formerly Education and Human Resources)	47.076	-	301,809	Education Development Center	12389 Amd 06 (reduction)	301,809	2,477
	STEM Education (formerly Education and Human Resources)	47.076	-	36,321	Education Development Center	12758 Amd 1	36,321	-
	STEM Education (formerly Education and Human Resources)	47.076	-	6,431	Rensselaer Polytechnic Institute	RPI-A20-0005-S005 Amd 2	6,431	-
	STEM Education (formerly Education and Human Resources)	47.076	-	22,527	Education, Training, and Research Associates (ETR)	PO-1935	22,527	-
	STEM Education (formerly Education and Human Resources)	47.076	-	575	Education, Training, and Research Associates (ETR)	PO-1935 Amd 1	575	-
	STEM Education (formerly Education and Human Resources)	47.076	-	13,750	American Educational Research Association	28-2022	13,750	-
	Polar Programs	47.078	271,672	-			271,672	-
	Office of International Science and Engineering	47.079	114,409	-			114,409	-
	Office of International Science and Engineering	47.079	-	15,780	University of Nevada Las Vegas	GR06611 AMD 6	15,780	-
	Integrative Activities	47.083	1,493,755	-			1,493,755	102,300
	Office of Integrative Activities	47.083	-	20,836	University of Michigan	3003847460	20,836	-
	NSF Technology, Innovation, and Partnerships	47.084	138,168	-			138,168	-
	NSF Technology, Innovation, and Partnerships	47.084	149,827	-			149,827	-
	NSF Technology, Innovation, and Partnerships	47.084	-	55,293	University of Michigan	SUBK00017438 Amendment 1	55,293	-
	NSF Technology, Innovation, and Partnerships	47.084	-	48,497	Carnegie Mellon University	1123649- 463141	48,497	17,816
	Convergence Accelerator Track G Phase 1	47.RD	-	64,894	AT&T Inc.	PO 0000010945 (Phase 2)	64,894	-
	Democratization of Data Analysis	47.RD	329,586	-			329,586	80,263
	Negative Bacteria	47.RD	59,167	-			59,167	-
<b>Total National Science Foundation</b>			<b>41,794,507</b>	<b>2,876,334</b>			<b>44,670,841</b>	<b>1,573,966</b>
Department of Veterans Affairs								
	Boston VA Contract	64.RD	172,959	-			172,959	-
	Preventing Suicide in Rural Veterans: Implementation of an Evidence-Based Telehealth Mindfulness Intervention Trial (The STAR Trial)	64.RD	(2,797)	-			(2,797)	-
	Trial (The STAR Trial)	64.RD	-	6,114	University of Pittsburgh	CNVA00056666 (413614-21)	6,114	-
<b>Total Department of Veterans Affairs</b>			<b>170,162</b>	<b>6,114</b>			<b>176,276</b>	<b>-</b>
U.S. Environmental Protection Agency								
	Science To Achieve Results (STAR) Research Program	66.509	319,509	-			319,509	200,616
	Science To Achieve Results (STAR) Research Program	66.509	-	(9,918)	University of California Davis	A21-2341-S001	(9,918)	-
<b>Total U.S. Environmental Protection Agency</b>			<b>319,509</b>	<b>(9,918)</b>			<b>309,591</b>	<b>200,616</b>

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
U.S. Department of Energy								
	Cybersecurity, Energy Security & Emergency Response (CESER)	81.008	299,812	-			299,812	87,669
	Office of Science Financial Assistance Program	81.049	2,580,386	-			2,580,386	66,429
	Office of Science Financial Assistance Program	81.049	-	159,709	Case Western Reserve University	RES513719 A05	159,709	-
	Office of Science Financial Assistance Program	81.049	-	192,631	College of William and Mary	744402 A02	192,631	-
	Office of Science Financial Assistance Program	81.049	-	1,376	Georgia Institute of Technology	AWD-100234-G2 Amd 16	1,376	-
	Office of Science Financial Assistance Program	81.049	-	249,516	Georgia Institute of Technology	AWD-100234-G2 A18	249,516	-
	Office of Science Financial Assistance Program	81.049	-	24,065	Northwestern University	SP0027267-PROJ0007140 A09	24,065	-
	Office of Science Financial Assistance Program	81.049	-	25	University of California San Diego	111163617 (S9002150) A004	25	-
	Office of Science Financial Assistance Program	81.049	-	123,912	University of California San Diego	111163617 (S9002150) A006	123,912	-
	Conservation Research and Development	81.086	-	91,078	Iowa State University	022853A Amd 1	91,078	-
	Renewable Energy Research and Development	81.087	120,820	-			120,820	-
	Renewable Energy Research and Development	81.087	-	44,217	Yale University	CON-80003263 (GR114316) Amend 1	44,217	-
	Advanced Research Projects Agency - Energy	81.135	-	(18,600)	Columbia University	1(GG017021) Amd 3	(18,600)	-
	A Platform for Scientific Data Management Modeling and Analysis with Machine Learning	81.RD	-	72,698	Parallel Works Inc.	DE-SC0020464-SA1 A01	72,698	-
	Adaptive Online Modeling and Neural Network Learning for the Hydro-Turbine System	81.RD	-	17,716	Oak Ridge National Laboratory	CW451431 Mod 1	17,716	-
	Advanced Dissolution-Based Monolayer Exfoliation/Transfer Methods	81.RD	-	2,725	Brookhaven National Laboratory	PR No. 390681	2,725	-
	AI-Based Modeling and Control for Traffic Flow Systems	81.RD	-	46,644	UT-Battelle LLC c/o Oak Ridge National Laboratory	4000188094 Mod 2	46,644	-
	COINFUPS: CO-Designed Improved Neural Foundations Leveraging Inherent Physics Stochasticity	81.RD	-	179,946	Sandia National Laboratories	2329277 Revision 4	179,946	-
	of the Design of Cyber Protection Architectures	81.RD	-	89,714	Ohio State University	GR121298-SPC-1000004799 Amd 1	89,714	-
	Ice Sheet Model Optimization and Uncertainty Quantification	81.RD	-	5,917	TRIAD National Security LLC	458494 Mod 5	5,917	-
	Spatial and Temporal-Transferable Model for Transit Ridership Forecasting	81.RD	-	102,650	The National Renewable Energy Laboratory	SUB-2022-10407 Mod 1	102,650	-
<b>Total U.S. Department of Energy</b>			<b>3,001,018</b>	<b>1,385,939</b>			<b>4,386,957</b>	<b>154,098</b>
U.S. Department of Education								
	Studies Program and Foreign Language and Area Studies Fellowship Program	84.015	559,207	-			559,207	59,274
	Studies Program and Foreign Language and Area Studies Fellowship Program	84.015	-	98,951	Columbia University	1(GG013993-04) - Amendment 4	98,951	-
	Studies Program and Foreign Language and Area Studies Fellowship Program	84.015	-	107,200	Columbia University	1(GG018046-02)	107,200	-
	Overseas Programs - Doctoral Dissertation Research Abroad	84.022	121,847	-			121,847	-
	Rehabilitation Services-Vocational Rehabilitation Grants to States	84.126	352,933	-			352,933	-
	Graduate Assistance in Areas of National Need	84.200	568,700	-			568,700	-
	Education Research, Development and Dissemination	84.305	3,579,641	-			3,579,641	409,543
	Education Research, Development and Dissemination	84.305	-	22,906	American Institutes for Research	0467100005 Mod 4	22,906	-
	Education Research, Development and Dissemination	84.305	-	65,653	Boston College	5108121-01 Amd 02	65,653	-
	Education Research, Development and Dissemination	84.305	-	23,459	Boston University	4500002734-003	23,459	-
	Education Research, Development and Dissemination	84.305	-	66,253	Manpower Demonstration Research Corporation	1413-NYU-01 Mod 2 (Y3 option)	66,253	-
	Education Research, Development and Dissemination	84.305	-	28,646	Manpower Demonstration Research Corporation	1480-NYU-2000-01 Mod 1	28,646	-
	Education Research, Development and Dissemination	84.305	-	89,850	Ohio University	UT21878 Amd 2	89,850	-
	Education Research, Development and Dissemination	84.305	-	2,743	The Children's Hospital of Philadelphia	20259641	2,743	-
	Education Research, Development and Dissemination	84.305	-	40,339	University of North Carolina Greensboro	A20-0008-S005 A02	40,339	-
	Teacher Quality Partnership Grants	84.336	-	59,104	American Museum of Natural History	802-2020-01 Amd 01	59,104	-
	A More Perfect Union - SBIR Phase II	84.RD	-	20,106	Gigantic Mechanic	91990019C0041 Amd 001	20,106	-
	Evaluating Policies Programs and Strategies to Support English Learners	84.RD	-	123,536	Westat Inc.	6861-S-004	123,536	-
<b>Total U.S. Department of Education</b>			<b>5,182,328</b>	<b>748,746</b>			<b>5,931,074</b>	<b>468,817</b>

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
U.S. Department of Health and Human Services								
	Training in General, Pediatric, and Public Health Dentistry	93.059	641,897	-			641,897	(179,293)
	Training in General, Pediatric, and Public Health Dentistry	93.059	624,773	-			624,773	-
	Chronic Diseases: Research, Control, and Prevention	93.068	1,839,475	-			1,839,475	574,717
	Chronic Diseases: Research, Control, and Prevention	93.068	-	294,747	Cicatelli Associates, Inc.	21-A0-00-1006723	294,747	-
	Environmental Public Health and Emergency Response	93.070	-	1,615	Health Research, Inc.	6750-01	1,615	-
	Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	156,215	-			156,215	-
	Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	-	22,528	University of California San Francisco	12400sc	22,528	-
	Food and Drug Administration Research	93.103	141,783	-			141,783	-
	Food and Drug Administration Research	93.103	-	2,148	Pharmerit International	19164	2,148	-
	Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED)	93.104	-	(21,034)	New York State Office of Mental Health	156246	(21,034)	-
	COVID-19 Environmental Health	93.113	(248)	-			(248)	-
	Environmental Health	93.113	7,765,332	-			7,765,332	955,534
	Environmental Health	93.113	465,406	-			465,406	-
	Environmental Health	93.113	-	1,121	Alaska Community Action on Toxics	R01-10-NYU	1,121	-
	Environmental Health	93.113	-	57,777	Boston University	4500003853	57,777	-
	Environmental Health	93.113	-	18,525	George Mason University	E2050591	18,525	-
	Environmental Health	93.113	-	512,237	Health Research, Inc.	6508-02	512,237	-
	Environmental Health	93.113	-	241,211	Northwestern University	60052569 NYU A03	241,211	-
	Environmental Health	93.113	-	54,825	Research Foundation for Mental Hygiene Inc.	21-A0-00-1005423	54,825	-
	Environmental Health	93.113	-	32,004	Massachusetts Institute of Technology	55876 PO# 868268	32,004	-
	Environmental Health	93.113	-	39,071	Icahn School of Medicine at Mount Sinai	0255-8391-4609	39,071	-
	Environmental Health	93.113	-	190,395	Michigan State University	RC111324A	190,395	-
	Oral Diseases and Disorders Research	93.121	1,280,964	-			1,280,964	64,241
	Oral Diseases and Disorders Research	93.121	5,161,256	-			5,161,256	570,845
	Oral Diseases and Disorders Research	93.121	-	(700)	Carolinas Healthcare System	13100310228 (A21-0106-S005)	(700)	-
	Oral Diseases and Disorders Research	93.121	-	196,842	Carolinas Healthcare System	U01DE022939-10	196,842	-
	Oral Diseases and Disorders Research	93.121	-	34,551	Loma Linda University	2210444-NYU Amend 1	34,551	-
	Oral Diseases and Disorders Research	93.121	-	137,308	Periomics Care LLC	2R42DE028212-03	137,308	-
	Oral Diseases and Disorders Research	93.121	-	574,164	University of Michigan	SUBK00017251	574,164	-
	Oral Diseases and Disorders Research	93.121	-	(9,124)	University of Pennsylvania	583210	(9,124)	-
	Oral Diseases and Disorders Research	93.121	-	11,420	The Regents of the University of California	13471sc	11,420	-
	Oral Diseases and Disorders Research	93.121	-	13,408	Virginia Commonwealth University	FP00016691_SA002 Amend 1	13,408	-
	Oral Diseases and Disorders Research	93.121	-	184,740	Virtually Better Inc.	PHASE II	184,740	-
	Grants to Increase Organ Donations	93.134	-	(18,913)	Hennepin Healthcare Research Institute	22-A0-00-1008729	(18,913)	-
	Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	1,977,147	-			1,977,147	221,862
	Injury Prevention and Control Research and State and Community Based Programs	93.136	333,682	-			333,682	19,203
	Injury Prevention and Control Research and State and Community Based Programs	93.136	312,447	-			312,447	7,720
	Injury Prevention and Control Research and State and Community Based Programs	93.136	-	23,245	Columbia University	4(GG014278-34)	23,245	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Community Programs to Improve Minority Health Grant Program	93.137	228,559	-			228,559	34,000
	Community Programs to Improve Minority Health Grant Program	93.137	-	58,874	Columbia University	1(GG017882-02)	58,874	-
	Community Programs to Improve Minority Health Grant Program	93.137	-	40,849	University of Arizona	682078	40,849	-
	NIEHS Hazardous Waste Worker Health and Safety Training Program Part D Women, Infants, Children and Youth WICY Program)	93.142	-	115,263	Rutgers University	SUB00002399	115,263	-
	Human Genome Research	93.153	475,001	-			475,001	197,834
	Human Genome Research	93.172	3,139,176	-			3,139,176	688,704
	Human Genome Research	93.172	385,347	-			385,347	18,620
	Human Genome Research	93.172	-	56,000	New York Genome Center	2019-0014-NYU-02	56,000	-
	Human Genome Research	93.172	-	36,042	Icahn School of Medicine at Mount Sinai	0255-C621-4609	36,042	-
	Human Genome Research	93.172	-	455,412	The Ontario Institute for Cancer Research	P2022-0001	455,412	-
	Research Related to Deafness and Communication Disorders	93.173	5,172,888	-			5,172,888	953,450
	Research Related to Deafness and Communication Disorders	93.173	4,787,125	-			4,787,125	615,135
	Research Related to Deafness and Communication Disorders	93.173	-	253,672	Brandeis University	403626	253,672	-
	Research Related to Deafness and Communication Disorders	93.173	-	4,392	Massachusetts General Hospital	241940	4,392	-
	Research Related to Deafness and Communication Disorders	93.173	-	53,397	Montclair State University	1R15DC019775-NYU Amd 2	53,397	-
	Research Related to Deafness and Communication Disorders	93.173	-	176,418	North Carolina State University	2018-2600-01	176,418	-
	Research Related to Deafness and Communication Disorders	93.173	-	200,689	North Carolina State University	2018-3244-01	200,689	-
	Research Related to Deafness and Communication Disorders	93.173	-	118,376	University of Texas at Dallas	1806253	118,376	-
	Research Related to Deafness and Communication Disorders	93.173	-	60,302	York Sound Inc.	19-AO-00-1003898	60,302	-
	Research Related to Deafness and Communication Disorders	93.173	-	251,662	York Sound Inc.	22-AO-00-1008207	251,662	-
	Improvement Projects	93.185	-	111,310	Asian/Pacific Islander American Health Forum	NYU-EVAC-2023	111,310	-
	National Research Service Award in Primary Care Medicine	93.186	705,329	-			705,329	69,005
	Research and Training in Complementary and Alternative Medicine	93.213	3,174,872	-			3,174,872	594,272
	Research and Training in Complementary and Alternative Medicine	93.213	-	26,842	Columbia University	1(GG017691-01)	26,842	-
	Research and Training in Complementary and Alternative Medicine	93.213	-	20,930	Johns Hopkins University	2005779854	20,930	-
	Research and Training in Complementary and Alternative Medicine	93.213	-	4,230	Mount Sinai Medical Center of Florida Inc.	UH3AT009149	4,230	-
	Research and Training in Complementary and Integrative Health	93.213	315,263	-			315,263	-
	National Research Service Awards_Health Services Research Training	93.225	624,246	-			624,246	77,473
	Research on Healthcare Costs, Quality and Outcomes	93.226	965,439	-			965,439	178,247
	Research on Healthcare Costs, Quality and Outcomes	93.226	14,148	-			14,148	-
	Research on Healthcare Costs, Quality and Outcomes	93.226	-	147,575	University of Utah	10061646-02-NYU	147,575	-
	Research on Healthcare Costs, Quality and Outcomes	93.226	-	97,637	Fund for Public Health in New York Inc.	84760	97,637	-
	Research on Healthcare Costs, Quality and Outcomes	93.226	-	37,796	Boston Children's Hospital	GENFD0002328206	37,796	-
	National Center on Sleep Disorders Research	93.233	603,637	-			603,637	44,412
	National Center on Sleep Disorders Research	93.233	-	68,385	Columbia University	GG015006-05	68,385	-
	Policy Research and Evaluation Grants	93.239	-	30,663	University of Wisconsin Madison	0000002609 Amd1	30,663	-
	Mental Health Research Grants	93.242	17,321,347	-			17,321,347	3,951,587
	Mental Health Research Grants	93.242	6,820,114	-			6,820,114	580,601
	Mental Health Research Grants	93.242	-	37,557	Boston Medical Center	4141-NYU-06A1	37,557	-
	Mental Health Research Grants	93.242	-	9,441	Brown University	00001444	9,441	-
	Mental Health Research Grants	93.242	-	11,576	Child Mind Institute Inc.	5R01MH115363 Sub N4_AMD5	11,576	-
	Mental Health Research Grants	93.242	-	15,183	Child Mind Institute Inc.	5R01MH115363-03 SubN 1	15,183	-
	Mental Health Research Grants	93.242	-	438,636	Cold Spring Harbor Laboratory	65500112	438,636	-
	Mental Health Research Grants	93.242	-	525,562	Downstate Medical Center (SUNY)	100-1147125-81588 A03	525,562	-
	Mental Health Research Grants	93.242	-	135,973	Hunter College	CM00003379	135,973	-
	Mental Health Research Grants	93.242	-	(654)	Johns Hopkins University	2004660765	(654)	-
	Mental Health Research Grants	93.242	-	59,733	Johns Hopkins University	2004361458 A02	59,733	-
	Mental Health Research Grants	93.242	-	140,501	Pennsylvania State University	NYUMH124605	140,501	-
	Mental Health Research Grants	93.242	-	14,858	Ponce Medical School Foundation Inc.	8571 Amd 2	14,858	-
	Mental Health Research Grants	93.242	-	11,891	Princeton University	SUB0000199	11,891	-
	Mental Health Research Grants	93.242	-	101,395	Princeton University	SUB0000484_003	101,395	-
	Mental Health Research Grants	93.242	-	5,815	Research Foundation for Mental Hygiene Inc.	154740	5,815	-
	Mental Health Research Grants	93.242	-	17,809	Research Foundation for Mental Hygiene Inc.	19-AO-00-1002259	17,809	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Mental Health Research Grants	93.242	-	6,095	Research Foundation for Mental Hygiene Inc.	_AMD 1	6,095	-
	Mental Health Research Grants	93.242	-	12,531	Trustees of Boston University	4500004172 A02	12,531	-
	Mental Health Research Grants	93.242	-	31,453	Universidad de O'Higgins	Subcontract Year 5	31,453	-
	Mental Health Research Grants	93.242	-	247	University of California San Francisco	12239sc-01 NCE	247	-
	Mental Health Research Grants	93.242	-	331,574	University of Minnesota	N006784001	331,574	-
	Mental Health Research Grants	93.242	-	189,293	University of Pennsylvania	583303	189,293	-
	Mental Health Research Grants	93.242	-	11,522	University of Pittsburgh Medical Center	AWD00003551 (135683-1)	11,522	-
	Mental Health Research Grants	93.242	-	45,210	Utrecht University	1R01MH111417-01-1_AMD 6	45,210	-
	Mental Health Research Grants	93.242	-	75,492	Yale University	GR107130 (CON-80001851)	75,492	-
	Mental Health Research Grants	93.242	-	60,137	Yale University, School of Medicine	GR 108340 (CON-80002129)	60,137	-
	Mental Health Research Grants	93.242	-	(2,420)	Washington University/St. Louis School of Medicine	WU-21-103	(2,420)	-
	Mental Health Research Grants	93.242	-	162,773	Washington University	WU-20-233-MOD-3	162,773	-
	Mental Health Research Grants	93.242	-	29,413	Washington University	WU-19-202-MOD-3	29,413	-
	Mental Health Research Grants	93.242	-	16,627	Washington University	WU-22-0246-MOD-2	16,627	-
	Mental Health Research Grants	93.242	-	3,486	Washington University	WU-19-413 MOD 4	3,486	-
	Mental Health Research Grants	93.242	-	(11,685)	University of Illinois at Chicago	17716	(11,685)	-
	Mental Health Research Grants	93.242	-	32,708	Florida State University	R000003114 Amd 1 (Y2)	32,708	-
	Substance Abuse and Mental Health Services_Proj	93.243	1,342,024	-			1,342,024	49,440
	Substance Abuse and Mental Health Services_Proj	93.243	-	83,644	American Academy of Addiction Psychiatry	MFG-18-1	83,644	-
	Substance Abuse and Mental Health Services_Proj	93.243	-	16,683	Frontline Service	001	16,683	-
	Substance Abuse and Mental Health Services_Proj	93.243	-	27,717	University of Connecticut Health Center	UCHC7-170594377	27,717	-
	Substance Abuse and Mental Health Services_Proj	93.243	-	39,555	The New York Foundling	20220422	39,555	-
	Substance Abuse and Mental Health Services_Proj	93.243	-	5,936	Lutheran Medical Center	21-AO-00-1006734	5,936	-
	Substance Abuse and Mental Health Services_Proj	93.243	-	70,909	Richmond University Medical Center	20-AO-00-1005530	70,909	-
	Geriatric Academic Career Awards Department of Health and Human Services	93.250	8,877	-			8,877	-
	COVID-19 Occupational Safety and Health Program	93.262	-	464,585	University of Washington	UWSC12030	464,585	-
	COVID-19 Occupational Safety and Health Program	93.262	-	11,100	Boston Children's Hospital	GENFD0002272614	11,100	-
	Occupational Safety and Health Program	93.262	5,481,892	-			5,481,892	167,493
	Occupational Safety and Health Program	93.262	-	74,848	Columbia University	1(GG015143-01)	74,848	-
	Occupational Safety and Health Program	93.262	-	2,919	Icahn School of Medicine at Mount Sinai	(NCE)	2,919	-
	Occupational Safety and Health Program	93.262	-	188,540	Icahn School of Medicine at Mount Sinai	0253-7132-4609 YEAR 2 FUNDING	188,540	-
	Occupational Safety and Health Program	93.262	-	8,590	Icahn School of Medicine at Mount Sinai	18-00)	8,590	-
	Occupational Safety and Health Program	93.262	-	6,618	Icahn School of Medicine at Mount Sinai	0253-7121-4609	6,618	-
	Occupational Safety and Health Program	93.262	-	56,446	Icahn School of Medicine at Mount Sinai	0253-7131-4609	56,446	-
	Occupational Safety and Health Program	93.262	-	127,920	Icahn School of Medicine at Mount Sinai	0254-B182-4609	127,920	-
	Viral Hepatitis Prevention and Control	93.270	-	58,930	University of Rochester	417702G/URFAO:GR511033 YEAR 3	58,930	-
	Alcohol Research Programs	93.273	6,041,619	-			6,041,619	1,068,390
	Alcohol Research Programs	93.273	82,806	-			82,806	1,233
	Alcohol Research Programs	93.273	-	223,249	Columbia University	1 (GG013596-01)	223,249	-
	Alcohol Research Programs	93.273	-	179	University of California San Francisco	13142sc	179	-
	Alcohol Research Programs	93.273	-	7,895	Pacific Institute For Research and Evaluation	1031	7,895	-
	Alcohol Research Programs	93.273	-	94,131	State University of New York Downstate Medical Center	100-1171618-92873	94,131	-
	Alcohol Research Programs	93.273	-	145,305	Narrows Institute for Biomedical Research	OSP31181-Narrows	145,305	-
	COVID-19 Drug Abuse and Addiction Research Programs	93.279	561,596	-			561,596	24,331
	Drug Abuse and Addiction Research Programs	93.279	40,148,211	-			40,148,211	22,758,170
	Drug Abuse and Addiction Research Programs	93.279	9,144,370	-			9,144,370	1,170,727
	Drug Abuse and Addiction Research Programs	93.279	-	58,457	Boston Medical Center	5701-NYU-03A2	58,457	-
	Drug Abuse and Addiction Research Programs	93.279	-	183,355	Brown University	1568; 1630; 2039	183,355	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Drug Abuse and Addiction Research Programs	93.279	-	27,225	Columbia University	06(GG015428-07)	27,225	-
	Drug Abuse and Addiction Research Programs	93.279	-	11,620	Columbia University	1(GG015428-07)	11,620	-
	Drug Abuse and Addiction Research Programs	93.279	-	153,445	Columbia University	2(GG017257-01)	153,445	-
	Drug Abuse and Addiction Research Programs	93.279	-	20,598	Columbia University	G16101_1(GG014271-01)	20,598	-
	Drug Abuse and Addiction Research Programs	93.279	-	25,389	Columbia University	3(GG013889-01)	25,389	-
	Drug Abuse and Addiction Research Programs	93.279	-	16,993	Columbia University	8(GG010654-01)	16,993	-
	Drug Abuse and Addiction Research Programs	93.279	-	2,087	Cornell University	223130	2,087	-
	Drug Abuse and Addiction Research Programs	93.279	-	16,291	Genecentrix, Inc.	21-AO-00-1007576	16,291	-
	Drug Abuse and Addiction Research Programs	93.279	-	741	Georgia State University	SP00014333-02 Year 3	741	-
	Drug Abuse and Addiction Research Programs	93.279	-	370,881	Hennepin Healthcare Research Institute	15477-06	370,881	-
	Drug Abuse and Addiction Research Programs	93.279	-	273,490	Johns Hopkins University	20-A1-00-1004519	273,490	-
	Drug Abuse and Addiction Research Programs	93.279	-	114,619	Ohio University	UT22399	114,619	-
	Drug Abuse and Addiction Research Programs	93.279	-	42,008	Research Foundation for Mental Hygiene Inc.	903-9014A, TIQR 19950	42,008	-
	Drug Abuse and Addiction Research Programs	93.279	-	34,991	RTI International	2-312-0217653-66169L Mod 3	34,991	-
	Drug Abuse and Addiction Research Programs	93.279	-	112,044	RTI International	3-312-0216573-65366L Mod 7	112,044	-
	Drug Abuse and Addiction Research Programs	93.279	-	(8,545)	SensoDX II LLC	25-67180-S0821	(8,545)	-
	Drug Abuse and Addiction Research Programs	93.279	-	11,197	The Miriam Hospital	7147185AMB	11,197	-
	Drug Abuse and Addiction Research Programs	93.279	-	(2,208)	The Miriam Hospital	7147185SC	(2,208)	-
	Drug Abuse and Addiction Research Programs	93.279	-	292,713	University of California Los Angeles	1557 G WC495	292,713	-
	Drug Abuse and Addiction Research Programs	93.279	-	29,221	University of California Los Angeles	0875 G LB754	29,221	-
	Drug Abuse and Addiction Research Programs	93.279	-	61,558	University of California San Francisco	12627sc Amend 03	61,558	-
	Drug Abuse and Addiction Research Programs	93.279	-	(4,481)	University of Chicago	AWD0662288 (SUB00000091)	(4,481)	-
	Drug Abuse and Addiction Research Programs	93.279	-	26,194	University of Chicago	AWD100228 (SUB00000245)	26,194	-
	Drug Abuse and Addiction Research Programs	93.279	-	98,593	University of Florida	SUB00003700	98,593	-
	Drug Abuse and Addiction Research Programs	93.279	-	30,176	University of Kentucky	3210001561-22-228	30,176	-
	Drug Abuse and Addiction Research Programs	93.279	-	108,531	University of Michigan	SUBK00013921 Year 2	108,531	-
	Drug Abuse and Addiction Research Programs	93.279	-	52,139	University of Minnesota	D009105901	52,139	-
	Drug Abuse and Addiction Research Programs	93.279	-	30,880	University of Washington	UWSC12904	30,880	-
	Drug Abuse and Addiction Research Programs	93.279	-	48,406	University of Washington	UWSC11152 Yr 4 (Amd 4)	48,406	-
	Drug Abuse and Addiction Research Programs	93.279	-	50,807	Wake Forest University	1734-45120-11000001105	50,807	-
	Drug Abuse and Addiction Research Programs	93.279	-	122,937	Wake Forest University	22-AO-00-1008749	122,937	-
	Drug Abuse and Addiction Research Programs	93.279	-	61,016	Wake Forest University	1782-32841-11000001500	61,016	-
	Drug Abuse and Addiction Research Programs	93.279	-	23,775	Weill Medical College of Cornell University	220398-2	23,775	-
	Drug Abuse and Addiction Research Programs	93.279	-	19,882	Weill Medical College of Cornell University	23918-1	19,882	-
	Drug Abuse and Addiction Research Programs	93.279	-	48,008	Yale University	GR110961 (CON-80002662)	48,008	-
	Drug Abuse and Addiction Research Programs	93.279	-	54,209	Yale University	GR104754 Amend 5 nce	54,209	-
	Drug Abuse and Addiction Research Programs	93.279	-	101,087	Yale University	GR104440 (CON-80001625) A05	101,087	-
	Drug Abuse and Addiction Research Programs	93.279	-	20,269	Westat Inc.	6410-S-03 MOD 10	20,269	-
	Drug Abuse and Addiction Research Programs	93.279	-	41,057	University of Rhode Island	0006817/111219	41,057	-
	Drug Abuse and Addiction Research Programs	93.279	-	47,271	Sam Houston State University	p22142A	47,271	-
	Centers for Disease Control and Prevention, Investigations and Technical Assistance	93.283	121,494	-			121,494	-
	Centers for Disease Control and Prevention, Investigations and Technical Assistance	93.283	-	3,000	Stony Brook University	20-AO-00-1005718	3,000	-
	Centers for Disease Control and Prevention, Investigations and Technical Assistance	93.283	-	99,984	Third Sector New England	13940	99,984	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	5,111,694	-			5,111,694	447,050
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	160,055	-			160,055	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	4,667	Children's Research Institute	30004680-04	4,667	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	27,889	Cincinnati Children's Hospital	314370	27,889	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	50,547	Emory University	A571715	50,547	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	34,676	Emory University	A723222 Amendment 1 (NCE)	34,676	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	19,011	Kitware Inc.	K003169-00-S02 Mod 04	19,011	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	134,837	Stanford University Medical Center	63037031-248841	134,837	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	34,369	Icahn School of Medicine at Mount Sinai	0255-F121-4609 Amd 1	34,369	-
	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	31,935	University of California Davis	A22-1701-S001	31,935	-



# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	COVID-19 Minority Health and Health Disparities Research	93.307	310,559	-			310,559	33,121
	Minority Health and Health Disparities Research	93.307	6,117,358	-			6,117,358	564,602
	Minority Health and Health Disparities Research	93.307	-	2,795	Columbia University	4(GG014329-02)	2,795	-
	Minority Health and Health Disparities Research	93.307	-	27,305	Columbia University	8(GG017227-08)	27,305	-
	Minority Health and Health Disparities Research	93.307	-	19,557	George Washington University	21-M44	19,557	-
	Minority Health and Health Disparities Research	93.307	-	61,141	Rutgers University	2139	61,141	-
	Minority Health and Health Disparities Research	93.307	-	563,923	University of California San Francisco	13035sc	563,923	36,540
	Minority Health and Health Disparities Research	93.307	-	26,851	Yale University	CON-80004282 (GR118922)	26,851	-
	Minority Health and Health Disparities Research	93.307	-	25,575	Yale University	CON-80004230(GR119472)	25,575	-
	Minority Health and Health Disparities Research	93.307	804,708	-			804,708	140,057
	Minority Health and Health Disparities Research	93.307	-	293	Boston College	5102111-01 Amd 05	293	-
	Minority Health and Health Disparities Research	93.307	-	72,365	Boston Medical Center	5386-NYU-03A2	72,365	-
	Minority Health and Health Disparities Research	93.307	-	590,219	Rutgers University	2830	590,219	-
	Minority Health and Health Disparities Research	93.307	-	21,180	Rutgers University	2899 (7P50MD017356-02)	21,180	-
	Trans-NIH Research Support	93.310	13,830,309	-			13,830,309	4,261,449
	Trans-NIH Research Support	93.310	1,748,314	-			1,748,314	142,121
	Trans-NIH Research Support	93.310	-	30,885	Columbia University	2(GG017680-01)	30,885	-
	Trans-NIH Research Support	93.310	-	83,330	Columbia University	3(GG017590-05)	83,330	-
	Trans-NIH Research Support	93.310	-	42,998	Columbia University	3(GG017590-11) A01	42,998	-
	Trans-NIH Research Support	93.310	-	16,905	Duke University	2037934	16,905	-
	Trans-NIH Research Support	93.310	-	23,725	Duke University	303001260	23,725	-
	Trans-NIH Research Support	93.310	-	251,531	Yale University	CON-80003429 (GR115119)	251,531	-
	Trans-NIH Research Support	93.310	-	11,590	Oregon Health and Science University	1014493_NYU	11,590	-
	Trans-NIH Research Support	93.310	-	5,039	Narrows Institute for Biomedical Research	19-A0-00-1002521	5,039	-
	Trans-NIH Research Support	93.310	-	1,480	Connecticut Children's Hospital	23-181118-05	1,480	-
	Cognitive Impairment, and Caregiving at the State and Local Levels	93.334	778,798	-			778,798	-
	COVID-19 National Center for Advancing Translational Sciences	93.350	7,969,748	-			7,969,748	2,272,250
	National Center for Advancing Translational Sciences	93.350	10,990,177	-			10,990,177	543,990
	National Center for Advancing Translational Sciences	93.350	-	(40)	Boston University	4500003370	(40)	-
	National Center for Advancing Translational Sciences	93.350	-	15,851	Boston University	4500004197 A005	15,851	-
	National Center for Advancing Translational Sciences	93.350	-	15,850	Boston University	4500004628 A006	15,850	-
	National Center for Advancing Translational Sciences	93.350	-	10,454	University of Illinois at Chicago	18565	10,454	-
	Research Infrastructure Programs	93.351	-	69,610	Cincinnati Children's Hospital	0500000070/400567	69,610	-
	21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	893,179	-			893,179	103,029
	21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	-	433,356	University of Utah	10048536-01	433,356	-
	21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	-	391,332	Dana-Farber Cancer Center	1205904	391,332	-
	21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	-	(9,612)	Dana-Farber Cancer Center	1244010	(9,612)	-
	Response	93.354	-	24,784	JSI Research and Training Institute Inc.	DrN-NYU1-10172022-0001	24,784	-
	Nursing Research	93.361	1,501,412	-			1,501,412	143,875
	Nursing Research	93.361	2,355,496	-			2,355,496	165,044
	Nursing Research	93.361	-	16,605	Icahn School of Medicine at Mount Sinai	0255-F241-4609	16,605	-
	Nursing Research	93.361	-	149,402	Icahn School of Medicine at Mount Sinai	AMENDMENT 2	149,402	-
	Nursing Research	93.361	-	15,265	Stanford University	05; Amendment 4	15,265	-
	Nursing Research	93.361	-	41,908	Yale University	CON-80004219 (GR119439)	41,908	-
	National Center for Research Resources	93.389	(424)	-			(424)	-
	Healthcare Crises	93.391	-	7,889	Asian Pacific Community in Action	NH750T000011	7,889	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Cancer Cause and Prevention Research	93.393	11,900,917	-			11,900,917	1,206,445
	Cancer Cause and Prevention Research	93.393	931,695	-			931,695	350,238
	Cancer Cause and Prevention Research	93.393	-	22,875	Boston Medical Center	6176-NYUSOM-01	22,875	-
	Cancer Cause and Prevention Research	93.393	-	61,144	George Washington University	20-M119 Yr 4 (Amend 03)	61,144	-
	Cancer Cause and Prevention Research	93.393	-	21,372	Iowa State University	023864A Mod 2	21,372	-
	Cancer Cause and Prevention Research	93.393	-	24,825	Johns Hopkins University	2005330186	24,825	-
	Cancer Cause and Prevention Research	93.393	-	18,545	Memorial Sloan Kettering Cancer Center	5 R01 CA207442-06	18,545	-
	Cancer Cause and Prevention Research	93.393	-	9,170	Memorial Sloan Kettering Cancer Center	MSKSUB00000177	9,170	-
	Cancer Cause and Prevention Research	93.393	-	11,743	Pennsylvania State University	NYUCA173465 A02	11,743	-
	Cancer Cause and Prevention Research	93.393	-	10,093	The Rockefeller University	SUB00000142	10,093	-
	Cancer Cause and Prevention Research	93.393	-	20,513	University of Florida	SUB00003497 Amd 1	20,513	-
	Cancer Cause and Prevention Research	93.393	-	304,142	University of North Carolina at Chapel Hill	5118235	304,142	-
	Cancer Cause and Prevention Research	93.393	-	89,080	University of Wisconsin Madison	000000901 Mod 4	89,080	-
	Cancer Cause and Prevention Research	93.393	-	38,823	University of New Mexico	3RCQ4	38,823	-
	Cancer Cause and Prevention Research	93.393	-	10,208	Harvard University	117202-5104484	10,208	-
	Cancer Cause and Prevention Research	93.393	-	77,061	New York-Presbyterian/Weill Cornell Medicine	228291	77,061	-
	Cancer Cause and Prevention Research	93.393	-	63,050	Georgetown University	425076_GR424531-NYUGSM	63,050	-
	Cancer Cause and Prevention Research	93.393	-	27,333	Georgetown University	424987_GR424901-NYUSM	27,333	-
	Cancer Cause and Prevention Research	93.393	-	9,087	Tufts Medical Center, Inc.	5024882_SERV	9,087	-
	COVID-19 Cancer Cause and Prevention Research	93.393	1,468,604	-			1,468,604	-
	Cancer Detection and Diagnosis Research	93.394	5,853,623	-			5,853,623	1,284,510
	Cancer Detection and Diagnosis Research	93.394	-	66,953	Boston University	4500004241, 4500004242	66,953	-
	Cancer Detection and Diagnosis Research	93.394	-	140,394	Emory University	A731030	140,394	-
	Cancer Detection and Diagnosis Research	93.394	-	100,699	Northwestern University	60058989 NYUSOM	100,699	-
	Cancer Detection and Diagnosis Research	93.394	-	9,876	University of Michigan	SUBK00014247	9,876	-
	Cancer Detection and Diagnosis Research	93.394	-	55,267	University of Pennsylvania	584913	55,267	-
	Cancer Detection and Diagnosis Research	93.394	-	43,650	University of Texas Southwestern Medical	GMO: 210504	43,650	-
	Cancer Detection and Diagnosis Research	93.394	-	200,581	Northshore University Health Systems	EH21-211-52	200,581	-
	Cancer Detection and Diagnosis Research	93.394	-	62,143	MD Anderson Cancer Center	3002054826	62,143	-
	COVID-19 Cancer Detection and Diagnosis Research	93.394	(5,477)	-			(5,477)	12,421
	Cancer Treatment Research	93.395	8,556,498	-			8,556,498	496,489
	Cancer Treatment Research	93.395	1,217,581	-			1,217,581	257,424
	Cancer Treatment Research	93.395	-	(820)	Case Western Reserve University	27469-123	(820)	-
	Cancer Treatment Research	93.395	-	135,276	Cynvec LLC	19-A0-00-1003874	135,276	-
	Cancer Treatment Research	93.395	-	(445)	Massachusetts General Hospital	#227583	(445)	-
	Cancer Treatment Research	93.395	-	244,834	Massachusetts General Hospital	233272	244,834	-
	Cancer Treatment Research	93.395	-	(558)	Medical University of South Carolina	A00-3465-S001	(558)	-
	Cancer Treatment Research	93.395	-	290,393	Medical University of South Carolina	A00-3465-S002	290,393	-
	Cancer Treatment Research	93.395	-	(13,093)	Memorial Sloan Kettering Cancer Center	C21957411	(13,093)	-
	Cancer Treatment Research	93.395	-	33,565	NRG Oncology	2021-001	33,565	-
	Cancer Treatment Research	93.395	-	66,557	NRG Oncology	BIQ5FP NRG-BN011	66,557	-
	Cancer Treatment Research	93.395	-	17,374	Public Health Institute	22-A0-00-1008106	17,374	-
	Cancer Treatment Research	93.395	-	50	Public Health Institute	AR13155	50	-
	Cancer Treatment Research	93.395	-	4,416	Public Health Institute	AR14591	4,416	-
	Cancer Treatment Research	93.395	-	32,021	Public Health Institute	AR10421	32,021	-
	Cancer Treatment Research	93.395	-	31,871	TEZCAT Laboratories	22-A0-00-1007484	31,871	-
	Cancer Treatment Research	93.395	-	(8,639)	The Children's Hospital of Philadelphia	15221_SUB868_01	(8,639)	-
	Cancer Treatment Research	93.395	-	30,541	The Children's Hospital of Philadelphia	FP00026529_SUB97_01	30,541	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Cancer Treatment Research	93.395	-	273,687	Boston Children's Hospital	GENFD0002202476	273,687	-
	Cancer Treatment Research	93.395	-	214,190	Dana-Farber Cancer Center	1288103	214,190	-
	Cancer Treatment Research	93.395	-	159,288	Dana-Farber Cancer Center	1226808	159,288	-
	Cancer Treatment Research	93.395	-	104,544	New York-Presbyterian/Weill Cornell Medicine	228320-1	104,544	-
	Cancer Treatment Research	93.395	-	229,170	MD Anderson Cancer Center	3001544835	229,170	-
	Cancer Treatment Research	93.395	-	165,834	Eastern Cooperative Oncology Group	U10CA180820-06-NYU1A	165,834	-
	Cancer Treatment Research	93.395	-	1,250	Eastern Cooperative Oncology Group	18-AO-00-1000945	1,250	-
	Cancer Treatment Research	93.395	-	123,709	Regulonix LLC	1841CA257845-01A1	123,709	-
	COVID-19 Cancer Treatment Research	93.395	1,004,072	-			1,004,072	36,883
	COVID-19 Cancer Treatment Research	93.395	-	63,092	Duke University	116	63,092	-
	Cancer Biology Research	93.396	13,368,109	-			13,368,109	950,289
	Cancer Biology Research	93.396	757,014	-			757,014	-
	Cancer Biology Research	93.396	-	462,629	Cincinnati Children's Hospital	0500000019	462,629	-
	Cancer Biology Research	93.396	-	124,409	Columbia University	1(GG013650-23)	124,409	-
	Cancer Biology Research	93.396	-	230,630	Memorial Sloan Kettering Cancer Center	BD523773D	230,630	-
	Cancer Biology Research	93.396	-	316,573	Memorial Sloan Kettering Cancer Center	SUB00000365AM2	316,573	-
	Cancer Biology Research	93.396	-	71,258	Northwestern University	60061067 NYU	71,258	-
	Cancer Biology Research	93.396	-	41,508	The Children's Hospital of Philadelphia	GRT-00001889	41,508	-
	Cancer Biology Research	93.396	-	17,189	University of California Los Angeles	0865 G YB606	17,189	-
	Cancer Biology Research	93.396	-	32,879	University of California San Francisco	12695sc	32,879	-
	Cancer Biology Research	93.396	-	5,138	Icahn School of Medicine at Mount Sinai	0255-H361-4609	5,138	-
	Cancer Biology Research	93.396	-	232,378	MD Anderson Cancer Center	3001751142	232,378	-
	Cancer Biology Research	93.396	-	(108)	Georgia Tech Research Corporation	AWD-101351-G1	(108)	-
	Cancer Biology Research	93.396	-	90,384	Microstructure Imaging, Inc.	20-A1-00-1002033	90,384	-
	Cancer Biology Research	93.396	-	26,119	Hackensack University Medical Center	G10188-2235	26,119	-
	Cancer Centers Support Grants	93.397	7,408,560	-			7,408,560	46,626
	Cancer Centers Support Grants	93.397	-	56,758	Albert Einstein College of Medicine	312138	56,758	-
	Cancer Centers Support Grants	93.397	-	20,829	Albert Einstein College of Medicine	312353 Amend 4	20,829	-
	Cancer Centers Support Grants	93.397	-	20,978	Indiana University	9554	20,978	-
	Cancer Centers Support Grants	93.397	-	1,700	Icahn School of Medicine at Mount Sinai	0259-G921-4605	1,700	-
	Cancer Research Manpower	93.398	1,654,271	-			1,654,271	25,942
	Cancer Research Manpower	93.398	-	(4,289)	H. Lee Moffitt Cancer Center and Research Institute	10-18711-05-01-G3	(4,289)	-
	Cancer Control	93.399	-	55,405	Case Western Reserve University	20-AO-00-070834	55,405	-
	Cancer Control	93.399	-	80,698	Leidos Biomedical Research, Inc.	TOW: 18X100F2	80,698	-
	Cancer Control	93.399	-	(2,439)	Luna, Inc.	3483.02NYU	(2,439)	-
	Cancer Control	93.399	-	600	Public Health Institute	UG1CA189955	600	-
	Cancer Control	93.399	-	1,052	Public Health Institute	23-AO-00-1010688	1,052	-
	Cancer Control	93.399	-	16,759	University of Arizona	680692	16,759	-
	Cancer Control	93.399	-	48,582	University of Georgia	SUB00002152-3U	48,582	-
	Cancer Control	93.399	-	460,589	Westat Inc.	6410-S-04-T01	460,589	-
	Protect the Nation's Health	93.421	-	(12,295)	Asian/Pacific Islander American Health Forum	20-AO-00-1005825	(12,295)	-
	Protect the Nation's Health	93.421	-	176,442	Asian/Pacific Islander American Health Forum	NYU-FRR-2021	176,442	-
	Protect the Nation's Health	93.421	-	(489)	The Task Force for Global Health, Inc.	PO 3837	(489)	-
	Protect the Nation's Health	93.421	-	84,648	The Task Force for Global Health, Inc.	NUJ80T000316	84,648	-
	Nation's Health	93.421	-	8,237	Docs for Tots	22-AO-00-1007971	8,237	-
	Nation's Health	93.421	-	21,414	University of Washington	UWSC14614	21,414	-
	Nation's Health	93.421	-	15,353	Asian/Pacific Islander American Health Forum	NYU-IPC-2021	15,353	-
	Nation's Health	93.421	-	10,636	Association of University Centers on Disabilities	22-AO-00-1008223	10,636	-
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	429,643	-			429,643	-
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	7,212	Indiana University	8694	7,212	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	88,440	Public Health Institute	03349-AR67041	88,440	-
	Funding Opportunity	93.488	-	9,518	University of Washington	UWSC11453 Amd 3	9,518	-
	Funding Opportunity	93.488	-	66,687	University of Washington	UWSC11453 Amd 4	66,687	-
	Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution	93.498	-	9,914	University of California Los Angeles	1638 P ZA230	9,914	-
	Mental and Behavioral Health Education and Training Grants	93.732	625,633	-			625,633	45,125
	Centers for Medicare and Medicaid Services (CMS) Research, Demonstrations and Evaluations	93.779	-	114,637	Yale New Haven Health System	21-A0-00-1007631	114,637	-
	Cardiovascular Diseases Research	93.837	32,884,096	-			32,884,096	4,268,274
	Cardiovascular Diseases Research	93.837	1,264,781	-			1,264,781	346,716
	Cardiovascular Diseases Research	93.837	-	186	Brigham and Women's Hospital	17-WH-CN-100027	186	-
	Cardiovascular Diseases Research	93.837	-	1,344	Columbia University	7(GG015243-01)	1,344	-
	Cardiovascular Diseases Research	93.837	-	52,852	Columbia University	6(GG015243-01) Amd 4	52,852	-
	Cardiovascular Diseases Research	93.837	-	6,403	Downstate Medical Center (SUNY)	100-1091654-93310 A02	6,403	-
	Cardiovascular Diseases Research	93.837	-	9,501	Johns Hopkins University	22-A0-00-1009305	9,501	-
	Cardiovascular Diseases Research	93.837	-	121,825	Mayo Clinic	NEW-271673/PO #67491353	121,825	-
	Cardiovascular Diseases Research	93.837	-	58,887	Nationwide Children's Hospital	700180-1123-00	58,887	-
	Cardiovascular Diseases Research	93.837	-	22,178	Ohio State University	GR126030   SPC-100006049	22,178	-
	Cardiovascular Diseases Research	93.837	-	267,890	Rutgers University	1733	267,890	-
	Cardiovascular Diseases Research	93.837	-	27,182	University of Miami	OS00000881	27,182	-
	Cardiovascular Diseases Research	93.837	-	71,875	Tufts University	NH0001 Yr. 2	71,875	-
	Cardiovascular Diseases Research	93.837	-	188,515	University of Alabama at Birmingham	000528903-SC002	188,515	-
	Cardiovascular Diseases Research	93.837	-	153,464	University of California San Francisco	11294sc	153,464	-
	Cardiovascular Diseases Research	93.837	-	96,644	University of California San Francisco	11294sc Amend 8	96,644	-
	Cardiovascular Diseases Research	93.837	-	9,327	University of Florida	SUB00003699	9,327	-
	Cardiovascular Diseases Research	93.837	-	48,458	University of Michigan	M5526VHUHNS.	48,458	-
	Cardiovascular Diseases Research	93.837	-	1,839	University of Rochester	417522G/UR FAO GR510851	1,839	-
	Cardiovascular Diseases Research	93.837	-	600,539	University of Washington	UWSC12145	600,539	-
	Cardiovascular Diseases Research	93.837	-	70,342	University of Washington	UWSC12146	70,342	-
	Cardiovascular Diseases Research	93.837	-	3,021	Vanderbilt University	VUMC99716	3,021	-
	Cardiovascular Diseases Research	93.837	-	514,011	Westat Inc.	6922-02-MHCP-5004	514,011	7,345
	Cardiovascular Diseases Research	93.837	-	2,580	Icahn School of Medicine at Mount Sinai	0249-4004-4605	2,580	-
	Cardiovascular Diseases Research	93.837	-	3,302	Icahn School of Medicine at Mount Sinai	0254-3895-4609	3,302	-
	Cardiovascular Diseases Research	93.837	-	605,573	Icahn School of Medicine at Mount Sinai	0255-E231-4609	605,573	-
	Cardiovascular Diseases Research	93.837	-	19,633	Icahn School of Medicine at Mount Sinai	0255-G151-4609 Mechanisti	19,633	-
	Cardiovascular Diseases Research	93.837	-	(1,433)	Washington University/St. Louis School of Medicine	WU-21-431	(1,433)	-
	Cardiovascular Diseases Research	93.837	-	15,820	Washington University	WU-22-0333-MOD-2	15,820	-
	Cardiovascular Diseases Research	93.837	-	24,505	New York-Presbyterian/Weill Cornell Medicine	222499	24,505	-
	Cardiovascular Diseases Research	93.837	-	195,383	New York-Presbyterian/Weill Cornell Medicine	224730-1	195,383	-
	Cardiovascular Diseases Research	93.837	-	356	New York Academy Of Medicine	GT002661_NYU_SOM	356	-
	Cardiovascular Diseases Research	93.837	-	214,663	Louisiana State University Health New Orleans	20-92-005	214,663	-
	Cardiovascular Diseases Research	93.837	-	25,815	Vanderbilt University Medical Center	VUMC75904	25,815	-
	Cardiovascular Diseases Research	93.837	-	33,544	University of Massachusetts, Worcester	OSP27238-NYU	33,544	-
	Cardiovascular Diseases Research	93.837	-	8,909	University of Miami	OS00000855	8,909	-
	Cardiovascular Diseases Research	93.837	-	16,332	Virginia Commonwealth University Health	FP00017333_SA001	16,332	-
	Cardiovascular Diseases Research	93.837	-	64,717	University of Miami Miller School of Medicine	OS00000775	64,717	-
	Cardiovascular Diseases Research	93.837	-	50,000	Duke Clinical Research Institute	383001136	50,000	-
	COVID-19 Cardiovascular Diseases Research	93.837	799,424	-			799,424	-
	COVID-19 Cardiovascular Diseases Research	93.837	-	1,611,740	Westat Inc.	6922-COVID-5013	1,611,740	628,005
	COVID-19 Lung Diseases Research	93.838	156,254,874	-			156,254,874	137,703,097
	COVID-19 Lung Diseases Research	93.838	-	(163)	RTI Health Solutions	31-312-0217571-66402L	(163)	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Lung Diseases Research	93.838	1,518,333	-			1,518,333	50,420
	Lung Diseases Research	93.838	-	74,073	Cvpath Institute, Inc.	21-A0-00-1007507	74,073	-
	Lung Diseases Research	93.838	-	145,976	Duke University	383001464	145,976	-
	Lung Diseases Research	93.838	-	2,038	Northwestern University	160053487 NYU	2,038	-
	Lung Diseases Research	93.838	-	17,023	Rhode Island Hospital	7137715	17,023	-
	Lung Diseases Research	93.838	-	40,679	Stanford University	62346242-131009	40,679	-
	Lung Diseases Research	93.838	-	21,611	University of Cincinnati	013615-00003/00004	21,611	-
	Lung Diseases Research	93.838	-	5,601,405	University of Pittsburgh Medical Center	AWD00002796-1A0	5,601,405	3,706,038
	Lung Diseases Research	93.838	-	79,968	Vanderbilt University	VUMC112170	79,968	-
	Lung Diseases Research	93.838	-	26,403	Yale University, School of Medicine	GR110769(CON-80002544)	26,403	-
	Lung Diseases Research	93.838	-	233,540	New York-Presbyterian/Weill Cornell Medicine	220367-4	233,540	-
	Lung Diseases Research	93.838	-	8,810	Northshore University Health Systems	EH17-325-52	8,810	-
	Lung Diseases Research	93.838	-	2,463	Virginia Commonwealth University Health	FP00018847_SA002	2,463	-
	Lung Diseases Research	93.838	-	401,843	Virginia Commonwealth University Health	OT2HL161847	401,843	-
	Blood Diseases and Resources Research	93.839	3,380,603	-			3,380,603	730,882
	Blood Diseases and Resources Research	93.839	-	(2,371)	Cleveland Clinic Foundation	CCF21110593	(2,371)	-
	Blood Diseases and Resources Research	93.839	-	11,594	Rutgers University	5501501	11,594	-
	Blood Diseases and Resources Research	93.839	-	282,357	University of Pennsylvania	583262	282,357	-
	Blood Diseases and Resources Research	93.839	-	(26,205)	Washington University	WU-18-220-MOD-3	(26,205)	-
	Blood Diseases and Resources Research	93.839	-	12,250	Washington University	WU-18-273-MOD-3	12,250	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	1,598,116	-			1,598,116	52,937
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	477,316	-			477,316	204,523
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	89,326	Covance Inc.	caProtocol # 20203331	89,326	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	101,078	Kintampo Health Research Centre	Hy-Trec 001	101,078	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	18,279	Moi University School of Medicine (Kenya)	19-A0-00-1002675	18,279	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	15,361	Northwestern University	60057974 NYU Amd 1	15,361	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	266,594	University of Abuja	NYU 001	266,594	-
	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	-	(63,809)	University of Washington	UWSC13675	(63,809)	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	11,881,374	-			11,881,374	1,199,655
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	43,786	-			43,786	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	93,247	Boston University	4500004451	93,247	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	10,841	Brigham and Women's Hospital	119899	10,841	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	25,000	Columbia University	1(GG014511-01)	25,000	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	22,372	Hospital for Special Surgery	001	22,372	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	7,737	Hospital for Special Surgery	5R01AR077145-02	7,737	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	34,919	Massachusetts General Hospital	241019	34,919	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	395,718	University of North Carolina at Chapel Hill	5125171	395,718	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	205,711	University of Pennsylvania	577986	205,711	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	152,238	University of Rochester	SUB00000298/URFAO:GR53226	152,238	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	40,946	Icahn School of Medicine at Mount Sinai	0255-G021-4609	40,946	-
	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	15,727	Regenosine	2021-1026	15,727	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	11,864,624	-			11,864,624	1,216,663
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	2,316,780	-			2,316,780	25,720
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	45,376	Albert Einstein College of Medicine	31219D	45,376	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	16,953	Albert Einstein College of Medicine	31219F	16,953	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,844	Albert Einstein College of Medicine	31241E	1,844	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	34,427	Augusta University Research Institute	32307-79	34,427	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	20,848	Columbia University	1(GG015926-02)	20,848	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	32,689	Columbia University	22-A0-00-1009338	32,689	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(338)	George Washington University	21-AO-00-1007095	(338)	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	36,593	George Washington University	23-AO-00-1009421	36,593	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	116,767	Johns Hopkins University	2005476879	116,767	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	66	Rutgers University	0113 (Mod 5)	66	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	41,404	Stanford University	62713287-213702 Amend 2	41,404	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	17,154	Tulane University	TUL-HSC-560068-22/23	17,154	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	22,778	University of California Los Angeles	1556 G 2B332 A01	22,778	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(290)	University of California San Francisco	20-00-00-1005229	(290)	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	79,222	University of Colorado Denver	FY22.269.003	79,222	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	21,681	University of Michigan	SUBK00012123	21,681	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	61,206	University of Pennsylvania	582534	61,206	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	12,172	University of Pennsylvania	585205	12,172	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	7,123	University of Utah	10053701-01	7,123	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	18,294	Vanderbilt University	VUMC104015	18,294	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	17,634	Wake Forest University	20-00-00-1004525	17,634	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(320)	Wake Forest University	21-AO-00-1006177	(320)	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	64,572	Icahn School of Medicine at Mount Sinai	0255-4476-4609	64,572	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(488)	MD Anderson Cancer Center	3001657188	(488)	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,075	University of South Florida	#3732	1,075	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	338,209	Rockefeller University	21-AO-00-1006207	338,209	-
	COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	944,994	-			944,994	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	38,653,841	-			38,653,841	7,242,118
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	3,809,817	-			3,809,817	858,345
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	261,584	Allen Institute	2022-0140	261,584	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	240,705	Allen Institute	2022-0140 A02	240,705	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	131,849	Baylor College of Medicine	PO 7000001288 A03	131,849	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	11,690	Boston University	4500004159	11,690	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	11,415	CND Life Sciences	1R44NS117214	11,415	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	73,422	Columbia University	1(GG017644-02)	73,422	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	443,148	Columbia University	1(GG017705-02)	443,148	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(454)	Columbia University	4(GG015295-01)	(454)	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	23,843	Columbia University	1(GG013374-01) AMD 3	23,843	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	289,978	Columbia University	9(GG017143-08)	289,978	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	43,172	Columbia University Irving Medical Center	1(GG015368-01)	43,172	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	18,358	Columbia University Irving Medical Center	1(GG012278-01)	18,358	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	158,291	Duke University	303-000278 A01	158,291	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	8,171	Emory University	A656023	8,171	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	17,785	Emory University	A748995	17,785	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	76,247	Indiana University	9316-NYU	76,247	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	210,579	Johns Hopkins University	2004835505	210,579	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	74,898	Johns Hopkins University	2005524632	74,898	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	98,710	Massachusetts General Hospital	22-A0-00-1007957	98,710	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	453	Massachusetts General Hospital	238069	453	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	133,912	Massachusetts General Hospital	238257	133,912	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	206,297	Massachusetts General Hospital	239654	206,297	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	313,709	Massachusetts General Hospital	239655	313,709	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(170)	Medical University of South Carolina	A20-0051-5002	(170)	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	554,303	New Jersey Institute of Technology	997809	554,303	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	86,501	New York Genome Center	2019-0018-NYU-01 A05	86,501	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	123,594	New York Genome Center	2019-0035-NYU-01 A02	123,594	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	72,461	New York Genome Center	2019-0035-NYU-01 A04	72,461	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	152	New York Stem Cell Foundation	2002-001	152	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	16,097	Northwestern University	60054977 NYU	16,097	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	20	Northwestern University	60054977-NYU-FR	20	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	195,560	Ohio State University	GR128737   SPC-1000006867	195,560	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,957	Purdue University	11000790-010	3,957	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	80,707	Research Foundation of CUNY on Behalf of City University of New York	CM00001407-04 A04	80,707	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	73,845	Stanford University	61752758-128582	73,845	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	22,160	Stanford University	61869960-125439	22,160	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	197,333	University of California Berkeley	00010180	197,333	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	104,594	University of Chicago	AWD101996 (SUB00000504)	104,594	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	687,357	University of Chicago	FP066214-02-PR-C	687,357	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	540,282	University of Chicago	FP066214-02-PR-F	540,282	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	57,779	University of Cincinnati	010785-138466	57,779	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,536	University of Cincinnati	012043-138466	3,536	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,888	University of Cincinnati	012044-138466	3,888	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	632	University of Cincinnati	012340-138466	632	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	19,450	University of Cincinnati	014386-00002	19,450	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,250	University of Cincinnati	013381-138466	9,250	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	167	University of Cincinnati	013985-138466 (MRI)	167	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	8,000	University of Cincinnati	013888-138466	8,000	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	48,121	University of Colorado Denver	FY21.620.002	48,121	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	105,906	University of Florida	SUB00003726	105,906	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(2)	University of Georgia	SUB00002740	(2)	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	75,178	University of Georgia	SUB00003041	75,178	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	216,633	University of Michigan	SUBK00010533	216,633	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	241,418	University of Rochester	417852-G/UR FAO GRS11130 A02	241,418	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	678,370	University of Rochester	417852-G/UR FAO GRS11130 A05	678,370	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	33,130	University of Southern California	132589641	33,130	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(26,043)	University of Washington	UWSC10761 A02	(26,043)	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	84,893	University of Washington	UWSC10761 A04	84,893	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	74,084	Weill Cornell Medicine	222501	74,084	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	250,013	Icahn School of Medicine at Mount Sinai	0255-E771-4609	250,013	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	30,000	Icahn School of Medicine at Mount Sinai	0255-F851-4609	30,000	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	21,668	Icahn School of Medicine at Mount Sinai	0255-G861-4609	21,668	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	70,822	Regulonix LLC	R41NS122545-01A1	70,822	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	39,475	University of Cincinnati College of Medicine	011337-138466	39,475	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	122,575	NeuroPace	13878	122,575	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	149,403	Epitel, Inc.	20-A0-00-1005233	149,403	-
	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	7,926	Temple University	264814-NYU	7,926	-
	Allergy and Infectious Diseases Research	93.855	24,776,467	-			24,776,467	2,134,458
	Allergy and Infectious Diseases Research	93.855	4,723,438	-			4,723,438	1,594,622
	Allergy and Infectious Diseases Research	93.855	-	29,349	Benaroya Research Institute at Virginia	FY21ITN421	29,349	-
	Allergy and Infectious Diseases Research	93.855	-	1,236,785	Benaroya Research Institute at Virginia	FY22ITN552	1,236,785	-
	Allergy and Infectious Diseases Research	93.855	-	(10,374)	Columbia University	1(GG017900-01)	(10,374)	-
	Allergy and Infectious Diseases Research	93.855	-	677,293	Columbia University	3(GG017735-05)	677,293	-
	Allergy and Infectious Diseases Research	93.855	-	77,123	Columbia University	1(GG017990-01)	77,123	-
	Allergy and Infectious Diseases Research	93.855	-	14,620	Columbia University	22-A0-00-1009336	14,620	-
	Allergy and Infectious Diseases Research	93.855	-	4,049	Columbia University	22-A0-00-1009337	4,049	-
	Allergy and Infectious Diseases Research	93.855	-	6,927	Columbia University	23-A0-00-1009335	6,927	-
	Allergy and Infectious Diseases Research	93.855	-	3,373	Columbia University	23-A0-00-1009439	3,373	-
	Allergy and Infectious Diseases Research	93.855	-	86,005	Emory University	A704157	86,005	-
	Allergy and Infectious Diseases Research	93.855	-	23,423	Emory University	A566295	23,423	-
	Allergy and Infectious Diseases Research	93.855	-	163,051	Icahn School of Medicine at Mount Sinai	0255-G611-4609 A01	163,051	-
	Allergy and Infectious Diseases Research	93.855	-	194,005	Ingenious Targeting Laboratory	22-A0-00-1007636	194,005	-
	Allergy and Infectious Diseases Research	93.855	-	2,096	Johns Hopkins University	18-A0-00-1001680	2,096	-
	Allergy and Infectious Diseases Research	93.855	-	3,106	Johns Hopkins University	19-A0-00-1003004	3,106	-
	Allergy and Infectious Diseases Research	93.855	-	53,170	Johns Hopkins University	TOH-LDR 04 MOD 02	53,170	-
	Allergy and Infectious Diseases Research	93.855	-	366,771	Johns Hopkins University	1X9PXMkW5KW8	366,771	-
	Allergy and Infectious Diseases Research	93.855	-	116,768	Johns Hopkins University	22-A0-00-1009931	116,768	-
	Allergy and Infectious Diseases Research	93.855	-	25,320	Massachusetts General Hospital	234439	25,320	-
	Allergy and Infectious Diseases Research	93.855	-	72,612	Northeastern University	500828-78052 Amd 1	72,612	-
	Allergy and Infectious Diseases Research	93.855	-	2,698	Northwestern University	60062888 NYU	2,698	-
	Allergy and Infectious Diseases Research	93.855	-	25,267	Quality Biological, Inc.	PO01015	25,267	-
	Allergy and Infectious Diseases Research	93.855	-	1,133	Quality Biological, Inc.	TonyuSAMP001-PO#43317	1,133	-



# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Allergy and Infectious Diseases Research	93.855	-	104,189	Stanford University	62561929-194071	104,189	-
	Allergy and Infectious Diseases Research	93.855	-	(4)	University of Florida	SUB00001704	(4)	-
	Allergy and Infectious Diseases Research	93.855	-	171,822	University of Georgia	SUB00002153-3U A06	171,822	-
	Allergy and Infectious Diseases Research	93.855	-	276,253	University of Georgia	SUB00002152 -4A	276,253	-
	Allergy and Infectious Diseases Research	93.855	-	434,468	University of Georgia	SUB00002153-4A	434,468	-
	Allergy and Infectious Diseases Research	93.855	-	(313)	University of Maryland	1701066C/UMB Ref.4468	(313)	-
	Allergy and Infectious Diseases Research	93.855	-	61,545	University of Maryland	20338-0761 Amend 1	61,545	-
	Allergy and Infectious Diseases Research	93.855	-	14,084	University of North Carolina at Chapel Hill	5120657	14,084	-
	Allergy and Infectious Diseases Research	93.855	-	154,019	University of Pennsylvania	583556	154,019	-
	Allergy and Infectious Diseases Research	93.855	-	230,763	University of Pennsylvania	585388	230,763	-
	Allergy and Infectious Diseases Research	93.855	-	46,816	University of Texas at Arlington	2021GC0742	46,816	-
	Allergy and Infectious Diseases Research	93.855	-	48,018	University of Texas at Arlington	2021GC0742 A002	48,018	-
	Allergy and Infectious Diseases Research	93.855	-	73,012	Yale University	FUTURE	73,012	-
	Allergy and Infectious Diseases Research	93.855	-	33,610	Zymeron Corporation	Z121/NYU	33,610	-
	Allergy and Infectious Diseases Research	93.855	-	(3,013)	Icahn School of Medicine at Mount Sinai	0255-D001-4609	(3,013)	-
	Allergy and Infectious Diseases Research	93.855	-	37,276	Icahn School of Medicine at Mount Sinai	0255-D341-4609	37,276	-
	Allergy and Infectious Diseases Research	93.855	-	775	Icahn School of Medicine at Mount Sinai	0255-E321-4609	775	-
	Allergy and Infectious Diseases Research	93.855	-	335,919	Icahn School of Medicine at Mount Sinai	0258-A504-4609	335,919	-
	Allergy and Infectious Diseases Research	93.855	-	34,553	Icahn School of Medicine at Mount Sinai	0255-H161-4609	34,553	-
	Allergy and Infectious Diseases Research	93.855	-	75,726	Rockefeller University	SUB00000211	75,726	-
	Allergy and Infectious Diseases Research	93.855	-	36,297	Rockefeller University	SUB00000336	36,297	-
	Allergy and Infectious Diseases Research	93.855	-	40,277	Stellenbosch University, South Africa	S006234	40,277	-
	Allergy and Infectious Diseases Research	93.855	-	(7,135)	Feinstein Institute for Medical Research	AWD00001202 - NYU	(7,135)	-
	Allergy and Infectious Diseases Research	93.855	-	(4,796)	Fred Hutchinson Cancer Research Center	0001064988	(4,796)	-
	Allergy and Infectious Diseases Research	93.855	-	83,526	University of Texas Health Science Center at San Antonio	171788/171384	83,526	-
	Allergy and Infectious Diseases Research	93.855	-	26,217	General Nutraceutical Technology, LLC	23-AO-00-1009426	26,217	-
	Allergy and Infectious Diseases Research	93.855	-	22,577	University of Surrey	RC6117	22,577	-
	Allergy and Infectious Diseases Research	93.855	-	23,174	University of Surrey	RC6118	23,174	-
	Allergy and Infectious Diseases Research	93.855	-	182,222	St Jude Children's Research Hospital	GR-0002332 A04	182,222	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	4,658,853	-			4,658,853	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	136,214	Humanetics Corporation	272201800011C	136,214	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	18,934	Ingenious Targeting Laboratory	20-00-00-1005256	18,934	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	96,070	Johns Hopkins University	M55Z6VHJH8	96,070	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	484,729	Leidos Biomedical Research, Inc.	22CTA-DM0013	484,729	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	390,855	Leidos Biomedical Research, Inc.	22CTA-DM0016	390,855	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	219,805	Leidos Biomedical Research, Inc.	22-AO-00-1008650	219,805	-
	COVID-19 Allergy and Infectious Diseases Research	93.855	-	(509)	Stanford University Medical Center	625000013-128779	(509)	-
	Biomedical Research and Research Training	93.859	14,327,943	-			14,327,943	163,157
	Biomedical Research and Research Training	93.859	13,525,078	-			13,525,078	463,289
	Biomedical Research and Research Training	93.859	-	87,501	Cornell University	213071	87,501	-
	Biomedical Research and Research Training	93.859	-	59,963	Drexel University	900003 Y2 Amd 02	59,963	-
	Biomedical Research and Research Training	93.859	-	23,398	Drexel University	900173	23,398	-
	Biomedical Research and Research Training	93.859	-	23,518	Drexel University	900210 Amd No. 1	23,518	-
	Biomedical Research and Research Training	93.859	-	18,718	University of California San Diego	122991430-001 (S9002428)	18,718	-
	Biomedical Research and Research Training	93.859	-	13,537	University of Connecticut	150946017	13,537	-
	Biomedical Research and Research Training	93.859	-	30,008	University of Connecticut	163354617	30,008	-
	Biomedical Research and Research Training	93.859	-	68,778	Yale University	CON-80004119 (GR119021)	68,778	-
	Child Health and Human Development Extramural Research	93.865	6,700,906	-			6,700,906	1,364,174
	Child Health and Human Development Extramural Research	93.865	5,246,348	-			5,246,348	1,036,694
	Child Health and Human Development Extramural Research	93.865	-	13,632	Brigham and Women's Hospital	127479	13,632	-
	Child Health and Human Development Extramural Research	93.865	-	28,169	Emory University	A513975 A01	28,169	-
	Child Health and Human Development Extramural Research	93.865	-	234,967	Emory University	A709195 A02	234,967	-
	Child Health and Human Development Extramural Research	93.865	-	306,016	Harvard School of Public Health	117267-0114-5119096	306,016	-
	Child Health and Human Development Extramural Research	93.865	-	233,068	Harvard School of Public Health	117267-0180-5119094	233,068	-
	Child Health and Human Development Extramural Research	93.865	-	11,118	Harvard School of Public Health	117267-0386-5125978	11,118	-
	Child Health and Human Development Extramural Research	93.865	-	4,620	Kessler Foundation	40568-01 Amd 1	4,620	-
	Child Health and Human Development Extramural Research	93.865	-	(14,889)	Princeton University	SUB00000200	(14,889)	-
	Child Health and Human Development Extramural Research	93.865	-	6,047	Rehabilitation Institute of Chicago	82327.NYU.Y2.A1	6,047	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Child Health and Human Development Extramural Research	93.865	-	8,238	Rutgers University	1471	8,238	-
	Child Health and Human Development Extramural Research	93.865	-	110,728	Rutgers University	20-A0-00-1003832	110,728	-
	Child Health and Human Development Extramural Research	93.865	-	21,785	Saint Louis University	21612-43391	21,785	-
	Child Health and Human Development Extramural Research	93.865	-	3,800	Seattle Children's Hospital	21-A0-00-1007264	3,800	-
	Child Health and Human Development Extramural Research	93.865	-	36,236	Tulane University	TUL-HSC-S57474-19/20 Amd 1	36,236	-
	Child Health and Human Development Extramural Research	93.865	-	(190)	University of Alabama at Birmingham	000509380-SP004-SC013 AAD1	(190)	-
	Child Health and Human Development Extramural Research	93.865	-	18,599	University of California Irvine	2022-1736	18,599	-
	Child Health and Human Development Extramural Research	93.865	-	36,823	University of California San Francisco	12343sc	36,823	-
	Child Health and Human Development Extramural Research	93.865	-	81,688	University of Minnesota	A008487501	81,688	-
	Child Health and Human Development Extramural Research	93.865	-	23,986	University of North Carolina at Chapel Hill	5126128 Amd 01	23,986	-
	Child Health and Human Development Extramural Research	93.865	-	7,258	Yale University, School of Medicine	CON-80004324 (GR119986)	7,258	-
	Child Health and Human Development Extramural Research	93.865	-	164,027	Washington University	WU-19-419-MOD-5	164,027	-
	Child Health and Human Development Extramural Research	93.865	-	94,862	Nathan S. Kline Institute For Psychiatric Research	148691	94,862	-
	Child Health and Human Development Extramural Research	93.865	-	11,027	The Trustees of Columbia University	1(GG017649-01)	11,027	-
	Aging Research	93.866	30,463,272	-			30,463,272	3,168,855
	Aging Research	93.866	4,592,272	-			4,592,272	833,489
	Aging Research	93.866	-	319,119	Arizona Board of Regents for and on Behalf of Arizona State University	ASUB00000533 A03	319,119	-
	Aging Research	93.866	-	(526)	Brown University	00000974	(526)	-
	Aging Research	93.866	-	33,001	Brown University	00001363	33,001	-
	Aging Research	93.866	-	49,314	Brown University	00001371	49,314	-
	Aging Research	93.866	-	466,163	Brown University	00002031	466,163	-
	Aging Research	93.866	-	26,381	Brown University	00002054 A1	26,381	-
	Aging Research	93.866	-	250,461	Brown University	00001370	250,461	-
	Aging Research	93.866	-	51,923	Columbia University	1(GG016423-01)	51,923	-
	Aging Research	93.866	-	44,225	Columbia University	11(GG015822-05)	44,225	-
	Aging Research	93.866	-	1,404	Columbia University	3(GG01242-03)	1,404	-
	Aging Research	93.866	-	(6,475)	Columbia University	GG015245 Yr 3	(6,475)	-
	Aging Research	93.866	-	9,344	Columbia University	3(GG012042-04)	9,344	-
	Aging Research	93.866	-	314,694	Dartmouth College	R1624	314,694	17,214
	Aging Research	93.866	-	(1,810)	Diamir, LLC	17-A0-00-006660	(1,810)	-
	Aging Research	93.866	-	27,186	Duke University	303000379	27,186	-
	Aging Research	93.866	-	56,334	Duke University Medical Center	303001205	56,334	-
	Aging Research	93.866	-	35,149	Emory University	Subaward No. A684268	35,149	-
	Aging Research	93.866	-	41,537	Icahn School of Medicine at Mount Sinai	0255-D552-4609; 5R01AG067045-02	41,537	-
	Aging Research	93.866	-	22,823	Icahn School of Medicine at Mount Sinai	0255-G331-4609	22,823	-
	Aging Research	93.866	-	25,000	Indiana University	Amendment No 2	25,000	-
	Aging Research	93.866	-	72,000	Indiana University	Subaward 9570	72,000	-
	Aging Research	93.866	-	243,267	Johns Hopkins University	2004459373	243,267	-
	Aging Research	93.866	-	15,802	Johns Hopkins University	22-A0-00-1008635	15,802	-
	Aging Research	93.866	-	96,948	Johns Hopkins University	2005915173	96,948	-
	Aging Research	93.866	-	(1,112)	Massachusetts General Hospital	236484	(1,112)	-
	Aging Research	93.866	-	7,139	Massachusetts General Hospital	236564	7,139	-
	Aging Research	93.866	-	30,275	Memorial Sloan Kettering Cancer Center	B0523817	30,275	-
	Aging Research	93.866	-	118,392	Memorial Sloan Kettering Cancer Center	C21919392	118,392	-
	Aging Research	93.866	-	50,242	Rutgers University	2874	50,242	-
	Aging Research	93.866	-	24,996	Rutgers University	22-A0-00-1008163	24,996	-
	Aging Research	93.866	-	11,315	Rutgers University	2802	11,315	-
	Aging Research	93.866	-	10,719	Rutgers University	3135; 7R01AG066139-04	10,719	-
	Aging Research	93.866	-	9,979	Rutgers University	2741	9,979	-
	Aging Research	93.866	-	27,771	Rutgers University	2703	27,771	-
	Aging Research	93.866	-	86,251	Translational Genomics Research Institute	SCHORK-19-01 Mod. 05	86,251	-
	Aging Research	93.866	-	203,842	University of California Irvine	2018-3569	203,842	-
	Aging Research	93.866	-	21,032	University of California San Diego	704546	21,032	-
	Aging Research	93.866	-	16,061	University of California San Francisco	(Year 2)	16,061	-
	Aging Research	93.866	-	364	University of Pennsylvania	580208	364	-
	Aging Research	93.866	-	12,408	University of Pennsylvania	5-R56-AG-069130-02	12,408	-
	Aging Research	93.866	-	349	University of Southern California	81622917	349	-

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
Aging Research		93.866	-	1,780	University of Southern California	120112427	1,780	-
Aging Research		93.866	-	11,505	University of Southern California	SCON-00003467	11,505	-
Aging Research		93.866	-	178,800	University of Washington	UWSC12989	178,800	-
Aging Research		93.866	-	92,672	University of Wisconsin	000001234	92,672	-
Aging Research		93.866	-	30,017	Yale University	Amendment No 1	30,017	-
Aging Research		93.866	-	43,144	Yale University	CON-80003446 (GR115071) A01	43,144	-
Aging Research		93.866	-	36,867	Ichan School of Medicine at Mount Sinai	0255-3651-4609	36,867	-
Aging Research		93.866	-	260,176	Ichan School of Medicine at Mount Sinai	0255-DS21-4609	260,176	-
Aging Research		93.866	-	41,541	Washington University	WU-19-57 ORG CODE CHANGE	41,541	-
Aging Research		93.866	-	(14)	New York-Presbyterian/Weill Cornell Medicine	201931	(14)	-
Aging Research		93.866	-	94,457	New York-Presbyterian/Weill Cornell Medicine	202565-1	94,457	-
Aging Research		93.866	-	5,847	New York-Presbyterian/Weill Cornell Medicine	220555	5,847	-
Aging Research		93.866	-	18,850	New York-Presbyterian/Weill Cornell Medicine	228338-1	18,850	-
Aging Research		93.866	-	16,800	MD Anderson Cancer Center	3001841638	16,800	-
Aging Research		93.866	-	40,105	University of Miami	O500001082	40,105	-
Aging Research		93.866	-	15,100	University of Miami	O500000960	15,100	-
Aging Research		93.866	-	16,583	Northern California Institute for Research and Education	79634841	16,583	-
Aging Research		93.866	-	110,121	St. Joseph's Hospital and Medical Center	32114-NYUSOM	110,121	-
Aging Research		93.866	-	104,325	Autotune Me LLC	585706 (P30AG073105)	104,325	-
Aging Research		93.866	-	34,632	Banner Research	0435-06-168033	34,632	-
Aging Research		93.866	-	65,455	Regenerix LLC	1R41AG069606-01-A1 Admen. 1	65,455	-
Aging Research		93.866	-	19,302	University of Texas San Antonio	1000005095 Amendment 0001	19,302	-
Vision Research		93.867	7,655,351	-			7,655,351	937,200
Vision Research		93.867	5,034,793	-			5,034,793	55,183
Vision Research		93.867	-	47,561	Arizona Board of Regents for and on Behalf of Arizona State University	ASUB00000931 A03	47,561	-
Vision Research		93.867	-	18,258	Baylor College of Medicine	7000000348 A04	18,258	-
Vision Research		93.867	-	130,060	Northwestern University	60060095 NYU	130,060	-
Vision Research		93.867	-	9,889	University of Alabama at Birmingham	000513702-SC003	9,889	-
Vision Research		93.867	-	205,085	University of California Irvine	2020-1255 A04	205,085	-
Vision Research		93.867	-	32,461	University of California San Francisco	12057sc	32,461	-
Vision Research		93.867	-	116,706	University of Pennsylvania	21-A1-00-1005378	116,706	-
Vision Research		93.867	-	14,884	Oregon Health and Science University	1020944_NYUGSM	14,884	-
Vision Research		93.867	-	164,318	Harvard Medical School	533387	164,318	-
Medical Library Assistance		93.879	673,788	-			673,788	29,911
Medical Library Assistance		93.879	284,293	-			284,293	-
Medical Library Assistance		93.879	-	97,266	Columbia University	1(GG016995-01)	97,266	-
Medical Library Assistance		93.879	-	2,617	Medical University of South Carolina	A00-3641-50003	2,617	-
Medical Library Assistance		93.879	-	136,145	Stevens Institute of Technology	2102971-01 Amd 06	136,145	-
Medical Library Assistance		93.879	-	115,606	Vanderbilt University Medical Center	VUMC100595	115,606	-
Medical Library Assistance		93.879	-	3,759	University of Massachusetts, Worcester	23-A0-00-1009920	3,759	-
Medical Library Assistance		93.879	-	534,654	University of Massachusetts School of Medicine	SUB00000030	534,654	-
Primary Care Training and Enhancement		93.884	26,410	-			26,410	-
National Bioterrorism Hospital Preparedness Program		93.889	-	686	Health Research, Inc.	22-A0-00-1009371	686	-
National Bioterrorism Hospital Preparedness Program		93.889	-	14,624	Yale University	GR107609 (CON-80001923) Amd 04	14,624	-
National Bioterrorism Hospital Preparedness Program		93.889	-	185,174	Public Health Solutions	19-A0-00-1001354	185,174	-
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease (Ryan White HIV/AIDS Program Part C)		93.918	719,573	-			719,573	228,047

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
	Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Grants	93.924	348,226	-			348,226	-
	Assistance Programs for Chronic Disease Prevention and Control	93.945	654,478	-			654,478	-
	CDC's Collaboration with Academia to Strengthen Public Health	93.967	-	4,077	Association of American Medical Colleges	21-A0-00-1008128	4,077	-
	Primary Care Medicine and Dentistry Clinician Educator Career Development Awards	93.976	35,020	-			35,020	(1,916)
	Primary Care Medicine and Dentistry Clinician Educator Career Development Awards	93.976	-	64,844	University of Rochester	SUB00000399 / GRS33478	64,844	-
	Quality Payment Program	93.986	-	23,576	Yale New Haven Health System	20-A0-00-1005685	23,576	-
	International Research and Research Training	93.989	509,656	-			509,656	139,419
	International Research and Research Training	93.989	236,087	-			236,087	51,637
	International Research and Research Training	93.989	-	33,600	Washington University	WU-23-0118-MOD-1	33,600	-
	Maternal and Child Health Services Block Grant to the States	93.994	(28)	-			(28)	-
	NIH Infant and Toddler Toolbox Task Order 4	93.RD	-	57,060	Northwestern University	SP0077551 60063489 NYU	57,060	-
	Pilot Testing, Refinement, and Validating of the NBT, and Preparation for Norming Study	93.RD	-	24,163	Northwestern University	SP0070625 60061130 TO 3 NYU	24,163	-
	Affinity Reagents for the Immune System of Golden Hamster	93.RD	-	9,486	Qoolabs, Inc.	22-A0-00-1008847	9,486	-
	Scientific Registry of Transplant Recipients	93.RD	-	280,102	Hennepin Healthcare Research Institute	22-A0-00-1008729	280,102	-
	<b>Total U.S. Department of Health and Human Services</b>		<u>628,992,618</u>	<u>60,022,069</u>			<u>689,014,687</u>	<u>219,499,644</u>
	<b>U.S. Department of Homeland Security</b>							
	Hazard Mitigation Grant Program (HMGP)	97.039	-	61,039	New York State Division of Homeland Security & Emergency Services	C000912	61,039	-
	Assistance to Firefighters Grant	97.044	484,709	-			484,709	-
	Centers for Homeland Security	97.061	-	100,934	University of Michigan	SUBK00015680 Amd 01	100,934	-
	<b>Total U.S. Department of Homeland Security</b>		<u>484,709</u>	<u>161,973</u>			<u>646,682</u>	<u>-</u>
	<b>U.S. Agency for International Development</b>							
	USAID Foreign Assistance for Programs Overseas	98.001	-	2,922	National Academy of Sciences	2000010558 03	2,922	-
	USAID Foreign Assistance for Programs Overseas	98.001	-	3,705	Purdue University	F9002550402096	3,705	-
	<b>Total U.S. Agency for International Development</b>		<u>-</u>	<u>6,627</u>			<u>6,627</u>	<u>-</u>
	<b>Total Research and Development Cluster</b>		<u>708,522,728</u>	<u>71,836,410</u>			<u>780,359,138</u>	<u>227,410,540</u>
Health Center Programs Cluster:								
	<b>U.S. Department of Health and Human Services</b>							
	Health Center Program (Community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care)	93.224	-	593,038	The Division of Public Health Services / Health Resources and Services Administration	21-FH-CN-100148	593,038	-
	<b>Total U.S. Department of Health and Human Services</b>		<u>-</u>	<u>593,038</u>			<u>593,038</u>	<u>-</u>
	<b>Total Health Center Programs Cluster</b>		<u>-</u>	<u>593,038</u>			<u>593,038</u>	<u>-</u>
Highway Planning and Construction Cluster:								
	<b>U.S. Department of Transportation</b>							
	Highway Planning and Construction (Federal-Aid Highway Program)	20.205	-	844,296	New York State Department of Transportation	C037859 NCE	844,296	575,602
	Highway Planning and Construction (Federal-Aid Highway Program)	20.205	-	672	Research Foundation of CUNY on Behalf of City College of New York	Subaward #: CM00006804-00	672	-
	Highway Planning and Construction (Federal-Aid Highway Program)	20.205	-	45,773	Research Foundation of CUNY on Behalf of City University of New York	57315-03-29 NCE	45,773	-
	<b>Total U.S. Department of Transportation</b>		<u>-</u>	<u>890,741</u>			<u>890,741</u>	<u>575,602</u>
	<b>Total Highway Planning and Construction Cluster</b>		<u>-</u>	<u>890,741</u>			<u>890,741</u>	<u>575,602</u>
Highway Safety Cluster:								
	<b>U.S. Department of Transportation</b>							
	Incentive Grant Program to Prohibit Racial Profiling	20.611	-	121,394	University of Connecticut	170302155	121,394	-
	<b>Total U.S. Department of Transportation</b>		<u>-</u>	<u>121,394</u>			<u>121,394</u>	<u>-</u>
	<b>Total Highway Safety Cluster</b>		<u>-</u>	<u>121,394</u>			<u>121,394</u>	<u>-</u>

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
TRIO Cluster:								
	U.S. Department of Education							
	TRIO-Student Support Services	84.042	437,678	-			437,678	600
	<b>Total U.S. Department of Education</b>		<u>437,678</u>	<u>-</u>			<u>437,678</u>	<u>600</u>
	<b>Total TRIO Cluster</b>		<u>437,678</u>	<u>-</u>			<u>437,678</u>	<u>600</u>
Student Financial Assistance Cluster:								
	U.S. Department of Education							
	Federal Supplemental Educational Opportunity Grants	84.007	10,350,765	-			10,350,765	-
	Federal Work-Study Program	84.033	7,279,864	-			7,279,864	-
	Teacher Education Assistance for College and Higher Education Grants (TEACH Grants)	84.379	209,638	-			209,638	-
	Teacher Education Assistance for College and Higher Education Grants (TEACH Grants)	84.379	-	1,000	Higher Education Services Corporation	APTS 2022-2023	1,000	-
	Federal Direct Student Loans	84.268	638,948,769	-			638,948,769	-
	Federal Pell Grant Program	84.063	32,649,893	-			32,649,893	-
	<b>Federal Perkins Loan Program</b>							
	• Outstanding loans at September 1, 2022	84.038	28,795,934	-			28,795,934	-
			<u>28,795,934</u>	<u>-</u>			<u>28,795,934</u>	<u>-</u>
	<b>Total U.S. Department of Education</b>		<u>718,234,863</u>	<u>1,000</u>			<u>718,235,863</u>	<u>-</u>
	U.S. Department of Health and Human Services							
	<b>Health Professions Student Loan Program</b>							
	Health Professions Student Loan Program/Loans to Disadvantaged Students	93.342						
	• Outstanding loans at September 1, 2022		25,419,063	-			25,419,063	-
	• New loans issued during fiscal year 2023		<u>3,540,913</u>	<u>-</u>			<u>3,540,913</u>	<u>-</u>
			<u>28,959,976</u>	<u>-</u>			<u>28,959,976</u>	<u>-</u>
	<b>Nursing Student Loans</b>							
	Undergraduate Nursing Student Loans	93.364						
	• Outstanding loans at September 1, 2022		1,478,396	-			1,478,396	-
	• New loans issued during fiscal year 2023		<u>214,598</u>	<u>-</u>			<u>214,598</u>	<u>-</u>
			<u>1,692,994</u>	<u>-</u>			<u>1,692,994</u>	<u>-</u>
	<b>Graduate Nursing Loans</b>							
	Graduate Nursing Student Loans	93.364						
	• Outstanding loans at September 1, 2022		120,284	-			120,284	-
			<u>120,284</u>	<u>-</u>			<u>120,284</u>	<u>-</u>
	<b>Nursing Faculty Loans</b>							
	Faculty Nursing Student Loans	93.264						
	• Outstanding loans at September 1, 2022		644,634	-			644,634	-
			<u>644,634</u>	<u>-</u>			<u>644,634</u>	<u>-</u>
	<b>Total U.S. Department of Health and Human Services</b>		<u>31,417,888</u>	<u>-</u>			<u>31,417,888</u>	<u>-</u>
	<b>Total Student Financial Assistance Cluster</b>		<u>749,652,751</u>	<u>1,000</u>			<u>749,653,751</u>	<u>-</u>
Other Programs:								
	U.S. Department of Agriculture							
	Agricultural and Rural Economic Research, Cooperative Agreements and Collaborations	10.250	119,495	-			119,495	45,727
	Agricultural Statistics Reports	10.950	44,302	-			44,302	-
	<b>Total U.S. Department of Agriculture</b>		<u>163,797</u>	<u>-</u>			<u>163,797</u>	<u>45,727</u>
	U.S. Department of Commerce							
	Multi-Modal Robot-Assisted Visual Localization System for First Responders	11.U01	-	5,501	Indiana University	A22-0798-001	5,501	-
	<b>Total U.S. Department of Commerce</b>		<u>-</u>	<u>5,501</u>			<u>5,501</u>	<u>-</u>

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
U.S. Department of Defense	Basic and Applied Scientific Research	12.300	2,729	-			2,729	-
<b>Total U.S. Department of Defense</b>			<u>2,729</u>	<u>-</u>			<u>2,729</u>	<u>-</u>
U.S. Department of Justice	Edward Byrne Memorial Justice Assistance Grant Program	16.738	-	172,679	National Policing Institute	S059 A02	172,679	-
	Girls in the Juvenile Justice System	16.830	29,823	-			29,823	-
	Girls in the Juvenile Justice System	16.830	-	201,702	New York State Unified Court System	C250867 (2022-23)	201,702	-
<b>Total U.S. Department of Justice</b>			<u>29,823</u>	<u>201,702</u>			<u>231,525</u>	<u>-</u>
			<u>29,823</u>	<u>374,381</u>			<u>404,204</u>	<u>-</u>
U.S. Department of State	International Programs to Combat Human Trafficking	19.019	650,824	-			650,824	601,932
	Investing in People in The Middle East and North Africa	19.021	107,383	-			107,383	-
	Educational and Cultural Exchange Programs Appropriation Overseas Grants	19.022	75,260	-			75,260	-
	Educational and Cultural Exchange Programs Appropriation Overseas Grants	19.022	-	2,528	International Research and Exchange Board	FY21-ILUF-NYU-01 mod 5	2,528	-
			<u>75,260</u>	<u>2,528</u>			<u>77,788</u>	<u>-</u>
	Public Diplomacy Programs	19.040	110,382	-			110,382	6,238
	Academic Exchange Programs - Scholars	19.401	-	207,231	University of Montana	PG23-6B010-03	207,231	-
<b>Total U.S. Department of State</b>			<u>943,849</u>	<u>209,759</u>			<u>1,153,608</u>	<u>608,170</u>
U.S. Department of Transportation	Highway Training and Education	20.215	16,089	-			16,089	-
	University Transportation Centers Program	20.701	1,053,221	-			1,053,221	458,494
<b>Total U.S. Department of Transportation</b>			<u>1,069,310</u>	<u>-</u>			<u>1,069,310</u>	<u>458,494</u>
Federal Council on the Arts and the Humanities	Promotion of the Arts Grants to Organizations and Individuals	45.024	94,714	-			94,714	-
	Promotion of the Humanities Teaching and Learning Resources and Curriculum Development	45.162	30,965	-			30,965	-
<b>Total Federal Council on the Arts and the Humanities</b>			<u>125,679</u>	<u>-</u>			<u>125,679</u>	<u>-</u>
Institute of Museum and Library Services	National Leadership Grants	45.312	191,441	-			191,441	-
	National Leadership Grant	45.312	-	67,148	Intrepid Museum Foundation	2019-10-1 Amd 1	67,148	-
	Laura Bush 21st Century Librarian Program	45.313	158,572	-			158,572	110,386
<b>Total Institute of Museum and Library Services</b>			<u>350,013</u>	<u>67,148</u>			<u>417,161</u>	<u>110,386</u>
National Endowment for the Humanities	Promotion of the Humanities Division of Preservation and Access	45.149	220,505	-			220,505	-
	Promotion of the Humanities Research	45.161	83,251	-			83,251	12,640
	Promotion of the Humanities Office of Digital Humanities	45.169	36,077	-			36,077	-
<b>Total National Endowment for the Humanities</b>			<u>339,833</u>	<u>-</u>			<u>339,833</u>	<u>12,640</u>
Department of Veterans Affairs	Vocational Rehabilitation for Disabled Veterans	64.116	(25)	-			(25)	-
<b>Total Department of Veterans Affairs</b>			<u>(25)</u>	<u>-</u>			<u>(25)</u>	<u>-</u>

# New York University

## Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

Cluster	Federal Agency and Program Title	Assistance Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Sponsor Number/ Contract Award Number	Total Expenditures	Passed to Sub-Recipients
U.S. Department of Education	Fund for the Improvement of Postsecondary Education	84.116	172,141	-			172,141	-
	Education Research, Development and Dissemination	84.305	-	11,073	Manpower Demonstration Research Corporation	1168-NYU-01 Mod 03	11,073	-
	Education Research, Development and Dissemination	84.305	-	254,870	University of Houston	R-20-0084 Amd 3	254,870	-
			-	265,943			265,943	-
	Education Innovation and Research (formerly Investing In Innovation (I3) Fund)	84.411	-	146,950	ExpandED Schools	U411C180023	146,950	-
	COVID-19 Education Stabilization Fund: Higher Education Emergency Relief Fund - Institutional Portion	84.425F	(150)	-			(150)	-
<b>Total U.S. Department of Education</b>			<b>171,991</b>	<b>412,893</b>			<b>584,884</b>	-
U.S. Department of Health and Human Services	Training in General, Pediatric, and Public Health Dentistry	93.059	(4,297)	-			(4,297)	-
	Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED)	93.104	-	1,945	Research Foundation for Mental Hygiene Inc.	162130 A01	1,945	-
	Maternal and Child Health Federal Consolidated Programs	93.110	-	31,359	The Children's Hospital of Philadelphia	3208960821 / PO# 20260738 Amd 2	31,359	-
	Maternal and Child Health Federal Consolidated Programs	93.110	-	9,999	The Children's Hospital of Philadelphia	3208960821	9,999	-
			-	41,358			41,358	-
	Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	553,490	-			553,490	-
	Plan for AIDS Relief	93.266	-	162	Brigham and Women's Hospital	116337 Amendmet 12	162	-
	COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution	93.498	10,982,578	-			10,982,578	-
	Block Grants for Community Mental Health Services	93.958	-	551,428	New York State Office of Mental Health	OMH01-C22376GG-3650000	551,428	76,962
	Maternal and Child Health Services Block Grant to the States	93.994	-	174	New York State Department of Health	17-WH-CN-100010	174	-
	The Rest of Us	93.U01	-	(5,504)	The Danya Institute Inc.	MHTTC-03	(5,504)	-
<b>Total U.S. Department of Health and Human Services</b>			<b>11,531,771</b>	<b>589,563</b>			<b>12,121,334</b>	<b>76,962</b>
U.S. Department of Homeland Security	COVID-19 Disaster Grants-Public Assistance (Presidentially Declared Disasters)	97.036	-	4,533,372	New York State Department of Health	DOH01-C39050GG-3450000	4,533,372	-
	Disaster Grants-Public Assistance (Presidentially Declared Disasters) - Capped Grant	97.036	-	47,651,556	New York State Division of Homeland Security and Emergency Management	PW4005	47,651,556	-
	Disaster Grants-Public Assistance (Presidentially Declared Disasters) - Project Worksheets	97.036	-	18,443	New York State Division of Homeland Security and Emergency Management	PW 00006	18,443	-
<b>Total U.S. Department of Homeland Security</b>			-	<b>52,203,371</b>			<b>52,203,371</b>	-
U.S. Agency for International Development	USAID Foreign Assistance for Programs Overseas	98.001	-	675,777	World Learning	S05-72026819CA00001 Mod 1	675,777	-
<b>Total U.S. Agency for International Development</b>			-	<b>675,777</b>			<b>675,777</b>	-
<b>Total Other Programs</b>			<b>14,697,805</b>	<b>54,471,245</b>			<b>69,169,050</b>	<b>1,312,379</b>
<b>Total Expenditures of Federal Awards</b>			<b>\$ 1,473,310,962</b>	<b>\$ 127,913,828</b>			<b>\$ 1,601,224,790</b>	<b>\$ 229,299,121</b>

# New York University

## Notes to Schedule of Expenditures of Federal Awards

### Year Ended August 31, 2023

---

#### 1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) presents the federal grant activity of NYU and is presented on the accrual basis of accounting.

The information in this Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and therefore, some amounts may differ from amounts presented in, or used in the preparation of NYU's consolidated financial statements. Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years arising out of the normal course of business. Assistance Listing Numbers (ALN) and pass-through numbers are provided when available.

The research expenditures for direct costs are recognized using the cost accounting principles contained in OMB Uniform Guidance. Under those cost principles, certain types of expenditures are not allowed for reimbursement. In addition, expenditures include a portion of costs associated with general NYU activities (facilities and administrative) which are allocated to federal awards under negotiated formulas commonly referred to as facilities and administrative rates (also under the provisions of OMB Uniform Guidance, where applicable).

As described in Note 2, NYU, with the exception of NYU Langone Hospitals, as described in Note 2, does not use the 10% de-minimis indirect cost rate for sponsored programs.

#### 2. Facilities and Administrative Cost Rates

The University had predetermined facilities and administrative cost rates for the year ended August 31, 2023, under a rate agreement with the Department of Health and Human Services (DHHS), the University's federal cognizant agency. The base rate for on-campus research was 60.5% for the year ended August 31, 2023. The base rate for off-campus research was 26% for the year ended August 31, 2023.

NYUGSoM and NYU Grossman Long Island School of Medicine had predetermined facilities and administrative cost rates for the fiscal year ended August 31, 2023, under separate rate agreements with the DHHS, their federal cognizant agency. The NYUGSoM base rates for on-campus and off-campus research, respectively, were 69.5% and 26% for the year ended August 31, 2023. The NYU Grossman Long Island School of Medicine base rates for on-campus and off-campus research, respectively, were 54% and 17% for the year ended August 31, 2023.



**New York University**  
**Notes to Schedule of Expenditures of Federal Awards**  
**Year Ended August 31, 2023**

---

**3. Federal Student Loan Programs**

NYU administers and accounts for all aspects of the campus-based student loan programs. Accordingly, NYU's consolidated financial statements include all activity related to these programs. The amount of loans outstanding under each of these programs at August 31, 2023 are presented below.

<b>Program</b>	<b>Assistance Listing</b>	<b>Amount Outstanding at August 31, 2023</b>
Federal Perkins Loan	84.038	\$ 10,045,938
Health Professions Student Loans - Loans to Disadvantaged Students	93.342	5,520,586
Health Professions Student Loans	93.342	21,505,059
Nursing Student Loans	93.364	1,523,597
Graduate Nursing Loans	93.364	114,506
Nursing Faculty Loans	93.264	529,932
Nursing Faculty Loans - ARRA	93.264	46,721
		<b><u>\$ 39,286,339</u></b>

With respect to the Federal Direct Loan Program, NYU is only responsible for the performance of certain administrative duties. Therefore, the transactions and the balances of loans outstanding related to this program are not included in NYU's consolidated financial statements. The Schedule includes the loans issued to NYU students during the year ended August 31, 2023.

The administrative cost allowance for the Pell Grant Program of \$29,280 and for the Federal Work Study Program of \$714,951 have been included in the Schedule.

NYU did not receive an administrative cost allowance from the Perkins Loan Program (ALN 84.038) for the year ended August 31, 2023.

**4. Department of Health and Human Services Provider Relief Funds**

The Schedule includes grant activity related to Federal ALN 93.498. As required based on guidance in the 2023 OMB Compliance Supplement, the Schedule includes all Period 4 funds received by NYU Langone Health between July 1, 2021 and December 31, 2021 and expended by December 31, 2022 as reported to the Health Resources and Services Administration via the Provider Relief Fund Reporting Portal. NYU Langone Health did not receive Period 5 funding.

**New York University**  
**Notes to Schedule of Expenditures of Federal Awards**  
**Year Ended August 31, 2023**

---

**5. Disaster Grants-Public Assistance (Presidentially Declared Disasters)**

As a result of Superstorm Sandy in October 2012, NYU Langone Health sustained widespread damage to the main campus facilities including NYU Langone Hospital's inpatient and outpatient facilities and the NYUGSoM research, faculty group clinical practice and education facilities, all of which were temporarily closed. Under Federal Emergency Management Agency (FEMA) regulations, NYU Langone Health qualified for funding as a private non-profit facility that supplies critical services to the community. For Superstorm Sandy, FEMA (through the U.S. Department of Homeland Security) reimburses eligible entities at 90% of all eligible costs awarded.

In 2014, FEMA awarded NYU Langone Health a fixed, capped Public Assistance Grant (Capped Grant) totaling \$1,088,252,436, which includes a reduction of \$3,383,139 due to a commercial insurance claim recovery. The award is to be spent over a 9-year performance period for activities covered in the agreed upon scopes of work. The \$1,088,252,436 will be subject to offset for future commercial insurance recoveries related to property damage. All reimbursement under the Capped Grant is passed through from New York State to the University, to NYU Langone Health. Included in the Schedule are \$47,651,556 of NYU Langone Health expenditures under the Capped Grant under Federal ALN 97.036.

For the year ended of August 31, 2023, NYU Langone Health recorded \$4,533,372 of claims to FEMA under Federal ALN 97.036. The claims submitted represented eligible capital and operating expenses attributed to NYU Langone Health's response to COVID-19, which were expended in previous periods but approved by the federal and state agencies in the current year. NYU Langone Health has additional claims outstanding and under review with FEMA related to COVID-19 as of August 31, 2023 which will be recognized in the year the related funds are approved by FEMA at the federal and state agencies.

# New York University

## Schedule of Financial Responsibility Data

### Year Ended August 31, 2023

(in thousands of dollars)

NYU participates in federal Title IV student financial assistance programs, which require it to meet standards of financial responsibility based on criteria determined by the U.S. Department of Education (ED), as set forth in 34 CFR 668.171. The criteria for private institutions include the annual calculation by ED of a financial responsibility composite score, as further specified in 34 CFR 668.172, using the institution's audited financial statements submitted with the annual Uniform Guidance report through ED's eZ-Audit system. The composite score is based on three ratios: Primary Reserve, Equity, and Net Income. These ratios utilize the following financial data of NYU, as of and for the year ended August 31, 2023:

Location in financial statements or related notes	Financial element	GAAP financial statement line item or disclosure	Amount used as ratio input
<b>Primary Reserve Ratio: Expendable Net Assets</b>			
Balance sheet	Net assets without donor restrictions	\$ 9,123,054	\$ 9,123,054
Balance sheet	Net assets with donor restrictions	5,036,111	5,036,111
Note 20, Financial Responsibility Data	Unsecured related party receivable		296,239
Note 20, Financial Responsibility Data	Total property, plant, and equipment, net	14,519,779	
Note 20, Financial Responsibility Data	Property, plant and equipment, net - pre-implementation		8,349,991
Note 20, Financial Responsibility Data	Property, plant and equipment, net - post-implementation with outstanding debt for original purchase		2,740,881
Note 20, Financial Responsibility Data	Property, plant and equipment, net - post-implementation without outstanding debt for original purchase		2,224,534
Note 20, Financial Responsibility Data	Construction in progress		1,204,373
Balance sheet	Total lease right-of-use assets	2,040,225	
N/A	Lease right-of-use assets, pre-implementation		-
Balance sheet	Lease right-of-use assets, post-implementation		2,040,225
Note 8, Other Assets	Intangible assets	51,105	51,105
Balance sheet	Accrued benefit obligation	229,087	229,087
	Accrued postretirement obligation (Accrued employee benefit liabilities)	456,817	456,817
Note 20, Financial Responsibility Data	Total long-term debt	9,668,268	
Note 20, Financial Responsibility Data	Long-term debt - for long-term purposes pre-implementation		6,637,111
Note 20, Financial Responsibility Data	Long-term debt - for long-term purposes post-implementation		2,995,827
Note 20, Financial Responsibility Data	Line of Credit for Construction in progress		35,330
Balance sheet	Total liability related to lease right-of-use assets	2,226,362	
Balance sheet	Liability related to lease right-of-use assets - pre-implementation		-
Balance sheet	Liability related to lease right-of-use assets - post-implementation		2,226,362
Note 20, Financial Responsibility Data	Annuities and life income funds with donor restrictions		89,167
Note 20, Financial Responsibility Data	Term endowments with donor restrictions		4,640
Note 20, Financial Responsibility Data	Net assets with donor restrictions: restricted in perpetuity		2,814,380
<b>Primary Reserve Ratio: Expenses and Losses</b>			
Statement of activities	Total expenses and losses without donor restrictions		\$ 16,004,066
<b>Equity Ratio: Modified Net Assets</b>			
Balance sheet	Net assets without donor restrictions	\$ 9,123,054	\$ 9,123,054
Balance sheet	Net assets with donor restrictions	5,036,111	5,036,111
Note 8, Other Assets	Intangible assets	51,105	51,105
Note 20, Financial Responsibility Data	Unsecured related party receivable		296,329
<b>Equity Ratio: Modified Assets</b>			
Balance sheet	Total assets	\$ 32,588,729	\$ 32,588,729
Balance sheet	Lease right-of-use assets, pre-implementation		-
Note 8, Other Assets	Intangible assets	51,105	51,105
Note 20, Financial Responsibility Data	Unsecured related party receivable		296,329
<b>Net Income Ratio</b>			
Statement of activities	Change in net assets without donor restrictions	\$ 1,633,814	\$ 1,633,814
Note 20, Financial Responsibility Data	Total revenues and gains without donor restrictions		17,637,880

**Part III**  
**Reports on Internal Control and Compliance**



## **Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards***

To the Board of Trustees of  
New York University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of New York University and its subsidiaries (the "Company"), which comprise the consolidated balance sheet as of August 31, 2023, and the related consolidated statements of activities, and of cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated December 20, 2023, except with respect to Note 20 to the consolidated financial statements and the opinion on the schedule of financial responsibility data, as to which the date is April 24, 2024.

### **Report on Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the Company's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control.

*A deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

### **Report on Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Company's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our



tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

**Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*PricewaterhouseCoopers LLP*

New York, New York

December 20, 2023, except with respect to Note 20 to the consolidated financial statements and the opinion on the schedule of financial responsibility data, as to which the date is April 24, 2024



## **Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance**

To the Board of Trustees of  
New York University

### **Report on Compliance for Each Major Federal Program**

#### ***Opinion on Each Major Federal Program***

We have audited New York University and its subsidiaries' (the "Company") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company's major federal programs for the year ended August 31, 2023. The Company's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2023.

#### ***Basis for Opinion on Each Major Federal Program***

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with relevant requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company's compliance with the compliance requirements referred to above.

#### ***Responsibilities of Management for Compliance***

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company's federal programs.

#### ***Auditors' Responsibilities for the Audit of Compliance***

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company's compliance based on our audit. Reasonable assurance is a high level of



assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Company's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

### ***Other Matters***

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the *OMB Compliance Supplement*, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 12 "Gramm-Leach-Bliley Act-Student Information Security." This section includes two suggested audit procedures with respect to verification that the institution (1) designated a Qualified Individual responsible for implementing and monitoring the institution's information security program, and (2) has a written information security program that addresses the remaining six required minimum elements that are detailed in the *OMB Compliance Supplement*, Part Five, Student Financial Assistance Cluster, Special Tests and Provisions, item 12, Gramm-Leach-Bliley Act – Student Information Security. Our procedures in relation to these two items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these two items. Our procedures did not include an analysis of the adequacy or completeness of the minimum required elements of the institution's information security program.

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule





of findings and questioned costs as item 2023-001. Our opinion on each major federal program is not modified with respect to this matter.

*Government Auditing Standards* requires the auditor to perform limited procedures on the Company's response to the noncompliance finding identified in our audit described in the accompanying management's view and corrective action plan. The Company's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

### **Report on Internal Control Over Compliance**

*A deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

*PricewaterhouseCoopers LLP*

New York, New York  
April 24, 2024

**Part IV**  
**Findings**

**New York University**  
**Schedule of Findings and Questioned Costs**  
**Year Ended August 31, 2023**

---

**Section I – Summary of Auditor’s Results**

**Financial Statements**

Type of auditor’s report issued:

**Unmodified Opinion**

Internal control over financial reporting:

- Material weakness(es) identified?
- Significant deficiency(ies) identified that are not considered to be material weaknesses?
- Noncompliance material to financial statements noted?

\_\_\_\_\_ Yes      \_\_X\_\_ No  
 \_\_\_\_\_ Yes      \_\_X\_\_ None reported  
 \_\_\_\_\_ Yes      \_\_X\_\_ No

**Federal Awards**

Internal control over major programs:

- Material weakness(es) identified?
- Significant deficiency(ies) identified that are not considered to be material weaknesses?

\_\_\_\_\_ Yes      \_\_X\_\_ No  
 \_\_\_\_\_ Yes      \_\_X\_\_ None reported

Type of auditor’s report issued on compliance for major programs:

**Unmodified Opinion**

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

\_\_X\_\_ Yes      \_\_\_\_\_ No

**Identification of major programs:**

**Assistance Listing Number(s)**

**Name of Federal Program or Cluster**

Various

Student Financial Assistance Cluster

93.498

COVID-19 Provider Relief Fund and Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

97.036

Disaster Grants-Public Assistance (Presidentially Declared Disasters) – Capped Grant

Dollar threshold used to distinguish between type A and type B programs:

\$4,803,674

Auditee qualified as low-risk auditee?

\_\_X\_\_ Yes      \_\_\_\_\_ No

# New York University

## Schedule of Findings and Questioned Costs

### Year Ended August 31, 2023

---

#### Section II- Financial Statement Findings

As a result of our audit, no instances of noncompliance related to the financial statements that are required to be reported in accordance with *Government Auditing Standards* were identified.

#### Section III - Federal Award Findings and Questioned Costs

##### 2023-001 - Non-Compliance with Timely Student Enrollment Change Submissions to the National Student Loan Data System (NSLDS)

**Grantor:** U.S. Department of Education

**Cluster Name:** Student Financial Assistance Cluster

**Award Names:** Federal Pell Grant Program and Federal Direct Loan Program

**Award Year:** 9/1/2022 - 8/31/2023

**Award Number:** Not applicable

**Assistance Listing Numbers:** 84.063 and 84.268

##### **Criteria:**

In accordance with 34 CFR 690.83(b)(2) and 685.309, institutions are required to report enrollment information under the Federal Pell Grant and Federal Direct Loan programs through the NSLDS. The enrollment information, inclusive of Campus Level and Program Level data, must be reviewed, updated and validated by the institution in a timely manner. Furthermore, specific to the Federal Direct Loan program, for a student who received a Direct Loan and was enrolled or accepted for enrollment at the institution, and the student had ceased to be enrolled on at least a half-time basis or failed to enroll on at least a half-time basis for the period for which the loan was intended, the institution must report the change within 60 days from which the change was identified.

##### **Condition:**

We reviewed a sample of twenty-five students enrolled at the University who received either Pell and/or Direct Loans and had a change of enrollment reporting data due date between March 1, 2023 through August 31, 2023 of the fiscal year. Of the twenty-five students tested, four students that graduated in the spring semester were not reported within the 60-day reporting timeframe. For these four students tested, the change in enrollment was reported to the NSLDS between 133-146 days from the date the change was identified.

##### **Cause:**

The University utilizes the National Student Clearinghouse (NSC) to report student enrollment data to NSLDS through roster updates. The University reported its graduation enrollment file to NSC after the Spring 2023 degrees were conferred, however, the file was not accepted by NSC based on its data validation checks that required management's review. Before the data validation checks were cleared by management, the first of term enrollment file for the Fall 2023 semester was reported to and accepted by NSC. As these four students tested were not included in the Fall 2023 semester enrollment file, the students' status within NSC was automatically updated to withdrawn, which was then reported to NSLDS. Once the graduation status was accurately updated in NSC, the student's graduation status was not reported by NSC to NSLDS, and the student's status in NSLDS remained as withdrawn until it was corrected by management in October 2023.

##### **Effect:**

A student's enrollment status determines eligibility for in-school status, deferment, and grace periods, as well as for the payment of interest subsidies all of which are impacted by late reporting.

**New York University**  
**Schedule of Findings and Questioned Costs**  
**Year Ended August 31, 2023**

---

**Questioned Costs:**

There are no questioned costs associated with the finding.

**Recommendation:**

We recommend the University implement a process to ensure the student enrollment information, specifically the student's graduation status, is reported to NSLDS accurately and timely.

**Management's View and Corrective Action Plan**

Management's View and Corrective Action Plan is included at the end of this report after the summary schedule of prior audit findings and status.

**New York University**  
**Summary Schedule of Status of Prior Audit Findings**  
**Year Ended August 31, 2023**

---

**Section II - Financial Statement Findings – 2022**

There are no findings from prior year that require an update in this report.

**Section III - Federal Award Findings and Questioned Costs – 2022**

There are no findings from prior year that require an update in this report.



## **2023-001 - Non-Compliance with Timely Student Enrollment Change Submissions to the National Student Loan Data System (NSLDS)**

### **Management View and Corrective Action Plan**

**April 24, 2024**

#### **Inaccurate Graduated Student Enrollment Reporting**

##### **Management View and Opinion**

NYU Registrar reports a student's enrollment, withdrawal and graduation status to the National Student Clearinghouse (NSC) weekly, per term, which includes a few weeks before and after the term has ended. NSC transfers this data to the National Student Loan Data System (NSLDS).

During the degree/graduation reporting period to NSC, the graduation records for some students are not processed prior to NSC's calculated withdrawal which occurs at the start of the subsequent enrollment reporting period. As such, some students are reflected as withdrawn from a term, when in fact they graduated. This impacts the accuracy of student data reported to the National Student Loan Data System.

##### **Corrective Action Plan**

Currently, students self-identify when their loan servicer reflects an incorrect enrollment or loan repayment status. In these cases, the Office of Financial Aid or Registrar manually adjust the NSLDS/NSC file. NSC procedural timelines impact and limit NYU staff's access to make manual adjustments.

Going forward, the Office of Financial Aid and Registrar will collaborate to upload an NYU Graduated Student file directly to NSLDS to update the records of all students to ensure their graduation status are reported accurately and in a timely manner. This upload will be done through the Enrollment Spreadsheet Submittal function on the NSLDS website. The file will include graduated status information for each conferred student in our most recent conferral period.

##### **Timeline for Action Plan**

The corrective action plan will be implemented as follows:

Starting in March 2024, the Office of Financial Aid will provide the NSLDS Graduated Student file template to the Registrar. At the close of each conferral period, the Registrar will populate the template spreadsheet with required data points for all graduating students. After the Office of Financial Aid securely receives the completed spreadsheet from the Registrar, it will be uploaded, within the required 60 days, to NSLDS for processing of the students' graduation records.

##### **Responsible Individual:**

Jason Crowe

Email: Jason.Crowe@nyu.edu

Signature:

*Art Crevier*